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ABSTRACT 
Diverse effects of the nucleoside adenosine have been 
reported including stimulation of respiration in man. 
This thesis discusses the results of studies undertaken 
to further characterise the respiratory and concomitant 
cardiovascular effects of infusion of adenosine in man. 
In healthy volunteers intravenous infusion of 
adenosine, but not its first metabolite inosine, caused a 
dose -related increase in minute ventilation, not due to 
hypotension or bronchoconstriction, and a fall in 
end -tidal carbon dioxide tension. 
The increase in minute ventilation was largely due to 
an increase in tidal volume (VT). Inspiratory duration 
(T1) was unchanged but expiratory duration was slightly 
reduced. Mean inspiratory flow (VT /TI) was increased as 
was functional residual capacity (FRC). These changes are 
similar to those that have been reported during 
equivalent ventilatory stimulation by hypoxia and 
hypercapnia. 
Adenosine caused various symptoms including 
discomfort in the epigastrium, chest and jaw, flushing, 
dyspnoea and paraesthesiae, which limited the maximum 
dose. 
Aminophylline antagonised the adenosine - induced 
increases in ventilation, heart rate and systolic blood 
pressure and reduced the symptoms, suggesting that these 
effects are mediated by cell- surface receptors. The 
venous plasma concentration of adenosine only increased 
at the higher maximum dose possible after aminophylline, 
consistent with the very short half -life of adenosine as 
determined in vitro. 
Three studies were performed in patients undergoing 
diagnostic cardiac catheterisation. In one study infusion 
of adenosine into the aorta proximal to the head and neck 
vessels caused respiratory stimulation whereas infusion 
into the upper descending thoracic aorta did not, 
although chest and epigastric discomfort were more 
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common. Since in animals adenosine depresses respiration 
within the central nervous system, this study supports 
the suggestion that adenosine may stimulate respiration 
by an action within the carotid bodies. Furthermore it 
suggests that the respiratory stimulation is not 
primarily due to symptoms caused by adenosine. 
In a second study the mean plasma adenosine 
concentration in the upper descending thoracic aorta 
increased from 0.07 µM at baseline to 1.2 µM during iv 
infusion at the maximum dose. Since micromolar 
concentrations may be achieved in tissues during hypoxia, 
due to hydrolysis of adenine nucleotides, these results 
are consistent with the suggestion that adenosine might 
participate in the ventilatory response to hypoxia. An 
unexpected finding was that respiration increased in 3 of 
the 7 patients before the adenosine concentration did. 
Since adenosine has a half -life of only a few seconds 
this finding is consistent with a more proximal effect of 
adenosine, e.g. within the lungs. 
In a third study, which investigated its haemodynamic 
effects, adenosine increased cardiac output and caused 
pulmonary and systemic vasodilation. The pulmonary 
vasodilation first developed at a dose which did not 
affect systemic vascular resistance suggesting that at 
low dose (< 60 µg /kg /min) adenosine might be useful as a 
selective pulmonary vasodilator. Higher doses produced an 
increase in left ventricular end -diastolic pressure of 
uncertain cause. 
Adenosine caused variable effects in 6 patients with 
chronic hypoxia due to obstructive airways disease. Four 
showed a slight increase in minute ventilation and 
improvement in arterial blood gas tensions. None 
developed worse spirometry but all showed an increase in 
FRC which was greatest in 2 patients whose tidal volume 
and arterial oxygen tension fell, suggesting that the 
changes in lung volume were disadvantageous. 
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ABBREVIATIONS 
In addition to standard abbreviations for commonly used 
units, the following abbreviations were used in this 
thesis. Some abbreviations used only once, or in figures 
or tables, are defined where used. 
ANOVA repeated measures analysis of variance 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ATP adenosine triphosphate 
BP blood pressure 
CAD coronary artery disease 
CI cardiac index 
CO cardiac output 
ECG electrocardiogram 
EHNA erythro -9 -(2- hydroxy -3- nonyl) adenine 
FEF25_75% forced expiratory flow rate between 25 and 
75% of forced vital capacity 
FEV1 forced expiratory volume in 1 second 
fR respiratory rate 
FRC functional residual capacity 
FVC forced vital capacity 
HPLC high performance liquid chromatography 
HR heart rate 
NECA 5'- N- ethylcarboxamidoadenosine 
Pa02 arterial oxygen tension 
PaCO2 arterial carbon dioxide tension 
PAP pulmonary artery pressure 
PCWP pulmonary capillary wedge pressure 
PEFR peak expiratory flow rate 
PETCO2 end -tidal PCO2 
PVR pulmonary vascular resistance 
RAP right atrial pressure 
RIP respiratory inductance plethysmograph 
R -PIA N6- R- phenyl isopropyladenosine 
SD standard deviation 
SEM standard error of the mean 
xii 
SVI stroke volume index 
SVR systemic vascular resistance 
TE expiratory duration 
T1 inspiratory duration 
TTOT total breath duration 
V minute ventilation 
VO2 total oxygen consumption 
VT tidal volume 
CHAPTER 1 - INTRODUCTION 
1.1 - GENERAL INTRODUCTION 
Adenosine is a purine nucleoside whose biological effects 
were first described in 1929 by Drury and Szent -Györgyi. 
Since those observations there has been much research 
into the biochemistry, physiology and pharmacology of 
adenosine. This has been especially true over the last 
three decades following the suggestion by Berne et al. 
(1963) that adenosine might be a mediator of the 
metabolic regulation of coronary blood flow. In a recent 
review it was estimated that over 20,000 studies of the 
formation and effects of adenosine have been performed 
since the work of Drury and Szent -Györgyi (Sollevi, 
1986) . 
This thesis contains results of studies undertaken to 
investigate the cardiovascular and respiratory effects of 
the infusion of adenosine in man. The starting point for 
this work was the observation by Watt and Routledge 
(1985) that bolus injections of adenosine cause transient 
powerful stimulation of respiration in man. The questions 
raised by that observation which this thesis seeks to 
answer are summarised in the final section of the 
introduction. In the preceding sections published 
articles on the biochemistry and effects of adenosine are 
reviewed. Emphasis is given to previous studies directly 
relevant to the present work. Discussion of some of the 
more recent papers is left to later chapters. 
1.2 - BIOCHEMICAL ASPECTS 
Adenosine is a nucleoside of molecular weight 267.2 
formed by the condensation of the purine adenine and the 
C5 sugar ribose (Fig. 1.1). It is produced in and metab- 
olised by most animal tissues. Some important pathways of 
adenosine metabolism are shown in Fig. 1.2. Adenosine is 
a precursor and degradation product of the nucleotides 
adenosine 5'- monophosphate, 5'- diphosphate and 5'- 

























Fig. 1.2 - Important pathways of adenosine metabolism. 
SAM, S-adenosylmethionine; SAH, S- adenosylhomocysteine; 1, 5'- nucleotidase; 
2,adenosine kinase; 3, adenosine deaminase; 4, S- adenosylhomocysteine hydrolase; 
5, cystathionine- ß- synthase; 6, betaine homocysteine methyltransferase; 7, purine 
nucleoside phosphorylase; 8, xanthine oxidase. (After: Lloyd & Schrader, 1987). 
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There are many reports of increased adenosine liberation 
in tissues when energy (or oxygen) requirements are 
increased or supply is reduced, situations which usually 
result in greater dephosphorylation of adenine 
nucleotides (e.g. Olsson, 1970; Rubio et al., 1975; 
Mentzer et al., 1975 and see Chapter 6). Following 
release in this way adenosine has been considered to act 
as a "local hormone" (Arch & Newsholme, 1978). Since many 
of its actions appear to reduce energy demand or increase 
energy supply and thereby redress the balance between 
supply and demand, adenosine has also been described as a 
"retaliatory metabolite" (Newby, 1984). 
Adenosine is also formed in the "transmethylation 
pathway" by the hydrolysis of S- adenosylhomocysteine 
(Schrader et al., 1981). Although the dephosphorylation 
of AMP has been considered primarily responsible for 
adenosine formation, the transmethylation pathway may be 
more important in some situations, e.g. the normoxic 
guinea pig heart (Lloyd and Schrader, 1987). 
Sattin and Rall (1970) showed, in guinea pig cerebral 
cortex, that adenosine can increase the intracellular 
concentration of adenosine 3',5'- monophosphate (cyclic 
AMP). Subsequently it was shown that adenosine can also 
decrease intracellular cyclic AMP concentrations (Fain et 
el., 1972; van Calker et al., 1978; Fain and Malbon, 
1979). Haslam and Lynham (1972) showed, using platelets, 
that at low concentrations (< 25 AM) adenosine stimulated 
adenylate cyclase in isolated membranes while at higher 
concentrations ( >100 AM) it was inhibitory. 
Burnstock (1978) proposed that cell- surface purine 
receptors are present in various tissues and divided them 
into P1 receptors which have a greater affinity for 
adenosine and P2 receptors which have a greater affinity 
for ATP. Van Calker et el. (1979) provided evidence of 
two classes of the adenosine receptors which they termed 
Al and A2. Their Al receptor mediated inhibition of 
adenylate cyclase at submicromolar concentrations of 
adenosine, whereas the A2 receptor mediated activation of 
3 
adenylate cyclase at concentrations of adenosine above 
micromolar. 
Londos et al. (1980) used the nomenclature Ri and Ra 
to denote the adenosine receptors mediating respectively 
the inhibition and the activation of adenylate cyclase. 
The same group had also described an intracellular site 
inhibitory to adenylate cyclase, termed the "P site" (not 
to be confused with Burnstock's Pl and P2 receptors) 
(Londos & Wolff, 1977). Presently the Al, A2 notation is 
used most widely to describe the cell -surface receptors, 
although additional classes and sub -classes have been 
proposed (Bruns, 1986). 
Van Calker et al. (1979) also showed that the order 
of potency of various adenosine analogues differs at the 
two types of cell- surface receptor. The order of potency 
of such analogues has proved to be a useful tool for 
classifying receptors involved in particular 
physiological processes as either Al or A2 (Daly et al., 
1987), e.g. at Al receptors N6- R- phenylisopropyladenosine 
(R -PIA) is more potent than 5'-N- ethylcarboxamido - 
adenosine (NECA) while at A2 receptors the reverse is 
true. This method is now preferred to classification 
according to effects on adenylate cyclase since receptor 
mediated effects of adenosine may in some situations 
involve different effector systems. Adenosine receptors 
are distributed widely throughout the body and mediate 
diverse effects (Table 1.1). 
Methylxanthines such as caffeine and theophylline 
have been shown to act as competitive antagonists of 
those actions of adenosine which are now known to be 
mediated by cell surface receptors. Nichols & Walaszek 
(1963) first showed that caffeine antagonised the 
hypotensive effect of adenosine and related nucleotides 
in various species. Methylxanthines antagonised the 
adenosine - induced increase in cyclic AMP in guinea pig 
cerebral cortex observed by Sattin & Rall (1970) and the 
activation of platelet adenylate cyclase reported by 
Haslam and Lynham (1972). Subsequently numerous studies 
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Table 1.1 - Adenosine receptors: distribution and 
function. 
Tissue or cell type Effects mediated 
Al (RI) adenosine receptors 
Brain Sedation 
Inhibition of neurotransmitter 
release 
Adipose tissue Inhibition of lipolysis 
Heart Suppression of contractility 
Inhibition of sinoatrial node 
Inhibition of atrioventricular node 
A2 (RA) adenosine receptors 
Brain Modulation of neurotransmission 
Carotid body Chemoexcitation 
Platelet Inhibition of aggregation 
Smooth muscle Relaxation 
Kidney Vasoconstriction 
Liver Stimulation of gluconeogenesis 
Neutrophils Inhibition of superoxide release 
After: Clarke & Coupe, 1989. 
have confirmed similar effects in a wide range of 
tissues. Methylxanthines have previously been considered 
to exert their biological effects largely by inhibiting 
intracellular phosphodiesterases which hydrolyse cyclic 
AMP. However higher concentrations are required to 
inhibit phosphodiesterases (50% inhibition by 
theophylline at approximately 400 to 1000 AM) than are 
required to antagonise the effects of adenosine (half 
maximal antagonism at approximately 4 to 60 AM: 1 to 10 
5 
µg /m1) (Butcher & Sutherland, 1962; Fredholm et al., 
1976; Smellie et al., 1979; Daly, 1983). Adenosine 
antagonism has therefore been proposed as a mechanism of 
the pharmacological actions of the methylxanthines 
(Fredholm, 1980; Snyder et al., 1981; Daly et al., 1981). 
Chronic consumption of caffeine or theophylline results 
in potentiation of the pharmacological effects of 
adenosine and upregulation of receptor number in 
animals (von Borstel et al., 1983; Wu et el., 1989). 
Xanthines have no effect on the intracellular P -site- 
mediated inhibition of adenylate cyclase (Daly, 1982). 
There are avid uptake mechanisms for adenosine in 
cell membranes and these have considerable importance for 
the actions of adenosine since they serve to remove the 
nucleoside from its site of action at cell- surface 
receptors (Huang & Daly, 1974). After transport into 
human red cells adenosine is rapidly metabolised 
(Schrader et al., 1972; Plageman et al., 1985). At 
extracellular concentrations of less than i to 3 µM 
adenosine is predominantly incorporated into adenine 
nucleotides whereas at concentrations greater than 6 to 
10 gM adenosine kinase is inhibited and most of the 
adenosine transported into cells is deaminated (Plageman 
et ál., 1985). Due to its rapid uptake into blood cells 
adenosine has a very short half -life. Klabunde (1983) 
estimated the half -life in human blood at 37° C to be 
less than 10s. Recently Möser et el. (1989) showed that 
at concentrations of 1 to 5 µM there is net removal of 
adenosine from human plasma with a half -life of 
approximately 1.5 s. 
Adenosine transport into cells is inhibited by a 
number of compounds including dipyridamole (Koss et al., 
1962; Bunag et el., 1964; Huang & Daly, 1974; Klabunde, 
1983). By increasing the extracellular concentration such 
compounds potentiate those effects of adenosine which are 
mediated by cell- surface receptors and have proved useful 
tools for investigating such effects. 
Adenosine may also be metabolised extracellularly, 
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e.g. by deamination, but this seems to be quantitatively 
less important than cellular uptake and intracellular 
metabolism (Arch & Newsholme, 1978). 
1.3 - BIOLOGICAL EFFECTS OF ADENOSINE 
1.3.1 - RESPIRATORY EFFECTS 
a) - Effects on the control of breathing 
Although some early investigators had observed that 
administration of adenosine or the related nucleotide ATP 
could affect breathing in various ways in a variety of 
species including man (Drury & Szent- Györgyi, 1929; 
Emmelin & Feldberg, 1948; Green & Stoner, 1950) it was in 
the 1980s that interest centred on the action of 
adenosine as a respiratory depressant. Several workers 
showed that administration within the central nervous 
system of adenosine (Kattwinkel & Darnall, 1982) and its 
long- acting analogues R -PIA (Hedner et el., 1982, 
Lagercrantz et el., 1984, Eldridge et el., 1984), 
2- chloroadenosine (Kattwinkel & Darnall, 1982, Mueller et 
el., 1982, Wessberg et al., 1985) N6- cyclohexyladenosine 
and NECA (Wessberg et al., 1985) could depress 
respiration in a variety of species. This was observed in 
both anaesthetised and naturally sleeping animals. Both 
depth and rate of respiration were affected. Inspiratory 
drive was decreased and expiratory time was prolonged 
(Wessberg et al., 1985). 
Similar effects have been shown with peripheral 
(intra- peritoneal or intravenous) administration of 
analogues, but much larger doses are required consistent 
with a central site of action (Lagercrantz et al., 1984, 
Wessberg et el., 1985). Such effects persist despite 
vagotomy and glomectomy, suggesting that pulmonary and 
peripheral chemoreceptor afferents are not required. 
Lagercrantz et al. (1984) observed respiratory depression 
in decerebrate animals suggesting that it is not mediated 
at a suprapontine level. Adenosine has been found to 
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reduce not only resting ventilation but also the 
ventilatory response to hypercapnia (Wessberg et al., 
1984) . 
The effects on respiration of R -PIA in neonatal 
animals are more marked in younger than older animals 
(Lagercrantz et al., 1984) and have been found to 
correlate with the affinity of R -PIA receptors in whole 
brains (Runold et al., 1986). 
Respiratory depression by adenosine and its analogues 
is antagonised by theophylline (Lagercrantz et el., 1984; 
Eldridge et al., 1985) and aminophylline (Watt et ál., 
1987a), but not by enprofylline, a xanthine without 
adenosine receptor- blocking activity (Wessberg et al., 
1985; Darnall et al., 1985). Millhorn et al. (1984) 
reported that theophylline reduced the magnitude of acute 
hypoxic and the duration of post -hypoxic depression of 
phrenic nerve activity in anaesthetised, paralysed, 
vagotomised and glomectomised cats. They suggested that 
an increased concentration of adenosine within the brain 
caused the long -lasting depression of respiration 
following hypoxia and was partially responsible for the 
acute effects. This is supported by the finding in a 
variety of species that the adenosine concentration in 
the brain is increased by hypoxia. Furthermore 
methylxanthines stimulate breathing (see Chapter 5) 
suggesting that adenosine might normally exert tonic 
modulation of respiration. Methylxanthines have been 
found to be effective treatment for neonatal apnoea 
(Kuzembo & Paala, 1973) and it has been suggested that 
this abnormality might therefore be mediated by a central 
respiratory depressant effect of adenosine (Lagercrantz 
et al., 1984). 
Despite such evidence for a respiratory depressant 
effect of adenosine and its analogues, several workers 
had previously noted that adenosine and related compounds 
can stimulate breathing. Drury and Szent -Györgyi (1929) 
observed that "panting respiration" might occur after 
subcutaneous injection of adenosine in guinea pigs. In 
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one patient after an intravenous bolus of adenosine Honey 
et al. (1930) observed that: 
"the breathing became deeper and more rapid, the 
patient became restless, felt breathless, and experienced 
a sense of constriction of the chest." 
In a further patient given a larger dose: 
"the breathing became faster and more shallow." 
Rowe et el. (1962) observed increased minute 
ventilation and CO2 elimination in dogs given intravenous 
ATP or adenosine. Gustafsson (1981) observed that 
infusion of adenosine into the left ventricle of 
anaesthetised rabbits sometimes induced "forceful 
spontaneous respiration" despite vagotomy, suggesting 
that the effect was not mediated by pulmonary afferents. 
ATP is rapidly hydrolysed in vivo thus many of its 
actions may be due to liberated adenosine. Emmelin and 
Feldberg (1948) reported variable responses to 
intravenous ATP, with some animals showing "strong 
hyperventilation ". Green and Stoner (1950) found that 
while intravenous ATP and to a lesser degree adenosine 
usually slowed respiration in animals acceleration of 
breathing often preceded this and was sometimes the only 
response. Davies et el. (1951) studied the effects of ATP 
in 28 patients with a variety of conditions and found 
that intravenous injection caused a marked increase in 
the depth of respiration with little change in rate. A 
similar but smaller response was seen with intra- arterial 
injection. These changes were accompanied by striking 
subjective responses including "a peculiar, painless 
sensation in the chest ", a feeling of suffocation and 
apprehension. 
In 1985 Watt and Routledge published the first 
detailed examination of respiratory stimulation by 
adenosine. They found that intravenous bolus injections 
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in healthy volunteers caused a dose -related increase in 
ventilation, mostly due to increased depth of breathing. 
The effect was transient, lasting approximately 20s, and 
began 15 to 20s after the injection. Adenosine also 
caused a transient sinus bradycardia followed by a brief 
sinus tachycardia. Watt and Routledge considered that 
because of the findings of Gustafsson (1981: see above) 
the respiratory stimulation was unlikely to be secondary 
to stimulation of pulmonary sensory afferents. 
Furthermore the evidence for a central depressant effect 
on respiration of adenosine suggested that a direct 
stimulant effect within the central nervous system was 
unlikely. Since the aortic chemoreceptors are unimportant 
in man (Lugliani et al., 1971) Watt and Routledge 
considered that the carotid bodies were the most likely 
site of action of adenosine. They also considered this 
consistent with their observation that respiratory 
stimulation began up to 2 s after the longest R -R 
interval. Blood pressure and airway calibre were not 
measured in the study of Watt and Routledge so 
contributory effects of hypotension and broncho- 
constriction, both of which can be caused by adenosine 
(see below), could not be excluded by their work. 
Evidence for an action of adenosine within the 
carotid bodies had previously been provided by McQueen 
and Ribeiro (1981) who showed that intracarotid 
injections of adenosine caused a dose -related increase in 
chemosensory discharges in the carotid sinus nerve of 
anaesthetised cats. Although initial work showed no 
antagonism of this effect by theophylline or 
aminophylline, the adenosine uptake blocker dipyridamole 
enhanced the effect suggesting an action of adenosine on 
cell- surface receptors (McQueen & Ribeiro, 1983). This 
suggestion was supported by the finding that adenosine 
analogues active at such sites caused chemoreceptor 
activation, whereas an agonist at the intracellular 
receptor, the P -site (Londos & Wolff, 1977), was without 
effect (McQueen & Ribeiro, 1983). These observations, the 
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finding that ATP, a precursor of adenosine, is stored in 
the carotid body (Böck, 1980) and the reports that 
adenosine production is increased in a number of organs 
during hypoxia (see above and Chapter 6), led Watt and 
Routledge (1985) to suggest that adenosine may be a 
mediator within the carotid body of the ventilatory 
response to hypoxia. Subsequent studies relating to this 
topic will be discussed in later chapters. 
b) - Effects on the airways 
It has been known since the work of Bennett and Drury 
(1931) that adenosine can relax tracheal smooth muscle. 
While some recent workers have observed that adenosine 
may cause contraction of tracheal muscle at resting tone 
(Fredholm et al., 1979; Advenier, 1982) several groups 
have confirmed that adenosine can cause relaxation when 
the tracheal muscle is preconstricted or has a high 
initial resting tone (Coleman & Levy, 1974). The 
relaxation is enhanced by adenosine uptake -blockers such 
as dipyridamole (Coleman, 1976; Farmer & Farrar, 1976) 
and antagonised by methylxanthines (Karlsson et al., 
1982) . 
While investigating whether adenosine may be 
similarly effective at relaxing bronchial smooth muscle, 
Cushley et ál. (1983a) were surprised to observe that 
inhaled adenosine caused bronchoconstriction in asthmatic 
subjects (Holgate et ál., 1987). This effect reached a 
peak within 1 to 3 minutes and abated slowly over the 
following hour. A similar effect was not seen in normal 
subjects. The related nucleoside guanosine was inactive 
suggesting that a non -specific irritant effect was not 
implicated (Cushley et ál., 1983a) and indices of 
non -specific bronchial responsiveness, ie) to 
methacholine and histamine, were only weakly correlated 
with the response to adenosine (Mann et ál., 1986; 
Cushley & Holgate, 1985). 
Subsequently the principle breakdown product of 
adenosine, inosine, was found to be inactive but the 
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nucleotides, AMP and ADP, which can be rapidly hydrolysed 
to adenosine in vivo, caused similar effects (Cushley et 
el., 1983b; Mann et al., 1986). Bronchoconstriction by 
adenosine was later shown to be specifically antagonised 
by theophylline (Cushley et al., 1984, Mann & Holgate, 
1985) and enhanced by dipyridamole (Cushley et al., 
1985), suggesting that this effect of adenosine is 
mediated by cell- surface receptors. Mann et al. (1985) 
later provided evidence suggesting that the effect is not 
mediated by stimulation of cholinergic reflexes or 
reduced ß2- adrenoceptor responsiveness of the airways. 
The mechanism of the bronchoconstrictor effect of 
adenosine remains to be fully elucidated but several 
strands of evidence suggest that potentiation of mast 
cell mediator release is implicated (Cushley & Holgate, 
1985; Holgate et el., 1987). 
Whether adenosine has a rôle in the pathogenesis of 
asthma remains unclear. Marquardt et el. (1984) reported 
release of adenosine by IgE- dependent activation of 
murine bone marrow -derived mast cells. Mann et al. (1986) 
showed an increase in plasma venous concentration of 
adenosine following both antigen and methacholine 
bronchial provocation in asthma, but since adenosine has 
a very short half -life it is uncertain whether the 
increase was due to adenosine release from the lungs. 
Although inhaled adenosine was used in most initial 
studies of its airway effects, Pauwels and van Der 
Straeten (1986) reported that intravenous adenosine 
caused bronchoconstriction in inbred rat strains. However 
they noted marked differences in response between rat 
strains and also found that inosine was active. Bilateral 
vagotomy did not alter the response but atropine caused 
slight inhibition. Theophylline, but not enprofylline, 
antagonised the response but no enhancement was seen with 
dipyridamole. The order of potency of various adenosine 
analogues led the authors to suggest that the effects of 
adenosine were mediated by A2 adenosine receptors. The 
type of anaesthetic used affected the response in some 
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strains so the relevance of their findings to those in 
conscious humans is uncertain. Taviot et al. (1986) 
reported a case of severe bronchospasm in an asthmatic 
patient approximately 2 min after he was given 
intravenous ATP, which is rapidly degraded to adenosine, 
to treat a supraventricular tachycardia. However at the 
same time as the injection the patient had performed 
various vagal manoeuvres which might have contributed to 
his bronchoconstriction. Results of studies specifically 
examining the airway effects of intravenous adenosine 
will be discussed in later chapters. 
c) - Effects on the diaphragm 
While various workers have suggested that the enhancement 
of diaphragmatic contractility produced by 
methylxanthines such as theophylline and caffeine might 
be due to antagonism of endogenous adenosine (Murciano et 
al., 1984; Aubier et el., 1983), Supinski et el. (1986) 
found that adenosine had no effect on the force of 
contraction of isolated guinea pig diaphragm, nor did it 
affect the increase in diaphragmatic tension produced by 
theophylline. 
1.3.2 - CARDIOVASCULAR EFFECTS 
a) - Vascular effects 
Drury & Szent- Györgyi (1929) first reported that 
adenosine increased coronary flow in a dog heart -lung 
preparation and reduced arterial blood pressure in dogs 
and cats. They concluded that adenosine is a coronary and 
systemic vasodilator. Subsequently it has been shown that 
adenosine causes potent vasodilation in many tissues 
including the heart (Wedd, 1931; Watt et al., 1987c), 
skeletal muscle (Dobson et al., 1971), brain (Berne et 
ál., 1974), adipose tissue (Sollevi & Fredholm, 1981) and 
gut (Granger & Norris, 1980). A different response has 
been seen in the kidney (see below) and hepatic veins 
where adenosine causes vasoconstriction. 
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In 1963 Berne proposed that adenosine may be a 
mediator of metabolic autoregulation of coronary blood 
flow. To date this hypothesis is unproven and evidence 
has been presented from various animal models which 
suggests that an adenosine -mediated effect is not 
necessary for the functional response to physiological 
stimuli such as increased work (e.g. Downing & Chen, 
1986; Bache et al., 1988). 
The mechanisms of adenosine -induced vascular smooth 
muscle relaxation remain to be fully elucidated. An 
endothelium -dependent mechanism has been demonstrated 
(Nees et el., 1987). However adenosine can also relax 
vascular smooth muscle directly (Herlihy et al., 1976). 
Alterations in cyclic AMP do not seem to be implicated in 
this response (Herlihy et al., 1976) but Kurtz (1987) 
showed that adenosine can stimulate guanylate cyclase, 
via an Al type receptor, and increase intracellular 
cyclic guanosine monophosphate, a known mediator of 
vascular smooth muscle relaxation. Fenton et al. (1982) 
suggested that adenosine causes smooth muscle relaxation 
by impairing calcium uptake during stimulation. 
As a coronary vasodilator adenosine has shown promise 
as an alternative to dipyridamole in the diagnosis of 
coronary disease by stress Thallium -201 myocardial 
scintigraphy (Verani et el., 1990) or 2- dimensional 
echocardiography (Trakhtenbroit et ál., 1990). It can 
also dilate coronary vein grafts (Torsell et al., 1985). 
Until recently the haemodynamic effects of the 
systemic administration of adenosine had been studied in 
detail only in laboratory animals. Since they cause 
systemic vasodilation the potential use of both ATP and 
adenosine as hypotensive agents during anaesthesia has 
been investigated in both animals and man (Fukunaga et 
el., 1982a; Fukunaga et el., 1982b; Fukunaga et el., 
1983). ATP may cause unwanted effects (Dedrick et el., 
1982; Boarini et al., 1984) and there is evidence that 
its action as a vasodilator depends on prior breakdown to 
adenosine (Sollevi et al., 1984a). 
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The reduction in blood pressure caused by adenosine 
is stable without either tachyphylaxis or rebound 
hypertension (Fukunaga et al., 1982a), possibly due to 
inhibition by adenosine of an increase in renin release 
(Lagerkranser et el., 1985). Adenosine has proved safe 
during administration at hypotensive doses for at least 
30 minutes (Öwall et al., 1987) although in occasional 
patients ECG changes suggesting myocardial ischaemia have 
developed (see Chapter 7). Although Sollevi (1986) 
reported that urine output is markedly reduced during 
adenosine - induced hypotension, postoperative serum 
creatinine concentrations were unchanged (Sollevi et ál., 
1984b) . 
Studies in anaesthetised animals and man which have 
examined the responses to systemic administration of 
adenosine will be discussed in Chapter 7. 
At the commencement of the present work little was 
known about the vascular effects of adenosine in 
conscious man. DiMarco et al. (1985) did not observe 
hypotension following bolus injections given to treat 
arrhythmias but the effects of continuous infusion had 
not been studied. 
b) - Electrophysiological effects 
Drury and Szent -Györgyi (1929) first reported slowing of 
the sinus rate and depression of AV conduction by 
adenosine in animals. Similar effects were subsequently 
observed following intravenous boluses in man (Honey et 
al., 1930; Jezer et al., 1933). More recently adenosine 
has been shown to be an effective treatment for 
supraventricular tachycardias in both adults and children 
(DiMarco et al., 1983; Watt et al., 1986a; Clarke et 
al., 1987; Till et al., 1989). Since adenosine slows 
conduction through the atrioventricular node it reduces 
the ventricular response to atrial tachyarrhythmias such 
as flutter and fibrillation (DiMarco et al., 1985). 
Reversal of atropine- resistant atrioventricular block 
complicating myocardial infarction by the adenosine 
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antagonist aminophylline suggests that an increased 
endogenous adenosine concentration might be implicated in 
the pathogenesis of that arrhythmia (Wesley et ál., 1986; 
Shah et al., 1987). 
The only patients with ventricular tachycardia in 
which adenosine has an antiarrhythmic effect comprise a 
small subset with exercise - induced arrhythmias and 
otherwise normal hearts (Lerman et al., 1986; Griffith et 
ál., 1988). Adenosine may therefore be useful for 
diagnosing the origin of broad complex tachycardias 
(Griffith et al., 1988; Rankin et al., 1989). 
The mechanisms of the electrophysiological effects 
remain to be fully elucidated (Bellardinelli & Lerman, 
1990) but include shortening of the action potential and 
membrane hyperpolarisation by increasing potassium 
conductance in the atrium (Bellardinelli et al., 1983) 
and antagonism of catecholamine- induced inward calcium 
currents in the ventricle (Isenberg & Belardinelli, 
1984) . 
c) - Effects on myocardial function 
Adenosine exerts a strong negative inotropic effect on 
atrial myocardium (Drury & Szent- Györgyi, 1929; Collis, 
1983; Böhm et al., 1985a), has little direct effect on 
ventricular function (Dobson, 1983) but can antagonise 
both the release of noradrenaline (Hedqvist & Fredholm, 
1979) and the ß- adrenoceptor mediated effects of 
catecholamines on contractility and metabolism of 
ventricular muscle (Schrader et al., 1977; Dobson, 1978; 
Endoh & Yamashita, 1980; Böhm et al., 1985b). It has been 
suggested that adenosine acts as a negative feedback 
modulator during stimulation of the ventricular 
myocardium by catecholamines (Dobson et ál., 1986). 
Whether the action on ventricular contractility is 
mediated by a reduced intracellular concentration 
(Dobson, 1983) or by a reduced effect (Böhm et el., 1984) 
of cyclic AMP remains controversial. 
Despite the above effects adenosine infusion has been 
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shown to improve myocardial recovery following 
cardioplegia, possibly by enhancing repletion of tissue 
adenine nucleotide content (Thelin et el., 1989; Bolling 
et al., 1990). 
1.3.3 - OTHER EFFECTS 
A wide range of other effects of adenosine has been 
reported (Watt & Routledge, 1986c; Anonymous, 1985). 
In the kidney adenosine infusion may cause transient 
vasoconstriction, a sustained redistribution in renal 
blood flow and a sustained reduction in glomerular 
filtration rate and salt and water excretion (Drury and 
Szent -Györgyi, 1929; Tagawa & Vander, 1970; Osswald, 
1975). The effect on renal blood flow and glomerular 
filtration correlates with the degree of activation of 
the renin -angiotensin system (Thurau, 1964; Osswald et 
el., 1978). Adenosine may inhibit renin release (Tagawa & 
Vander, 1970; Osswald et al., 1978), an effect which may 
contribute to its usefulness as a vasodilator (Fukunaga 
et el., 1982a; Lagerkranser et al., 1985). Katholi et al. 
(1984) showed that intrarenal infusion of adenosine in 
the dog causes increased sympathetic activity resulting 
in increased heart rate, cardiac output and blood 
pressure. The effects were abolished by renal 
denervation. 
In laboratory animals adenosine and its analogues 
cause marked behavioural effects such as sedation (Maitre 
et al., 1974; Dunwiddie & Worth, 1982), reduced locomotor 
activity (Dunwiddie & Worth, 1982) and induction of sleep 
(Haulica et el., 1973). Adenosine receptors have been 
identified throughout the brain (Bruns et al., 1987). 
Adenosine can modulate neurotransmission by inhibiting 
spontaneous and evoked neuronal firing and release of 
neurotransmitters (including acetylcholine, noradrenaline 
and dopamine) in the central and peripheral nervous 
system (Ginsborg & Hirst, 1972; Hedqvist & Fredholm, 
1976; Michaelis et el., 1979). Adenosine may also be 
implicated in hypoxic depression of neuronal activity in 
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the brain (Millhorn et al., 1984) and spinal cord (LLoyd 
et ál., 1988). Since methylxanthines such as caffeine and 
theophylline are adenosine antagonists their stimulant 
effects may be due to reversal of the central actions of 
adenosine (Snyder et ál., 1981). Adenosine can suppress 
ictal activity (Maitre et al., 1974; Dunwiddie & Worth, 
1982; Dragunow, 1986) and may be implicated in the 
actions of some anticonvulsants (Weir et al., 1984). 
Adenosine may have a rôle in the causation of pain 
although some of the evidence appears contradictory. 
Gourley and Beckner (1973) showed that intraperitonial 
injection of adenosine, or adenine and its nucleotides, 
antagonised the analgesic effect of morphine in mice. 
Furthermore Bleehen and Keele (1977) reported that 
adenosine caused pain when applied to blister bases in 
man. However Ho et al. (1973) showed that theophylline, a 
known adenosine antagonist, inhibited the analgesic 
effect of morphine in mice and Stone and Perkins (1979) 
suggested, on the basis of experiments in rats, that 
endogenous adenosine might mediate the analgesic effect 
of opiates. Morphine had been shown to enhance adenosine 
release from rat cerebral cortex (Fredholm & Vernet, 
1978; Phillis et ál., 1980b) and several groups have 
subsequently demonstrated anti -nociceptive effects of 
adenosine and its analogues in various animal models 
(Snyder et al., 1981; Yarbrough & McGuffin- Clineschmidt, 
1981; Ahlijanian et ál., 1985). 
However more recently Sylvén et el. (1986) observed 
that intravenous injections of adenosine in normal 
volunteers provoked chest pain and suggested that 
adenosine release during ischaemia may mediate the 
warning symptom of angina. Watt et al. (1987) also 
reported that in patients with recently active peptic 
ulcers intravenous injections of adenosine precisely 
reproduced their pain and Sylvén et ál. (1988) showed 
that injections of adenosine into the brachial artery of 
volunteers caused pain in the forearm. 
The apparent contradictions of studies so far suggest 
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that adenosine might have an analgesic action within the 
brain and spinal cord but an algogenic effect on 
peripheral nerves. The putative rôle of adenosine as a 
mediator of angina will be discussed further in Chapters 
4 and 7. 
Adenosine may cause hypothermia (Dunwiddie & Worth, 
1982) and various metabolic effects, e.g. antagonism of 
the effects of catecholamines in the heart (Schrader et 
el., 1977) and adipose tissue, and inhibition of insulin 
secretion but enhancement of its action (Schwabe et al., 
1974). 
Adenosine inhibits platelet aggregation in vitro 
(Born, 1964; Born et al., 1964; Edlund et al., 1987) and 
has been shown to reduce platelet consumption during 
cardiopulmonary bypass (Sollevi et el., 1985). Since the 
cellular uptake of adenosine is inhibited by 
dipyridamole, the antiplatelet effect of that drug might 
be mediated by an increase in the endogenous adenosine 
concentration. 
Adenosine may impair immune functions, e.g. at the 
high concentrations found in the rare condition adenosine 
deaminase deficiency adenosine may be toxic for lymphoid 
cells (Hershfield et ál.,1987). Adenosine has been shown 
to inhibit many activities of neutrophils, e.g. release 
of oxygen free radicals (Cronstein et al., 1987). Such 
effects may contribute to the observed reduction by 
adenosine of reperfusion injury in experimental animals 
(Olafsson et al., 1987). 
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1.4 - PROPOSALS FOR A THESIS 
The observation by Watt and Routledge (1985) that 
intravenous bolus injections of adenosine caused marked 
transient stimulation of respiration in man raised a 
number of questions: 
1) Is the respiratory stimulant effect of adenosine 
sustained during continuous infusion ? 
2) Do haemodynamic changes, e.g. hypotension, 
contribute? 
3) Does the response show tachyphylaxis? 
4) Is it dose -dependent? 
5) At what concentrations of adenosine are its 
effects produced? 
6) Is the effect produced by adenosine per se or 
one of its metabolites? 
7) Is the response modified by aminophylline, an 
antagonist at adenosine cell -surface receptors? 
8) Is the response potentiated by dipyridamole, an 
inhibitor of cellular uptake of adenosine? 
9) Is the effect mediated by the carotid body? 
11) Does intravenous adenosine cause broncho- 
constriction in normal subjects, patients with 
asthma or chronic airflow limitation? 
12) Does adenosine have a physiological rôle in the 
control of respiration? 
13) Is the response to intravenous adenosine altered 
in patients with respiratory failure? 
14) Does adenosine have a potential therapeutic rôle 
in respiratory failure? 
The work described in this thesis attempts to give 
answers to some of these questions and also to further 
pertinent questions raised as the work proceeded. 
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CHAPTER 2 - METHODS 
2.1 - GENERAL INTRODUCTION 
This chapter describes the methods and materials used for 
measuring respiration and plasma adenosine concentrations 
and the infusion technique employed. It also discusses 
some general and ethical considerations. Other methods 
used are described in the relevant chapters. 
2.2 - MEASUREMENT OF RESPIRATION 
2.2.1 - INTRODUCTION 
In all studies described in this thesis the subjects' 
respiration was measured. Measurement of minute 
ventilation and its component parts, respiratory 
frequency and tidal volume, has been widely used for the 
assessment of drug effects on the control of breathing 
(Jordan, 1982). Methods which employ either a mouth piece 
and nose clips or a closely fitting face mask have 
commonly been used but have several disadvantages. 
Firstly such methods can alter breathing pattern, mainly 
by increasing tidal volume (Gilbert et ál., 1972; 
Askanazi et al., 1980). Secondly it is harder for 
subjects to speak while using a mouth -piece or face mask, 
making it difficult for them to report adverse effects. 
Thirdly such apparatus may be uncomfortable and therefore 
not tolerated for long periods. For these reasons less 
invasive methods were employed in this work. Two methods 
were used, both of which rested upon the assumption that 
volume changes of the lungs could be estimated from 
changes in the external dimensions of the torso. These 
methods are now discussed. 
2.2.2 - RESPIRATION TRANSDUCER 
a) - Description and Use 
The initial equipment available was a respiration 
transducer (Type 4320. Lectromed Limited, St. Peter, 
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Jersey) which employs an elasticated band connected to 2 
strain gauges which form part of a Wheatstone bridge 
network. Changes in volume and therefore diameter of the 
thorax cause stretch of the elasticated band which, by 
Hooke's law, should cause a linearly related increase in 
tension. Changes in tension applied to the strain gauges 
alter the relative potential difference across the 2 
halves of the bridge network. The voltage difference 
between no load and a load of approximately 0.45 kg 
applied across the transducer is between 1 mV and 2 mV 
when an excitation voltage of 8 V is used. 
The elasticated band of the transducer was secured 
around the chest approximately at the level of the 
xiphisternum where respiratory excursions were maximum. 
The signal from the transducer was amplified and recorded 
using a chart recorder (Ormed MX 216). Respiratory 
frequency and tidal volume were determined manually from 
the recordings and used to calculate minute ventilation. 
b) - Volume Calibration 
For each subject approximately 10 separate breaths over a 
range of tidal volumes were recorded, in the posture 
maintained throughout the study, simultaneously using the 
respiration transducer and either a Vitalograph 
spirometer (Vitalograph Limited, Buckingham, England) or 
a Pocket spirometer (Micro Medical Instruments, Strood, 
Kent) which has been validated previously (Chowienczyk & 
Lawson, 1982). The recorded tidal volumes and transducer 
signal deflections for each subject were plotted and a 
regression line through the origin was fitted by the 
method of least squares to obtain a calibration curve. An 
example is shown in Fig. 2.1. 
c) - Reliability 
One indication of the precision of the technique is 
provided by the scatter of values about the regression 
lines obtained during volume calibration. In the study 
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Fig. 2.1 - Lectromed respiration transducer: example of a 
calibration curve. 
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volumes as calculated from the transducer output using 
the calibration curves were within ± 10% of the values 
measured simultaneously with a spirometer (n = 11). A 
mean of 57 (SD: 22) % of calculated breath volumes were 
within ± 20% of spirometer values (n = 11). 
The main limitation of the technique is that it 
assumes that the thorax moves with a single degree of 
freedom during respiration. As discussed below a more 
reliable estimate of the volume changes of the lungs is 
obtained when account is taken of the diaphragmatic 
contribution by separate measurement of abdominal wall 
motion. Therefore a technique employing such measurement 
was used for subsequent studies when it became available 
to me. 
Despite the limitations of the technique it proved 
adequate to answer the main questions posed in the 
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studies in which it was used, as described in Chapters 3 
and 4. 
2.2.3 - RESPIRATORY INDUCTANCE PLETHYSMOGRAPH 
a) - Description and Use 
An inductive plethysmograph was first described by 
Milledge and Stott in 1977, but the first description of 
a device employing separate measurement of rib cage and 
abdominal movement was published the following year (Cohn 
et al., 1978). The rationale for using such an approach 
was provided by Konno and Mead (1967) who showed that 
during breathing the behaviour of the respiratory system 
could be approximated by 2 degrees of freedom such that 
the volume change of the lungs is equal to the sum of the 
volume changes of the rib cage and the abdomen. 
The respiratory inductance plethysmograph (RIP; 
Respitrace Corporation, Ardsley, New York, USA) consists 
of 2 coils of Teflon insulated wire sewn in a zig -zag 
fashion onto separate elasticated bands. One band is 
placed around the rib cage with the upper edge just below 
the axillae and the other around the abdomen midway 
between the lower ribs and the iliac crests (Fig. 2.2). 
The coils are connected to a small oscillator unit. 
Respiratory movements cause changes in the cross - 
sectional area of each coil altering its self- inductance 
and the frequency of the oscillator to which it is 
connected. The relationship between change in area and 
frequency is linear (Cohn et el., 1982). The oscillator 
unit is connected via an optocoupler, to ensure 
electrical isolation, to a demodulator /calibrator unit. 
The demodulator provides DC output signals. There is an 
optional low pass filter with a time constant of 
approximately 100 s which can be used, in AC coupled 
mode, to restore signals to a fixed baseline. 
For the longer studies described in Chapters 5 and 7 
in which subjects were semi -recumbent I used an 
elasticated net around each subject's torso supplemented 
24 
Fig. 2.2 - The respiratory inductance plethysmograph. The 
rib -cage and abdominal bands can be seen held in place by 
an elasticated net. The bands are connected to the 
oscillator which has an output lead to the demodulator/ 
calibrator unit. 
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as necessary by sticking plaster to prevent movement of 
the RIP bands. Positioning marks were also made on each 
subject's skin so that slippage of the bands could be 
detected and corrected. These methods were not considered 
necessary for the shorter studies described in Chapters 6 
and 8 in which subjects were recumbent. Where subjects 
were semi -recumbent a foot board was used to prevent them 
slipping down the bed since this would have altered their 
posture and therefore the relative volume- motion 
coefficients of the rib cage and abdomen. 
Prior to all studies the demodulator /calibrator unit 
was allowed to warm up for at least 1 hour. The unit was 
always used in DC coupled mode to allow assessment of 
changes in end -expiratory volume from deviations of the 
baseline. The RIP signals and, when necessary, the 
spirometer signal were recorded on a chart recorder 
(Rikadenki, Model R -03). In 3 studies (Chapters 5, 6 and 
8) respiratory frequency and tidal volume were determined 
manually and used to calculate minute ventilation. For 
the study described in Chapter 7 the RIP signals were fed 
to both the chart recorder and to a BBC Master 
microcomputer, via its analogue to digital converters. A 
computer program (Respitrace Management Programme kindly 
supplied by Dr. J. R. Stradling, Radcliffe Infirmary, 
Oxford) was used to generate a breath -by- breath analysis 
of respiratory variables and to determine mean values 
during measurement periods. I found that the frequency of 
respiration, tidal volume and minute ventilation 
determined using this program correlate very highly with 
values obtained manually from a simultaneous chart 
recording. Artefacts, eg due to coughing or talking, were 
demonstrated by inspection of the traces recorded and 
were excluded from the analyses. 
b) - Calibration 
Based on the observations of Konno and Mead (1967) volume 
change of the lungs ((VOL) can be expressed as: 
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SVOL = A.SRC + B.SABD (Eq. 2.1) 
where SRC and SABD represent the change in the RIP 
signals of the rib -cage and abdomen respectively and A 
and B represent volume- motion coefficients linking change 
in these signals to change in volume. Once determined A 
and B can be used as gain factors for the corresponding 
RIP signals. The change in the sum of these signals, 
which can also be obtained from the demodulator/ 
calibrator unit, then becomes proportional to the change 
in lung volume. 
A number of techniques have been described for the 
determination of A and B in Eq. 2.1. Two were used in 
this study and are described here and discussed further 
in section c) below. 
1) Change in posture technique 
Based on the method of Chadha et al. (1982) this relies 
on the variation in relative contributions of rib cage 
and abdominal movement in different postures. Abdominal 
and rib cage excursions predominate in the supine and 
standing positions respectively (Sharp et el., 1975). 
Subjects recorded at least 10 breaths in both standing 
and supine positions whilst breathing into a rolling -seal 
spirometer (Ohio 840). Abdominal and rib cage RIP 
signals, with gains of both set to 1, and the spirometer 
signal were recorded simultaneously. Peak heights of the 
signals were measured and the graph of SRC /SV vs. SABD /SV 
plotted. This gives 2 clusters of points corresponding to 
the 2 postures. A regression line was then fitted using 
the method of least squares (Fig. 2.3). 
Rearrangement of Eq. 2.1 gives: 
SRC 1 B.SABD 
SV A A.SV 
(Eq. 2.2) 
From this it can be seen that the X and Y -axis intercepts 
of the graph represent 1/B and 1/A respectively. 
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y = -0.483x + 0.338 
r = -0.985 
r 2 = 0.970 
0 0.2 0.4 
ABD/VOL 
0.6 0.8 
Fig. 2.3 - Respiratory inductance plethysmograph: example 
of data obtained by changing posture from lying to 
standing and regression line used to determine rib -cage 
and abdominal volume -motion coefficients as described in 
the text. RC, ribcage deflection; ABD, abdominal 
deflection; VOL, corresponding spirometer deflection. 
2) Isovolume technique 
Konno and Mead (1967) also showed that during isovolume 
manoeuvres, in which, with the mouth piece occluded, a 
subject shifts air from the thorax to the abdomen by 
voluntary movements of his abdominal wall, the movements 
of the rib cage and abdomen show a high degree of 
dependency. The movements are paradoxical and since: 
A.SRC = -B.SABD (Eq. 2.3) 
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Subjects therefore performed isovolume manoeuvres in the 
posture maintained during the study and the mean of at 
least 10 estimations of - SABD /SRC was obtained. This 
estimate of A/B was used to set the rib cage signal gain 
with the abdominal signal gain set to 1. 
In the first study in this thesis in which the RIP 
was used (Chapter 5) the 2- posture technique was used. In 
all later studies (Chapters 6 to 8) the isovolume 
technique was used because of its simplicity. After 
determination of the absolute or relative volume 
coefficients by either method a final comparison was made 
between the RIP and a spirometer, in the posture 
maintained during the study, to obtain accurate volume 
calibration (Fig.2.4). A rolling -seal spirometer (Ohio 
840) was used in Chapters 5 and 8 and a Pocket Spirometer 
in Chapters 6 and 7. All volumes are expressed at body 
temperature, ambient pressure and saturation with water 
vapour (BTPS). 
c) - Reliability 
Methods used for the calibration of RIP broadly fall into 
2 groups: those that employ a change in body posture to 
obtain breaths of varying abdominal and ribcage 
contribution and those that perform calibration in a 
single posture. 
Cohn et al. (1982) described a 2- posture technique in 
which 2 simultaneous equations of the form of Eq. 2.1 
were solved to obtain values for A and B. More recently a 
least squares regression technique similar in concept to 
that described above was developed (Chadha et al., 1982). 
These methods have been criticised on the ground that a 
change in posture induces changes in the relative 
volume- motion coefficients of the abdomen and rib cage. 
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Fig.2.4 - Example of a volume calibration curve for the 
respiratory inductance plethysmograph, performed after 
initial determination of the rib -cage and abdominal 
volume- motion coefficients using the two posture 
technique. 
from the standing to the semirecumbent position caused 
changes of +20% and -21% in the rib cage and abdomen 
coefficients respectively. Using a 2- posture calibration 
technique these authors found that measurements of tidal 
volume by RIP deviated a mean of 16 to 17% from 
spirometer values in different postures. However they did 
not recalibrate RIP for absolute volume in each posture 
used for comparison. They also acknowledged that a tight 
linear relationship can exist between RIP and spirometer 
estimations of tidal volume in any position provided that 
the relative contributions of the rib cage and abdomen 
are nearly constant over the range of breaths measured. 
Despite the theoretical criticisms of the 2- posture 
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techniques several workers have found them to give 
acceptable results in practice. Cohn et al. (1982) found 
that using the simultaneous equation method 86% of mean 
tidal volumes in 7 different postures fell within ± 10% 
of spirometer values. Chadha et al. (1982) similarly 
found 93% of mean tidal volumes in 2 postures fell within 
± 10% when they used a least squares technique. In their 
hands this was more precise than they achieved using an 
isovolume technique, where 83% in the supine position and 
90% in the standing position fell within ± 10 %. However 
others have found the 2 techniques equally good (Gonzalez 
et ál., 1984; Dadzie et al., 1985). 
The most widely used single posture calibration 
technique has employed the isovolume manoeuvre as 
described above. This has been criticised because some 
subjects find the manoeuvre difficult to perform. An 
interaction between the rib cage and abdomen during the 
manoeuvre may lead to a consistent underestimation of the 
abdominal volume motion coefficient (Stradling et ál., 
1985). However Stradling et el. (1985) found the 
isovolume technique only slightly less reliable in normal 
subjects than a more sophisticated multiple linear 
regression technique. The latter technique relied on 
phase shifts between the abdomen and rib cage during 
ordinary breathing and multiple sampling of points within 
each breath to generate sufficient scatter in rib cage 
and abdomen contributions to allow computation of the 
volume motion coefficients. In patients with chronic 
obstructive airways disease the 2 calibration techniques 
were equally good ( Stradling et ál., 1985). 
Several workers have examined the reliability of the 
RIP in patients with chronic respiratory disease. It is 
recognised that a significant proportion of such patients 
may manifest abnormalities of thoracoabdominal motion 
such as indrawing of the costal margins on inspiration or 
paradoxical motion of the rib cage and abdomen (Ashutosh 
et ál., 1975; Sharp et al., 1977). Nevertheless several 
studies have shown that with care the RIP can be used in 
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such patients with an acceptable degree of accuracy 
(Tobin et ál., 1983; Gonzalez et al., 1984; Dadzie et 
el., 1985; Stradling et al., 1985). In these patients the 
estimates of the proportion of mean tidal volumes 
measured by RIP lying within ± 10% of spirometer values 
range from 57% (Dadzie et al. (1985) to 100% (Tobin et 
ál., 1983; Gonzalez et al., 1984) with 1- or 2- posture 
calibration techniques equally reliable. 
In view of the previous reports on the reliability of 
the RIP a formal validation was not performed as part of 
this work. However one indication of the precision of the 
technique is provided by the scatter of values about the 
regression lines obtained during volume calibration. In 
the study in normal subjects described in Chapter 5 a 
mean of 91 (SD: 10) % of breath volumes as calculated 
from the RIP output using the calibration curves were 
within ± 10% of the values measured simultaneously with a 
spirometer (n = 10). Furthermore a mean of 61 (SD: 17) % 
were within ± 5% of spirometer values (n = 10). 
A criticism of my use of the RIP is that the 
calibration was not checked after any study except the 
one described in Chapter 7. However all studies except 
those described in Chapters 5 and 7 were short, which 
would make the occurrence of significant changes in 
calibration less likely. It is conceivable that such 
changes occurred in the longer study described in Chapter 
5. However during the "placebo leg" of that study (see 
Chapter 5) mean baseline minute ventilation before the 
final infusion stage differed by only 5% from the value 
before the first adenosine infusion stage. It is 
therefore unlikely that a significant systematic change 
occurred. 
In the study in patients with chronic obstructive 
airways disease a check calibration was performed after 
the study and revealed a change in the volume calibration 
slope in some patients. This is discussed further in 
Chapter 7. Had changes in calibration of a similar 
magnitude occurred in any of the other studies the 
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possible resultant errors in measurement of minute 
ventilation would have been small compared with the 
changes caused by adenosine. It is therefore unlikely 
that any such change would have affected the conclusions. 
2.2.4. - DISCUSSION 
It has long been recognised that conscious and 
psychological factors can act as stimuli to breathing 
(Krogh & Lindhard, 1913). Even knowledge by a subject 
that he is undergoing an intervention that can affect 
respiration can do this (Barcroft et al., 1957). As far 
as possible such factors were avoided, eg by keeping 
unnecessary noise to a minimum. It was considered 
unethical not to inform subjects of the expected effects 
of adenosine. No patient had received adenosine 
previously but some of the normal subjects in the study 
described in Chapter 3 had. At the end of each infusion 
stage each subject was asked to report any symptoms and 
asked if he /she was willing to continue to the next 
stage. For this reason subjects were aware when infusions 
were being given. However all studies except those 
described in Chapters 4 and 6 employed a placebo or 
comparison infusion, with all infusions being given 
single -blind. Where subjects were studied on more than 
one occasion (Chapter 5) studies were done at the same 
time of day. 
2.3 - MEASUREMENT OF ADENOSINE CONCENTRATIONS 
2.3.1 - INTRODUCTION 
Several methods have been used to determine 
concentrations of nucleosides, such as adenosine, in 
biological materials. Previously one of the most widely 
used was a modification (Olsson, 1970) of a 
spectrophotometric method first developed by Kalckar 
(1947a,b). This method is, however, insensitive and 
requires large sample volumes. Numerous other methods 
have therefore been developed, including radioenzymatic 
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(Namm & Leader, 1974), competitive protein binding 
(Olsson et ál., 1978), enzymatic fluorometric (Gardiner, 
1979; Slowiaczek & Tattersall, 1982), radioimmunoassay 
(Schrader et ál., 1978; Sato et al., 1982), HPLC 
(Hartwick & Brown, 1977; Pfadenhauer & Tong, 1979; 
Fredholm & Sollevi, 1980) and chemiluminescent (Kather et 
el., 1987). 
Techniques using high performance liquid 
chromatography (HPLC) have recently been the most widely 
used, but some earlier methods lacked sensitivity 
(Hartwick & Brown, 1977). One refinement which provides 
greater sensitivity than methods using detection by 
ultraviolet absorption (Jacobson et al., 1983), has been 
the use of fluorometry to detect adenosine after its 
conversion to a fluorescent derivative (Barrio et al., 
1972; Kuttesch et al., 1978). Such a method was used in 
the present work. This was developed by WJ Penny and AC 
Newby (personal communication) as a modification of the 
method of Wojcik and Neff (1982) in which adenosine is 
converted to 1,N6- ethenoadenosine prior to 
quantification. This method is described below. 
Several workers have measured blood adenosine 
concentrations in man using various techniques. Reported 
values show considerable variation, for reasons that are 
not always immediately apparent. In peripheral venous 
plasma from normal volunteers the adenosine concentration 
has been found to range from undetectable (Hartwick & 
Brown, 1977) to 2 gM (Slowiaczek & Tattersall, 1982). 
Examples illustrating the range of reported values and 
techniques used are shown in Table 2.1. 
Several authors have stressed the importance of the 
blood sampling technique. As discussed in Chapter 1 red 
blood cells possess avid uptake mechanisms for adenosine 
which then undergoes intracellular metabolism. Various 
workers have shown that when small amounts of 
radiolabelled adenosine are added to human blood, the 
activity in plasma rapidly falls with a half -life of < 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Schrader, 1984). Adenosine transport into cells is 
inhibited by various compounds, of which the most studied 
is dipyridamole. At 10 -6 to 10 -5 M dipyridamole causes 
almost complete inhibition of adenosine uptake into red 
cells (Koss et al., 1962; Bunag et al., 1964; Klabunde, 
1983). Several workers have therefore mixed blood with 
dipyridamole solution either during or following sampling 
(Ontyd & Schrader, 1984; Grum et al., 1985; Biagionni et 
al., 1986). Ontyd and Schrader (1984) devised a 
double -syringe technique to allow rapid mixing of blood 
with a "stopping" solution containing dipyridamole 
during blood sampling (Fig. 2.5). Slowiaczek and 
Tattersall (1982) however found that when blood was 
sampled into a solution containing erythro-9-(2- hydroxy- 
3-nonyl) adenine (EHNA), an inhibitor of adenosine 
deaminase, (discussed further below) the addition of 
dipyridamole made little difference to the measured 
adenosine concentration. These workers only however 
measured basal adenosine concentrations. Cellular uptake 
of adenosine may have more effect on plasma adenosine 
concentrations when the latter are increased by the 
addition of exogenous adenosine (see Discussion below). 
Addition to sampled blood of inhibitors of adenosine 
deaminase such as EHNA, has been shown to result in 
higher measured adenosine concentrations (Slowiaczek & 
Tattersall, 1982; Tattersall et al., 1983). Capogrossi et 
al. (1982) could only detect adenosine in plasma when 
another such inhibitor, 2'- Deoxycoformycin, was used. 
Blood clotting has been shown to cause marked 
liberation of adenosine (Capogrossi et el., 1982) 
possibly from ADP released by activated platelets or 
nucleotides released from damaged red cells. Adenosine 
from such sources may have contributed to the high 
concentrations of adenosine reported by some workers. 
Anticoagulation of blood following sampling has been 
employed by several workers, eg Kuttesch et al. (1978), 
Capogrossi et al. (1982) and Slowiaczek and Tattersall 
(1982). This may not however be necessary provided plasma 
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Fig 2.5 - "Double- syringe" used for sampling blood for 
measurement of adenosine concentration. As blood is drawn 
into the larger syringe it is mixed with an ice -cold 
"stopping solution ", containing inhibitors of adenosine 
metabolism, expelled from the smaller syringe. 
is quickly separated and deproteinised. Furthermore 
dipyridamole, if used, inhibits platelet aggregation and 
thereby ADP liberation during the release reaction (Born 
& Cross, 1963). Even when they used anticoagulation 
Slowiaczek and Tattersall (1982) found that plasma 
purines gradually increased. This was partially but not 
completely prevented by cooling to 4 °C. Following removal 
of cellular elements plasma purines were "relatively 
stable" provided enzyme inhibitors were present. 
The blood sampling technique used in the present work 
employed rapid mixing of sampled blood with a "stopping" 
solution, rapid cooling and rapid separation and 
deproteinisation of plasma. 
2.3.2 - METHOD USED IN THIS STUDY 
a) - Blood sampling 
Blood (approximately 3 ml) for measurement of adenosine 
concentration was mixed during sampling with 1.5 ml of an 
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ice -cold "stopping" solution to inhibit metabolism of 
adenosine. For the study described in Chapter 5 the 
mixing was achieved by use of a double- syringe technique, 
as described by Ontyd and Schrader (1984) (Fig. 2.5). For 
the study described in Chapter 6 blood was drawn directly 
into syringes containing the "stopping" solution. This 
solution consisted of dilazep (Astra -Werke AG), a more 
potent inhibitor of cellular transport of adenosine than 
dipyridamole and EHNA (final concentrations: 
approximately 130 AM and 10 gM respectively) in 0.9% 
sodium chloride. 
b) - Extraction 
A 3 ml aliquot of the diluted sample was immediately 
separated by centrifugation (Eppendorf Model 5413) at 
8000 g for 30 s and 1.2 ml of the supernatant was 
deproteinised by addition of an equal volume of 10% (w /v) 
trichloroacetic acid at 4 °C. The mixture was allowed to 
stand on ice for at least 5 min and was then centrifuged 
at 1200 g for 15 min at 4 °C. The deproteinised 
supernatant was neutralised using paired ion extraction 
(Khym, 1975) by shaking it with a mixture of 
tri -n- octylamine (0.9 g) and 1,1,2- trichlorotrifluoro - 
ethane (5 ml) until the pH was at least 5.5. The aqueous 
phase was filtered (Millipore GS 0.22 µm) and then stored 
at -20 °C for later analysis. 
c) - Assay 
Samples (0.5 ml) of neutralised deproteinised plasma were 
incubated with 0.05 ml of 0.5 M ammonium acetate buffer 
(pH 5) and 0.025 ml of 4 M bromoacetaldehyde for 20 min 
at 80 °C to convert adenosine to 1,N6- ethenoadenosine. The 
reaction was stopped on ice. Aqueous solutions of 
standard concentrations of adenosine (0, 0.0025, 0.025, 
0.25 and, in some cases, 1 AM) were also processed in 
this way. The resultant ethenoadenosine standards were 
used to construct a 4 -point calibration curve for each 
batch of samples assayed (Fig. 2.6). There was a linear 
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Fig. 2.6 - Adenosine assay: typical calibration curve. 
The inset shows the data (excluding the point for a 
concentration of 0 µM) plotted on a log -log curve (see 
section 2.3.3). 
relationship between the ethenoadenosine fluorescence 
peak heights and the adenosine concentrations (r > 
0.999). Peak heights were therefore used for measurement 
of samples. 
Penny and Newby (personal communication) showed that 
conversion to ethenoadenosine of standard adenosine (0.25 
.M) added to deproteinised plasma was 92 (SD: 4) % (n = 
10) after taking into account the endogenous adenosine in 
plasma. I compared chromatographic peak heights of 
aqueous solutions of commercially produced etheno- 
adenosine and derivatised standard adenosine (both 0.025 
AM). This suggested conversion of 102 (SD: 18) % (n = 6) 
of adenosine to ethenoadenosine. 
1,N6- ethenoadenosine was quantified by HPLC using 
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fluorometric detection (excitation at 254 nm and emission 
at 300 to 400 nm) (LDS Fluoromonitor 111) with output to 
a chart recorder (Servogar BBC). Samples (200 µl) were 
chromatographed isocratically at ambient temperature on a 
250 x 4.6 mm column of Apex ODS (Jones Chromatography 
Ltd., Llanbradach, S. Glam.) using ammonium acetate 
buffer (pH 4.5) containing 7% acetonitrile as eluate at a 
flow rate of 1.5 ml /min (LDC Constametric 111 pump). 
Ethenoadenosine in samples was identified primarily 
by retention time, determined from injected standard 
solutions of ethenoadenosine. For selected samples a 
duplicate was either "spiked" with ethenoadenosine to 
increase the peak height or the adenosine peak was 
removed by incubating the sample, prior to 
derivatisation, with adenosine deaminase which converts 
adenosine to inosine (Wojcik and Neff, 1982) (Fig. 1.2). 
Addition of 10 gl of an aqueous solution containing 0.9 
units (0.016 mg) of adenosine deaminase per 200 gl 
aliquot of the neutralised deproteinised plasma and 
incubation at room temperature for 30 min resulted in 
almost complete removal of the adenosine peaks in the 
samples tested (Fig. 2.7). 
d) - Quantification 
The plasma concentration of adenosine was determined from 
the measured concentration of ethenoadenosine by the 
following equation: 
[adenosine] = [ethenoadenosine] x 2 / A (Eq. 2.5) 
where the factor 2 corrects for dilution by 
trichloroacetic solution and A corrects for dilution by 
the stopping solution during sampling: 
A = (1 
/ H1) 1 
x 
M1 
(1 / H2) - 1 M2 
(Eq. 2.6) 
Here H1 and H2 are the haematocrits of the patients blood 
before and after dilution by the stopping solution, and 
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Fig. 2.7 - Adenosine assay: a) typical chromatogram 
showing ethenoadenosine peak (arrow); b) a duplicate 
sample showing removal of the ethenoadenosine peak by 
prior incubation of the sample with adenosine deaminase. 
before and after dilution. The correction for red cell 
size was made because I found that M2 was often slightly 
larger than M1, possibly because of an osmotic effect of 
the stopping solution. 
e) - Reliability of the blood sampling technique 
Sampling of blood through a catheter as was done in the 
study described in Chapter 6 poses particularly problems. 
Firstly adenosine might be liberated into plasma from 
adenine nucleotides released from activated platelets or 
damaged red cells. Secondly the very rapid turnover of 
adenosine in blood might reduce the plasma concentration. 
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Penny and Newby (personal communication) found that 
the basal adenosine concentration in blood drawn through 
a catheter might be slightly higher than in blood drawn 
through a short cannula. I found in a small comparison in 
one subject that there was no significant difference 
between the adenosine concentration in blood drawn 
through a short cannula, 0.05 (SD: 0.01) gM (n = 2), and 
blood sampled through a narrow plastic infusion line 1 m 
long connected to a cannula, 0.06 (SD: 0.01) µM (n = 6). 
However the 95% confidence interval for the difference is 
consistent with the concentration in blood drawn through 
the infusion line being 0.04 µM higher or 0.01 µM lower 
than blood sampled through the cannula only. If this 
indicates the maximum expected error for basal adenosine 
concentrations when sampling through a catheter then this 
is acceptable for studies where changes in adenosine 
concentration of the magnitude reported in Chapter 6 (up 
to 2 AM) are found. The large changes observed during 
adenosine infusion in that study are unlikely to have 
been due to blood clotting in the catheters, since the 
values at baseline and following the infusion were the 
same (see Chapter 6). 
When plasma adenosine concentration is acutely 
increased net transport into cells occurs. Möser et ál. 
(1989) showed that in vitro, at plasma concentrations in 
the range 1 to 5 AM, exogenous adenosine has a half -life 
of approximately 1.5 s. The transit time of blood through 
the sampling catheters in the study described in Chapter 
6 was approximately 0.75 s, as estimated in vitro. 
Therefore the measured concentrations, at the highest 
infusion rates of adenosine, may have underestimated, but 
were very probably of the same order of magnitude as, the 
true values. 
Comparison of the double syringe technique with a 
single syringe technique showed no significant difference 
in mean plasma concentrations obtained. With the single 
syringe the measured concentration in a single subject 
was 0.06 (SD: 0.02) µM (n = 4) compared with 0.05 (SD: 
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0.01) µM (n = 4) with the double syringe technique. The 
difference between the variances was not significant but 
the 95% confidence interval was compatible with the 
variance using the single syringe technique being up to 
8 -fold higher, i.e. implying a greater scatter of 
results. Since I found no evidence of a large difference 
in mean concentrations measured by the 2 sampling 
techniques the single syringe technique was used for 
blood sampling down catheters (see Chapter 6) because it 
was practically much simpler. 
f) - Reliability of the assay 
Penny and Newby (personal communication) assessed 
recovery of adenosine during the sampling procedure by 
adding 2,5,8 -3H- adenosine (0.25 AM) to the stopping 
solution. Chromatography of the neutralised plasma 
extracts showed recovery of 105 (SD: 4) % (n = 7) of the 
3H- adenosine in the adenosine peak. I assessed recovery 
using a somewhat cruder technique. In a single subject 
multiple blood samples for measurement of adenosine 
concentration were taken on two occasions. The stopping 
solution used for some of these was "spiked" with 
adenosine at one of three concentrations (0.06 AM, 0.6 µM 
or 2.4 AM). Recovery of the added adenosine was estimated 
by comparing the measured adenosine concentration in each 
"spiked" sample with a paired "unspiked" sample. 
Estimated recovery at the three concentrations was 108 
(SD: 158) %, 107 (SD: 19) % and 113 (SD: 16) % 
respectively (n = 6 for each estimate). 
In my hands the detection limit of the assay was 
0.001 gM (equivalent to undiluted plasma adenosine 
concentration < 0.01 AM). 
I determined coefficients of variation by assaying 
paired samples of 2 standard adenosine solutions (0.01 
and 1.0 AM). One sample of each pair was assayed at the 
beginning and one at the end of a batch of assays. 
Coefficients of variation, C, were calculated using the 
formula: 
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C = s / µ x 100 (Eq. 2.7) 
where s is the standard deviation and g the mean of a 
group of measured concentrations. For intra -assay 
coefficients the mean of values obtained from several 
paired samples was calculated. Results were: 
1) Mean intra -assay coefficients of variation: 
9% (n = 8) at 1.0 pM (equivalent to plasma adenosine 
concentration approximately 5 to 10 AM) and 18% (n = 6) 
at 0.01 µM (equivalent to plasma adenosine concentration 
approximately 0.05 to 0.1 AM). 
2) Interassay coefficients of variation: 
16% (n = 10) at 1.0 µM and 27% (n = 14) at 0.01 AM. 
2.3.3 - DISCUSSION 
Recently further workers have made pertinent observations 
on measurement of adenosine concentrations in man. Hamm 
et ál. (1988) reported that neither breakdown of 
adenosine by plasma enzymes nor binding of adenosine to 
plasma proteins precipitated during acid extraction 
caused significant loss of recovery of adenosine. The 
first of these observations is at variance with some 
previous reports which are discussed above. Hamm et ál. 
also observed that adenosine was rapidly generated in 
incubated plasma, presumably from adenine nucleotides, 
suggesting that enzyme inhibitors should be used to 
prevent this. However Ontyd and Schrader (1984) 
previously found that addition of a,ß- methylene adenosine 
5'- phosphate, an inhibitor of the 5'- nucleotidase 
responsible for extracellular nucleotide degradation, 
made no difference to their measured adenosine 
concentrations. Ontyd and Schrader used a system of blood 
sampling very similar to that employed in the present 
work. Hamm et al. (1988) also confirmed the previously 
reported rapid turnover of adenosine and found that rapid 
cooling of blood was more effective than dipyridamole in 
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preventing this. 
Möser et el. (1989) recently reported that incubation 
of heparinised blood for up to 1 hour after sampling had 
little effect on the basal adenosine concentration 
suggesting that at such concentrations an equilibrium 
exists between influx and efflux of plasma adenosine. 
Furthermore use of a "stopping" solution containing 
dipyridamole and EHNA during blood sampling had little 
effect on measured basal values. They also found that 
degradation of extracellular nucleotides contributed 
greatly to the formation of adenosine in that steady 
state. They confirmed the rapid turnover of adenosine and 
showed that when the plasma adenosine concentration was 
increased to approximately i gM the subsequent fall was 
rapid with a half -life of 1.4 s. This suggests that 
measures to inhibit adenosine metabolism during blood 
sampling are more important when concentrations are 
increased than at basal values. The implications of the 
findings of Möser et al. will be discussed further in 
Chapter 6. 
There are several possible criticisms of the present 
assay. Samples required considerable processing prior to 
chromatography which was a fairly slow process so that 10 
to 15 samples at most could be analysed per day. It 
became apparent towards the end of the work that large 
changes in ambient temperature affected the etheno- 
adenosine peak retention time and the separation of this 
peak from adjacent peaks. Therefore determination and 
maintenance of the optimum column temperature might have 
increased the precision of the assay. Minor changes in 
the acetonitrile concentration were sometimes necessary 
to improve separation of the ethenoadenosine peak. For 
this reason samples were injected manually rather than 
automatically. An initial purification step, e.g. using 
phenyl boronate affinity gel as employed by several 
workers, might have improved the chromatographic 
separation. 
An internal standard was not used. However recovery 
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during the sampling procedure was high and adenosine 
standard solutions used for calibration were submitted to 
the derivatisation process at the same time as samples to 
correct for incomplete derivatisation to ethenoadenosine. 
The concentrations of adenosine used for calibration 
curves were such that the slope of the linear regression 
line was heavily influenced by the point at the highest 
concentration (Fig. 2.6). It might have been preferable 
to calculate calibration curves after plotting the data 
on a log -log plot. However, as shown in Fig. 2.6 (inset), 
concentrations determined from such a curve are unlikely 
to have been very different from those obtained from the 
non -logarithmic plot. Coefficients of variation were high 
but, as shown in Chapter 5, the assay was sensitive 
enough to detect a change in the mean adenosine 
concentration as small as 0.03 µM. 
2.4 - INFUSION TECHNIQUE 
All infusions were administered using a Harvard infusion 
pump, model 2681 and 50 ml plastic syringes. Except where 
indicated, infusions were given via a plastic cannula 
inserted in an antecubital vein. Flow rates of 27 to 281 
ml /h were used. Successive increments using this pump 
follow an approximate geometric progression with a ratio 
of 1.4:1. 
Infusion fluids were sterile solutions of adenosine 
or inosine (Sigma Chemical Company) at a concentration of 
5 mg /ml in 0.9% sodium chloride, 0.9% sodium chloride, or 
aminophylline (6 mg /kg in 30 ml sterile water). Solutions 
of adenosine and inosine for human use were prepared 
according to usual quality control criteria by the 
Pharmacy Department, University Hospital of Wales, Heath 
Park, Cardiff. 
2.5 - GENERAL CONSIDERATIONS 
Except where indicated subjects were asked to abstain 
from caffeine -containing beverages on any day of study. 
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2.6 - ETHICAL AND SAFETY CONSIDERATIONS 
Protocols for all studies were submitted to and approved 
by the ethics committee of the Division of Medicine, 
South Glamorgan Health Authority. All subjects gave 
informed, written consent to their inclusion in the 
relevant study. 
With one exception (see Chapter 5) patients or 
volunteers with a history of asthma were not studied, 
because of the known bronchoconstrictor effect of inhaled 
adenosine in such patients. Aminophylline, which was 
considered to be a probable antagonist of the 
cardiovascular and respiratory effects of adenosine, was 
available for intravenous administration if necessary 
during all studies. All subjects were aware that any 
infusion would be stopped at any point at their request. 
2.6 - STATISTICAL METHODS 
Standard statistical methods were used throughout (Zar, 
1984). Individual methods used are indicated in each 
chapter. A frequently used method was repeated measures 
(randomised block) analysis of variance (referred to in 
this thesis as ANOVA). For occasional missing values 
estimates were obtained and the degrees of freedom for 
ANOVA were appropriately modified using the method of 
Glenn and Kramer (1958). Computation was performed using 
an IBM compatible personal computer (Amstrad 1640, 
Amstrad PLC) and a spreadsheet (Ability, Migent (UK) 
Ltd.) or a pocket personal computer (Casio FX -720P, Casio 
Computer Company Ltd., Japan). Some of the programmes for 
the latter were written by Professor Philip Routledge. 
All other programmes were written by the author. In all 
analyses significance was assumed if P was less than 
0.05, unless otherwise stated. 
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CHAPTER 3 - A COMPARISON OF THE CARDIOVASCULAR AND 
RESPIRATORY EFFECTS OF INTRAVENOUS INFUSION OF ADENOSINE 
AND INOSINE 
3.1 - INTRODUCTION 
As discussed in Chapter 1 Watt and Routledge (1985) 
observed dose -dependent stimulation of respiration in man 
produced by intravenous boluses of adenosine. In view of 
the very short half -life of adenosine significant 
metabolism of adenosine would be expected during the 15 
to 20 s interval Watt and Routledge observed between 
injection of adenosine and the onset of respiratory 
stimulation. It was therefore unclear whether the 
observed effects on respiration were due to adenosine 
itself or a metabolite. 
Furthermore adenosine had been reported to cause 
hypotension when infused during anaesthesia (Sollevi et 
al., 1984a). If a similar effect was produced in 
conscious subjects this might cause respiratory 
stimulation (Landgren & Neil, 1951; Heistad et al., 
1975). Watt and Routledge did not measure blood pressure 
during their studies with adenosine boluses. 
The adenosine - induced increase in respiration 
observed by Watt and Routledge was a transient phenomenon 
following intravenous bolus injections. It was not known 
whether a sustained effect would be seen during 
continuous infusion. 
To address the above points the effects on 
respiration, heart rate and blood pressure of intravenous 
infusions of adenosine and its metabolite inosine were 
compared. 
3.2 - SUBJECTS AND METHODS 
3.2.1 - SUBJECTS 
The subjects were 8 healthy volunteers (7 male) aged 23 
to 33 years (Appendix 1). 
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3.2.2 - INFUSION PROTOCOL 
Adenosine and inosine were administered in random order, 
single- blind, by intravenous infusions separated by 30 
min. This interval was chosen on the basis of the finding 
in a pilot study that the cardiorespiratory effects 
produced by adenosine infusion resolve within 1 to 2 min 
of stopping the infusion. The infusion rate of each 
nucleoside was initially 3.1 mg /min and was increased 
stepwise every 2 min up to a possible maximum of 23.4 
mg /min (maximum possible number of stages: 7). Each 
infusion was discontinued following the maximum dose or 
earlier at the request of a subject. 
3.2.3 - MEASUREMENTS 
A single -lead electrocardiogram (ECG) was monitored 
throughout each infusion. Recordings of the ECG and 
measurements of blood pressure (using an Accoson mercury 
sphygmomanometer, taking phase five as diastolic) were 
made at baseline and at 1 min intervals throughout each 
infusion. Respiration was recorded using a respiration 
transducer (Lectromed type 4320) as described in Chapter 
2. End -tidal PCO2 (PETCO2) was measured continuously in 
gas sampled by a fine -bore cannula, whose tip was clipped 
to the upper front teeth, using a high speed response CO2 
analyser (Type 901 MK 2. PK Morgan Limited). The 
respiratory and PCO2 traces were recorded on an Ormed 
MX216 recorder. Respiratory variables were subsequently 
derived from the traces obtained: respiratory rate (fR), 
tidal volume (VT), minute ventilation (V) and PETCO2 at 1 
minute intervals, and inspiratory duration (T1), 
expiratory duration (TE), total breath duration (TTOT) 
and mean inspiratory flow rate (VT /TI) at baseline and at 
the maximum doses of each compound. The end -expiratory 
plateau in the CO2 trace was used since this provides an 
approximate measure of the arterial PCO2 ( Bülow, 1963). 
Subjects were asked to report any symptoms at 1 min 
intervals and were aware that an infusion would be 
stopped immediately at their request. In four subjects 
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(nos. 4,5,6 and 7) spirometry was performed prior to and 
immediately after each infusion using a Pocket Spirometer 
(Micromedical Instruments, Strood, Kent). 
3.2.4 - STATISTICAL ANALYSIS 
Comparisons of respiratory rate, tidal volume, minute 
ventilation, PETCO2, heart rate and blood pressure at 
different infusion rates, up to 8.5 mg /min for adenosine 
and 16.8 mg /min for inosine, were made using repeated 
measures analysis of variance and Student -Newman -Keuls 
test. Student's paired t -test was used to compare 
baseline values of the above variables as well as VT /TI 
and inspiratory duration over total breath duration 
(TI /TTOT) with values at the maximum dose of each 
nucleoside, and to compare spirometric variables (peak 
expiratory flow rate (PEFR), forced expiratory volume in 
1 s (FEV1) and forced vital capacity (FVC)) before and 
after each infusion. In one subject (no. 8) the study was 
stopped because of occipital headache and in one subject 
(no. 7) an inadequate respiratory trace was obtained. All 
data, apart from symptoms and spirometry, were therefore 
analysed for six subjects. 
3.3 - RESULTS 
The maximum dose rates received ranged from 8.5 to 23.4 
mg /min (mean: 13.5, SD: 5.7 mg /min) for adenosine and 
16.8 to 23.4 mg /min for inosine. Data are therefore 
presented for infusion rates up to 8.5 mg /min and for the 
maximum infusion rate received by each subject for 
adenosine and for infusion rates up to 16.8 mg /min for 
inosine. 
3.3.1 - CHANGES IN RESPIRATION DURING ADENOSINE INFUSION 
The effects of adenosine infusion on respiratory rate, 
tidal volume, minute ventilation and PETCO2 are shown in 
Fig. 3.1. During adenosine infusion minute ventilation 
increased significantly from 6.6 (SD: 4.5) 1 /min at 
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Fig. 3.1 - Changes in respiratory rate, tidal volume, 
minute ventilation and end -tidal PCO2 during adenosine 
infusion. *P < 0.05; * *P < 0.01; * * *P < 0.001 for 
comparisons with baseline values. n = 6 except for 
minutes 1 and 2 where n = 5. 
8.5 mg /min, and 19.2 (SD: 11.2) 1 /min at the maximum 
infusion rate (P < 0.001 and P < 0.005 respectively). 
These changes were predominantly due to an increase in 
tidal volume from 0.54 (SD: 0.39) 1 at baseline to 0.94 
(SD: 0.36) 1 during adenosine infusion at 8.5 mg /min, and 
1.20 (SD: 0.63) 1 at the maximum infusion rate (P < 0.001 
and P < 0.05 respectively). 
Respiratory rate at the maximum dose of adenosine, 16 
(SD: 4) breaths /min, was significantly greater than the 
baseline value, 13 (SD: 3) breaths /min (P < 0.01). There 
were no other significant changes in respiratory rate. 
The increase in minute ventilation during adenosine 
infusion was accompanied by an increase in VT /TI from 17 
(SD: 10) 1 /min at baseline to 47 (SD: 21) 1 /min at the 
maximum infusion rate (P < 0.05). TE fell from 3.1 (SD: 
1.0) s at baseline to 2.4 (SD: 0.9) s at the maximum 
infusion rate (P < 0.01) but there was no significant 
change in T1 (mean: 1.7, SD: 0.5 s at baseline vs. mean: 
1.5, SD: 0.5 s at the maximum infusion rate) or TI /TTOT 
(mean: 0.36, SD: 0.09 at baseline; mean: 0.39, SD: 0.07 
at the maximum infusion rate). 
PETCO2 fell significantly from 38 (SD: 3) mmHg at 
baseline to 32 (SD: 4) mmHg during adenosine infusion at 
8.5 mg /min, and 27 (SD: 5) mmHg at the maximum infusion 
rate (P < 0.001 and P < 0.01 respectively). 
3.3.2 - CHANGES IN HEART RATE AND BLOOD PRESSURE DURING 
ADENOSINE INFUSION 
Heart rate increased from 67 (SD: 7) beats /min at 
baseline to 86 (SD: 15) beats /min during adenosine 
infusion at 8.5 mg /min, and 105 (SD: 9) beats /min at the 
maximum infusion rate (P < 0.01 and P < 0.001 
respectively) (Fig. 3.2). One subject developed a 
transient bradycardia of 30 beats /min with second degree 
heart block for a few beats during breath -holding 
immediately after discontinuing adenosine infusion (at 
16.8 mg /min). His rhythm quickly reverted to sinus 
tachycardia. In no other subject was a bradycardia seen. 
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Fig. 3.2 - Changes in heart rate and blood pressure 
during adenosine infusion. Significance symbols as in 
Fig. 3.1. n = 6 except for minutes 1 and 2 where n = 5. 
Systolic blood pressure increased significantly from 
120 (SD: 10) mmHg at baseline to 131 (SD: 11) mmHg during 
adenosine infusion at 8.5 mg /min, and 134 (SD: 15) mmHg 
at the maximum infusion rate (P < 0.01 and P < 0.05 
respectively). Diastolic blood pressure changed 
biphasically, increasing from 73 (SD: 14) mmHg at 
baseline to 80 (SD: 10) mmHg during adenosine infusion at 
4.3 mg /min, with a subsequent fall to 66 (SD: 19) mmHg at 
the maximum infusion rate. These changes were, however, 
not statistically significant. 
Significant hypotension did not occur during 
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Fig. 3.3 - Respiratory rate, tidal volume, minute 
ventilation and end -tidal PCO2 during inosine infusion. 
n = 6 except for minute 2 where n = 5. 
3.3.3 - HAEMODYNAMIC AND RESPIRATORY VARIABLES DURING 
INOSINE INFUSION 
In contrast to the changes observed during adenosine 
infusion, no significant changes in the above variables 
were observed during inosine infusion, despite the higher 
maximum infusion rate (16.8 mg /min) received by all 
subjects. Respiratory variables are shown in Fig. 3.3 and 
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Fig. 3.4 - Heart rate and blood pressure during inosine 
infusion. n = 6 except for minute 2 where n = 5. 
Results for VT /TI, T1, TE and TI /TTot (baseline vs. 
infusion at 16.8 mg /min) were 21 (SD: 10) 1 /min vs. 19 
(SD: 7) 1 /min, 1.5 (SD: 0.6) s vs. 1.7 (SD: 0.5) s, 3.4 
(SD: 0.7) s vs. 3.3 (SD: 0.9) s, and 0.31 (SD: 0.08) vs. 
0.34 (SD: 0.10) respectively (all changes not 
significant) . 
3.3.4 - SPIROMETRY 
No subject reported wheeziness and spirometry showed no 
significant changes following either adenosine or inosine 
in the four subjects tested (Table 3.1). 
55 
Table 3.1 - Spirometry before and after adenosine and 
inosine infusion (best of 3 readings for each subject). 







PEFR (1/min) 635 594 572 588 
(65) (48) (60) (73) 
FEV1 (1) 4.25 4.10 4.12 4.19 
(0.50) (0.47) (0.45) (0.49) 
FVC (1) 5.24 5.27 5.20 5.30 
(0.63) (0.56) (0.72) (0.63) 
3.3.5 - SYMPTOMS 
During adenosine infusion facial flushing was reported by 
all 8 subjects, dyspnoea by 7, throat discomfort by 5, 
epigastric discomfort by 4, headache by 4, paraesthesiae 
by 3 and retrosternal discomfort by 2. One subject was 
able to tolerate the maximum dose of adenosine infused 
(23.4 mg /min). In all other subjects the infusion was 
stopped at a lower dose rate because of the degree of 
dyspnoea and other sensations experienced. All sensations 
resolved within 1 to 2 min after stopping the infusion. 
During inosine infusion one subject reported 
lightheadedness but all other subjects were asymptomatic. 
3.4 - DISCUSSION 
3.4.1 - CHANGES IN RESPIRATION DURING ADENOSINE AND 
INOSINE INFUSION 
This study confirms the dose -dependent respiratory 
stimulant effect of adenosine in man, which was first 
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demonstrated as a transient phenomenon following 
intravenous boluses of adenosine (Watt & Routledge, 
1985), and shows that ventilatory stimulation is 
sustained during infusion of the nucleoside. At the 
maximum infusion rate minute ventilation was trebled and 
mean PETCO2 reduced by 11mmHg. Several workers have 
reported similar observations (Maxwell et al., 1986; 
Fuller et el., 1987; Biaggioni et al., 1987). 
As discussed in Chapter 1 adenosine is rapidly 
removed from the circulation principally by cellular 
uptake followed by metabolism. The present study has 
shown that intravenous inosine is without effect on 
respiration in the dose range studied. Therefore the 
respiratory stimulation produced by adenosine in this 
dose range does not depend on prior metabolism to 
inosine. These observations are supported by the findings 
of Norsted et al. (1987) that whereas intravenous and 
intracarotid injections of adenosine increased central 
inspiratory activity in anaesthetised cats inosine did 
not. Recently Lagerqvist et el. (1990) have also shown, 
using intravenous bolus injections, that inosine does not 
stimulate respiration nor cause chest discomfort such as 
can be caused by adenosine. 
This study does not exclude the possibility that 
phosphorylation of adenosine is a prerequisite for its 
respiratory stimulant effect. However, as discussed in 
later chapters, there is considerable evidence that 
adenosine stimulates respiration at least in part by an 
action in the carotid bodies and it has been shown in the 
cat that a stable analogue of ATP does not stimulate the 
peripheral chemoreceptors (McQueen & Ribeiro, 1983). In 
addition studies in animals using long acting analogues 
of adenosine suggest that it acts via cell surface 
receptors of the A2 subtype in the carotid body (Monteiro 
& Ribeiro, 1987). 
It has been suggested that useful information can be 
gained about the effects of ventilatory stimuli on the 
control of breathing by analysis of the component parts 
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VT / T1 = MEAN INSPIRATORY FLOW 
Fig. 3.5 - Diagram of a single respiratory cycle. Insp, 
inspiration; Exp, expiration. Other abbreviations as in 
text. 
of ventilation. 
Milic -Emili and Grunstein (1976) expressed minute 
ventilation in an equation of the form: 




In this analysis mean inspiratory flow, VT /TI is regarded 
as an index of "inspiratory drive" and TI /TTOT represents 
an index of "respiratory timing ". VT /TI has been shown to 
be closely related to the level of chemical stimulation 
(Gardner, 1975; Newsom Davis & Stagg, 1975) and can 
provide a reasonable index of "inspiratory drive" 
provided inspiration starts at functional residual 
capacity and the mechanical properties of the respiratory 
system are fixed (Milic -Emili & Grunstein, 1976). 
The changes observed in this study during adenosine 
infusion, namely an increase in VT /TI and a reduction in 
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TE are qualitatively similar to those produced by a 
number of respiratory stimuli, including hypoxia and 
hypercapnia (Gardner, 1975; Remmers, 1976). We found no 
change in T1 during adenosine infusion. It has been 
suggested that whereas T1 may remain constant during 
hypercapnia until a threshold level of tidal volume is 
reached for termination of inspiration by Hering- Breuer 
reflexes (Clark & von Euler, 1972; Rebuck et al., 1976) 
there is a progressive shortening of inspiratory duration 
during progressive isocapnic hypoxia (Rebuck et al., 
1976). Others, however, have found no consistent change 
in inspiratory duration during ventilatory stimulation by 
hypoxia, hypercapnia and exercise (Cunningham & Gardner, 
1972; Jennett et ál., 1974; Newsom Davis & Stagg, 1975). 
In any case a reduction in inspiratory duration when it 
occurs is considerably less than the reduction in 
expiratory duration. As shown by a later study (Chapter 
5) functional residual capacity is probably increased by 
adenosine infusion, as it may be by hypoxia and 
hypercapnia, so mean inspiratory flow may not be a very 
reliable index of inspiratory drive in this situation. 
3.4.2 - CHANGES IN HEART RATE AND BLOOD PRESSURE DURING 
ADENOSINE INFUSION 
As discussed in Chapter 1 adenosine acts as a vasodilator 
in several vascular beds and both ATP, which is rapidly 
hydrolysed to adenosine in vivo, and adenosine have been 
used as hypotensive agents in man (Fukunaga et el., 
1982b; Sollevi et ál., 1984b). In the present study 
adenosine did not cause hypotension. On the contrary a 
slight, but statistically significant, increase in 
systolic blood pressure was observed. The observed 
respiratory stimulation is therefore not attributable to 
hypotension. A similar conclusion has been reached by 
others (Maxwell et al., 1986; Fuller et ál., 1987; 
Biaggioni et el., 1987; Smits et el., 1987). 
In healthy volunteers intravenous bolus injections of 
adenosine produce a biphasic heart rate response: an 
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initial transient bradycardia, probably due to a direct 
effect on the sinoatrial node as discussed in Chapter 1, 
followed by a more sustained tachycardia, probably reflex 
in origin (Watt & Routledge, 1986b). In the present study 
only an increase in heart rate was seen during adenosine 
infusion as has been reported by others (Biaggioni et 
al., 1986; Maxwell et ál., 1986; Fuller et al., 1987). 
During sustained infusion lower concentrations of 
adenosine perfusing the sinus node and /or simultaneous 
activation of reflexes causing an increase in heart rate 
may explain the apparent absence of a negative 
chronotropic effect as seen after bolus injections. 
Possible mechanisms of the increase in heart rate will be 
discussed in Chapter 7. 
3.4.3 - SPIROMETRY FOLLOWING ADENOSINE INFUSION 
As discussed in Chapter 1 inhaled adenosine causes 
bronchoconstriction in asthmatic subjects, but not in 
normal subjects (Cushley et al., 1983). In the rat 
intravenous adenosine was shown to cause broncho- 
constriction (Pauwels & Van Der Straeten, 1983). In the 
present study no subject reported a sensation of wheeze 
and in the four subjects in who spirometry was performed 
there were no significant changes. Biaggioni et el., 
(1986) similarly observed no change in spirometry in 8 
subjects receiving adenosine infusion. Unlike the 
bronchoconstriction produced by inhaled adenosine in 
asthmatic subjects, which had not fully abated within 30 
min (Cushley et al., 1983), the increased respiration 
produced by intravenous adenosine in the present study 
was observed to resolve within 1 min. These observations 
suggest that the respiratory stimulation is not secondary 
to airflow limitation. It is however possible that 
adenosine produces more subtle changes in airway calibre 
than could be detected by measurement of PEFR, FEV1 and 
FVC and this question will be addressed further in later 
chapters. 
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3.4.4 - SYMPTOMS CAUSED BY ADENOSINE 
In this study adenosine infusion was limited in all 
subjects except one by the development of various 
symptoms. Such effects may have contributed to the 
stimulation of ventilation. However Maxwell et al. (1986) 
observed stimulation of breathing at a dose of adenosine 
not associated with symptoms suggesting that they are not 
a necessary factor. 
With regard to the question whether adenosine has a 
potential therapeutic rôle in the treatment of 
respiratory failure: the adverse subjective sensations 
noted in this study, in which I examined the 
dose -response relationship between ventilation and 
adenosine infusion rate up to the limit of each subject's 
tolerance, may not be relevant to longer term use of 
lower dose infusion of the nucleoside. If adenosine were 
to adversely affect airway calibre, this may be a 
limiting factor in patients with airways obstruction. 
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CHAPTER 4 - A COMPARISON OF THE EFFECTS OF INTRA- AORTIC 
INFUSION OF ADENOSINE PROXIMAL AND DISTAL TO THE CAROTID 
CIRCULATION. 
4.1 - INTRODUCTION 
Watt and Routledge (1985) suggested that adenosine might 
stimulate respiration by an action in the carotid bodies. 
The delay they observed between the injection of 
adenosine and the onset of respiratory stimulation was 
compatible with this suggestion. In support of this was 
the observation of McQueen and Ribeiro (1981) that 
adenosine increased afferent neural discharges from the 
carotid body of the cat. An action within the central 
nervous system was considered unlikely for the reasons 
discussed in Chapter 1. Involvement of a pulmonary reflex 
was thought to be unlikely because Gustafsson (1981) 
observed respiratory stimulation after injection of 
adenosine into the left ventricle of the rabbit. 
Nevertheless further work was clearly necessary to 
determine the site or sites of action of adenosine in 
man. 
As discussed in Chapter 1 adenosine has a half -life 
in human blood measured in seconds. Therefore if 
adenosine - induced respiratory stimulation in man is 
mediated by the carotid bodies it would be expected that 
infusion of adenosine proximal to the carotid circulation 
would stimulate respiration whereas more distal 
administration would not. In this study the effects of 
such infusions were compared in patients with arterial 
catheters inserted for diagnostic purposes. 
4.2 - METHODS 
4.2.1 - SUBJECTS 
The subjects were 12 patients (10 male) aged 46 to 67 
(mean: 55) years and weighing 72 to 90 (mean: 74) kg (n = 
10) scheduled to undergo cardiac catheterisation for 
investigation of chest pain (Table 4.1). A further 
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1 60 M B No CAD 
2 56 M C N 1-VD 
3 50 M 1.72 72 BC NA 1-VD 
4 52 M 1.75 81 BC 1-VD 
5 64 M 1.69 79 C 3-VD 
6 60 M 77 BC N 3-VD 
7 46 M 1.64 70 B N F 1-VD 
8 46 M 1.82 90 N 2 VD 
9 53 F 1.65 71 B D 1 VD 
10 55 M 1.70 65 B 3 VD 
11 67 F 57 B DN 1 VD 
12 57 M 1.68 83 BC N 3 VD 
Mean 55 1.71 74 
SD 7 0.06 10 
M, male; F, female; CAD, coronary artery disease; 1 -VD, 1 vessel coronary artery 
disease; 2 -VD, 2 vessel disease; 3 -VD, 3 vessel disease; B, ß- adrenoceptor 
antagonist; C, calcium antagonist; D, diuretic; N, long- acting nitrate; 
A, aspirin; F, fenoprofen. 
patient who agreed to participate was not included 
because a satisfactory position for the respiration 
transducer could not be found. 
Eleven of the patients proved to have coronary 
disease. Careful consideration was given to the 
possibility of adverse cardiac events in such patients 
but it was considered that clinically significant adverse 





Fig. 4.1 - Sites of adenosine infusion. AV, aortic valve; 
RCA, right common carotid artery; LCA, left common 
carotid artery; LSA, left subclavian artery; DTA, 
descending thoracic aorta. 
Prior to the study patients were receiving a variety 
of medications (Table 4.1). All therapy, other than 
sublingual nitrates, was stopped at least 12 h prior to 
the study but patients received premedication with 
diazepam 10 mg orally 1 hour prior to catheterisation. 
4.2.2 - INFUSION PROTOCOL 
Adenosine was administered by continuous intra- aortic 
infusion sequentially at five sites: (1) immediately 
above the aortic valve, (2) mid -ascending thoracic aorta, 
(3) top of the aortic arch, (4) mid -descending thoracic 
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aorta and (5) just proximal to the innominate artery 
(Fig. 4.1). Site 3 is close to the origin of the head and 
neck vessels and site 4 is situated distal to those 
vessels. Infusions were administered, prior to diagnostic 
angiography, through a pigtail catheter (8F) which had 
been inserted under local anaesthetic through the right 
femoral artery. 
The initial rate of intra- aortic adenosine infusion 
was derived from the findings described in Chapter 1: an 
intravenous infusion rate of 6 mg /min of adenosine was 
sufficient to produce slight respiratory stimulation. A 
half -life of adenosine in blood of about 10 s (Klabunde, 
1983) and a circulation time of 20 s from an antecubital 
vein to the aorta were assumed. The infusion rate at site 
1 was therefore initially set at 1.6 mg /min, and was 
increased if necessary to produce a moderate increase in 
minute ventilation. In this group of patients the mean 
final dose was 2.9 (SD: 1.0) mg /min. Each infusion was 
thereafter continued at a constant rate while the cardiac 
catheter was moved at 1 min intervals from one site to 
the next. Patients were "blind" to the timing and 
direction of catheter movements. 
4.2.3 - MEASUREMENTS 
A single -lead electrocardiogram was recorded throughout 
the study. Respiration was recorded at 1 min intervals 
using a respiration transducer (Lectromed type 4320) and 
an Ormed MX216 recorder as described in Chapter 2. 
Intra- aortic pressure was measured in 8 subjects (nos. 3 
to 11) via the cardiac catheter before and immediately 
after the adenosine infusion. In 4 patients (nos. 7, 8, 9 
and 11) right femoral artery pressure was measured at 1 
min intervals via the side -arm of an arterial sheath 
through which the cardiac catheter had been inserted. 
Patients were asked at 1 min intervals to report any 
symptoms. 
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4.2.4 - STATISTICAL ANALYSIS 
Comparisons of minute ventilation, tidal volume, 
respiratory rate, heart rate (HR) and blood pressure (BP) 
at different sites were made using ANOVA and Student - 
Newman-Keuls test. Prior log transformation of minute 
ventilation and tidal volume data was performed. Blood 
pressure before and after the adenosine infusion was 
compared using Student's paired t -test. Changes in heart 
rate in patients receiving and in those not receiving 
ß- adrenoceptor antagonists were compared with the 
Mann -Whitney test. In one patient (no. 12) the study was 
stopped prematurely because of epigastric discomfort. 
Haemodynamic data were therefore analysed for the 
remaining 11 patients, but data on side -effects included 
all 12 patients. In one patient who completed the study 
(no. 8) the respiratory trace recorded at position 4 was 
of poor quality and could not be measured. Respiratory 
data are therefore presented for 10 patients. 
4.3 - RESULTS 
Respiratory, heart rate and blood pressure data are 
summarised in Table 4.2. 
There was a significant difference in minute 
ventilation at different infusion sites (P < 0.002). 
Minute ventilation at baseline and site 4 did not differ 
from each other (P > 0.5) but were significantly less 
than minute ventilation at sites 1, 2 or 5 (P < 0.025 for 
each comparison). Minute ventilation at site 3 was 
intermediate and did not differ significantly from that 
at any other site. In 7 patients ventilation decreased as 
the catheter was moved from site 2 to site 3 and in 3 it 
increased, but in only one of these (no. 7) did the 
increase exceed 25 %. There were no other significant 
inter -site differences in minute ventilation. 
The difference in minute ventilation was attributable 
to inter -site differences in tidal volume (P < 0.02). 
Tidal volume during adenosine infusion at sites 1, 2 and 
5 was higher than at baseline (P < 0.05 for each 
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Table 4.2 - Respiratory variables, heart rate and mean 
blood pressure during intra- aortic adenosine infusion at 
the sites described. Data are shown as mean (SD). RFA, 
right femoral artery. Other abbreviations as in text. The 
sites of infusion are in their anatomical order. 
Variable Baseline 
Infusion Site 
1 2 5 3 4 
V (1/min) 5.3 8.8 10.1 9.7 6.8 5.1* 
(n = 10) (1.7) (3.5) (8.9) (6.2) (2.3) (2.5) 
fR (breaths 16 16 17 17 15 14* 
/min) (n = 10) (4) (4) (5) (3) (2) (3) 
VT (1) 0.35 0.57 0.60 0.62 0.46 0.38* 
(n = 10) (0.14) (0.29) (0.34) (0.45) (0.18) (0.18) 
HR (beats/min) 59 64 70 76 71 70 
(n = 11) (9) (13) (15) (17) (14) (14) 
Mean RFA BP 92 94 99 102 94 92 
(mmHg) (n = 4) (10) (16) (12) (13) (14) (12) 
*n = 9 
comparison). Tidal volume at site 4 did not differ from 
baseline (P > 0.5), but approached a significant 
difference from sites 1, 2 and 5 (0.05 < P < 0.1 for each 
comparison). There was no significant difference in 
respiratory rate at different infusion sites. 
There was also a significant difference in heart rate 
at different infusion sites (P < 0.001). Heart rate at 
baseline and at site 1 was significantly less (P < 0.01 
for each comparison) than heart rate at sites 2, 3, 
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Table 4.3 - Symptoms reported during intra- aortic 
adenosine infusion at the sites described. 
infusion are in their anatomical order. n = 
The sites of 
12. 
Symptom Site Total 
no. 
1 2 5 3 4 Patients 
Dyspnoea 5 6 1 5 8 
Chest discomfort 1 4 6 8 
Epigastric discomfort 1 1 2 7 8 
Flushing 1 5 3 1 6 
Dizziness 2 3 5 
Headache 1 3 2 5 
Throat, neck & face 1 1 3 2 5 
discomfort 
4 or 5 which were not significantly different from one 
another. In the 3 patients who were not receiving 
B- adrenoceptor antagonists the increase in heart rate 
(mean: 30, range: 19 to 38 beats /min) was significantly 
greater than the increase (mean: 12, range: 8 to 16) in 
those patients who were receiving such drugs (P = 0.02). 
In the eight patients in whom mean intra- aortic 
pressure was measured before and immediately after 
adenosine infusion, there was no significant change 
(mean: 89, SD: 12 mmHg before vs. mean: 84, SD: 12 mmHg 
following adenosine). In the four patients in whom right 
femoral artery pressure was measured at each infusion 
site no significant changes were demonstrable but the 
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small sample size may have allowed a Type II statistical 
error. 
Adverse effects were reported by a number of patients 
during adenosine infusion but these were mild with one 
exception. That patient (number 4), who had a symptomatic 
hiatus hernia, experienced epigastric pain during 
adenosine infusion at site 3 and the study was promptly 
terminated at the patient's request. No other subject 
requested that the study be terminated (although all were 
aware that they might do so). Other symptoms and their 
relationship to the site of infusion are shown in Table 
4.3. All symptoms resolved within 60 s of stopping the 
adenosine infusion. 
4.4 - DISCUSSION 
This study confirmed with an intra- aortic infusion the 
respiratory- stimulant effect of adenosine in man 
previously observed with intravenous administration (Watt 
& Routledge, 1985; Maxwell et ál., 1986; this thesis 
Chapter 3). Further the results demonstrate that the 
respiratory- stimulant effect of intra- aortic adenosine 
depends on the site of administration. Adenosine infused 
distal to the carotid circulation (site 4) caused no 
respiratory stimulation, but infusion of adenosine 
proximal to the carotid circulation caused respiratory 
stimulation both before (sites 1 and 2) and after (site 
5) more distal adenosine infusion. 
4.4.1 - SITE OF ACTION OF ADENOSINE 
These findings raise the question of why adenosine - 
induced respiratory stimulation should depend on 
perfusion of the carotid circulation. The effect could be 
mediated by the carotid bodies or brain chemoreceptors. 
The latter alternative appears unlikely because, as 
already discussed (Chapter 1), adenosine and its 
long- acting analogues depress respiration when applied 
locally to the brain. Buss et J. (1986) found that 
adenosine caused respiratory stimulation in the rabbit 
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and that the effect was abolished by bilateral division 
of the afferent nerve supply of the carotid bodies. 
Monteiro & Ribeiro (1987) demonstrated the same 
phenomenon in the rat. These observations suggest that 
adenosine stimulates respiration by an action on the 
carotid body in those species. 
The present data support but do not prove the 
hypothesis that adenosine - induced respiratory stimulation 
in man is also carotid body mediated. Further support for 
this hypothesis and also for the suggestion (Watt & 
Routledge, 1985) that adenosine may be a physiological 
mediator or modulator of the ventilatory response to 
hypoxia was provided by Maxwell et al. (1986). These 
authors reported that adenosine infusion in normal 
subjects potentiated the ventilatory response to hypoxia, 
a response mediated in man by the carotid bodies 
(Lugliani et el., 1971). Furthermore Griffiths et al. 
(1990) recently showed that adenosine did not stimulate 
respiration in 2 patients whose ventilatory response to 
hypoxia was depressed following carotid endarterectomy. 
In view of the evidence that separate mechanisms subserve 
the responses to hypoxia and hypercapnia in the carotid 
body (Eyzaguirre, 1984) it is of interest that Maxwell et 
al. found that adenosine had no effect on the ventilatory 
response to hypercapnia. 
The mechanisms by which changes in blood gas tensions 
and pH alter neural discharges from the carotid bodies 
(chemotransduction) remain to be elucidated (Eyzaguirre, 
1984). Although expressed in various forms, the 
"metabolic hypothesis" proposes that a decrease in 
intracellular ATP in the carotid bodies during hypoxia 
results in the release from Type 1 (glomus) cells of a 
transmitter which excites synaptically connected fibres 
of the carotid sinus nerve (Eyzaguirre, 1984). Obeso et 
al. (1985) showed that the ATP content in the cat carotid 
body falls during hypoxia, although Acker et el. (1984) 
had previously observed no change. To my knowledge the 
concentration of adenosine in the carotid body has not 
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been measured in any species. However in view of the 
weight of evidence from other tissues studied (see 
Chapter 6) it seems very likely that the interstitial 
adenosine concentration in the carotid body should 
increase when there is increased breakdown of ATP, e.g. 
during hypoxia. It remains to be shown whether such an 
increase in adenosine concentration would participate in 
the mechanism(s) of chemotransduction, but given the 
abundant evidence of neuromodulation by adenosine in 
other tissues (see Chapter 1) this is an attractive 
hypothesis. Since adenosine generally inhibits 
neurotransmission, any participation of the nucleoside in 
chemotransduction is likely to involve a complex 
interaction with other neurally active substances. 
The bronchial arteries arise most commonly from the 
antero -lateral aspect of the descending thoracic aorta 
to 1 inch distal to the left subclavian artery (Marchand 
et el., 1950), although they may arise from: lower in the 
thoracic aorta, the inferior aspect of the aortic arch, 
the first right aortic intercostal artery and 
occasionally the right internal mammary artery (Romanes, 
1968; Harris & Heath, 1986). Therefore the possibility 
that site 5 was distal to the origin of the bronchial 
arteries in some patients cannot be excluded. For this 
reason it is possible that an increased adenosine 
concentration perfusing the lungs via the bronchial 
arteries during adenosine infusion into the aorta at 
sites 1,2 and 5 caused the observed changes in 
respiration by an intra- pulmonary effect. However if that 
were the case an increase in ventilation might have been 
expected in the majority of patients as the catheter tip 
was moved from site 2 to site 3 which is nearer to the 
most likely origin of the bronchial arteries. 
Whether adenosine might have stimulated respiration 
via an effect on the baroreceptors is uncertain. 
Hypotension can stimulate respiration via a baroreflex 
effect (Heistad et ál., 1975). However no fall in blood 
pressure was observed in this study. Since adenosine 
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usually relaxes vascular smooth muscle any local effect 
might be expected to cause changes in wall stretch in the 
carotid sinus opposite to those caused by hypotension and 
therefore unlikely to stimulate ventilation. However a 
direct depressant effect of adenosine on neural 
discharges from the carotid sinus, mimicking the effect 
of hypotension, cannot be excluded. 
4.4.2 - EFFECTS OF ADENOSINE ON HEART RATE AND BLOOD 
PRESSURE 
The pattern of site -dependent changes in heart rate 
differed from that of minute ventilation. Heart rate 
increased after adenosine infusion was started; the 
increase over baseline values being apparent during 
infusion at sites 2, 3, 4 and 5. There was no fall in 
blood pressure to suggest that a baroreceptor reflex 
mediated the changes in heart rate. It is not clear why 
heart rate did not increase at site 1. It is possible 
that a sufficiently high concentration of adenosine was 
perfusing the coronary circulation, to exert a negative 
chronotropic effect on the sinoatrial node (see Chapter 
1) thereby opposing any increase in heart rate produced 
by other mechanisms. 
The increase in heart rate seen at other sites may 
have been secondary to the increase in ventilation 
similar to the response elicited by hypoxic stimulation 
of the carotid body observed in the dog (Daly & Scott, 
1958). If this is the case it is unclear why the changes 
in heart rate show a pattern different from the 
respiratory changes. Heart rate does not return rapidly 
to baseline following boluses of adenosine (Watt & 
Routledge, 1986b) so it is possible that in the present 
study there was insufficient time during the period of 
infusion at site 4 for a return to baseline heart rate to 
occur. Alternatively a reflex secondary to the adverse 
effects or stimulation of other peripheral receptors may 
have contributed to the increased heart rate and hence 
its persistence during infusion at site 4 where some 
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adverse effects were more common. 
Eight of the 11 patients who completed the study were 
receiving treatment with ß- adrenoceptor blockers and this 
seems to have reduced the magnitude of the heart rate 
changes in those patients. Effects of adenosine on heart 
rate will be discussed further in Chapters 7 and 8. 
Measurement of intra- aortic blood pressure before and 
immediately after the adenosine infusions revealed no 
significant change. However it is possible that because 
of the short half -life of adenosine the post- infusion 
measurement was too late to detect a change. Nevertheless 
no change was seen in the 4 patients in whom blood 
pressure was monitored throughout, confirming the finding 
in the previous study that adenosine - induced respiratory 
stimulation is not due to hypotension. There was a trend 
in these 4 patients for blood pressure to be higher when 
adenosine was infused proximal to the carotid 
circulation. This was not significant but numbers were 
small and a Type II statistical error is therefore 
possible. 
4.4.3 - SYMPTOMS CAUSED BY ADENOSINE 
It has been proposed that exogenous adenosine produces 
transient chest discomfort by directly stimulating 
afferent cardiac nerves, and that adenosine released 
spontaneously during cardiac ischaemia might contribute 
to the symptom of angina pectoris (Sylvén et ál., 1986). 
The present observations provide information on the site 
of origin of adenosine - induced chest discomfort. In seven 
of the eight patients reporting such discomfort, it 
occurred during adenosine infusion at sites 3 or 4. In 
view of the short half -life of adenosine in human blood 
it is unlikely that such chest sensations in those 
patients are cardiac in origin. In the single patient who 
reported "chest tightness" during adenosine infusion at 
site 1 but at no other site, the heart might have been 
the source of adenosine - induced discomfort. 
Adenosine reproduces the epigastric pain of duodenal 
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ulceration (Watt et el., 1987b). While epigastric 
discomfort of some degree occurred in 8 patients in this 
study, this was only marked in the patient with a hiatus 
hernia. It may be, therefore, that not only duodenal 
ulceration but also other inflammatory lesions of the 
upper gastrointestinal tract may predispose to 
adenosine - induced epigastric discomfort by mechanisms as 
yet undefined. Adenosine - induced pain will be discussed 
further in Chapter 7. 
The finding in this study that some symptoms were 
more common during adenosine infusion at site 5 (Table 
4.3) and that minute ventilation was no different from 
the baseline value at that time suggests that symptoms do 
not play a large rôle in causing the ventilatory 
stimulation produced by adenosine. 
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CHAPTER 5 - ANTAGONISM OF THE EFFECTS OF ADENOSINE 
INFUSION BY AMINOPHYLLINE 
5.1 - INTRODUCTION 
As discussed in Chapter 1 cell- surface adenosine 
receptors of at least 2 classes have been described. 
Methylxanthines such as theophylline have been shown to 
act as competitive antagonists at these receptors and 
therefore are useful tools for investigating the possible 
sites of action of adenosine in mediating its biological 
effects. Antagonism by such a methylxanthine suggests 
that an effect of adenosine is probably mediated by 
cell -surface receptors. The purpose of the study 
described in this chapter was to examine the effect of 
aminophylline (theophylline ethylenediamine) on the 
responses to adenosine infusion, to test the hypothesis 
that the direct effects of adenosine are mediated by 
stimulation of cell- surface receptors. 
Since adenosine - induced respiratory stimulation 
causes reduced end -tidal and therefore arterial PCO2, the 
observed effects of adenosine on minute ventilation 
during sustained infusion will not fully reflect the 
magnitude of the ventilatory stimulus because of 
antagonistic effects of reduced PaCO2 and increased pH on 
the peripheral and central chemoreceptors. This problem 
could be obviated by increasing the CO2 content of the 
inspired gas as necessary to maintain end -tidal PCO2 
constant. However this would entail the use of a 
mouthpiece or facemask with the attendant disadvantages 
discussed in Chapter 2. In this study an intermittent 
adenosine infusion protocol was used, with recovery 
periods between infusions at each dose, to minimise the 
effects of alterations in blood gas tensions and pH. It 
was hoped that the peak minute ventilation during each 
infusion would reflect the ventilatory stimulus by 
adenosine better than data obtained with a continuous 
step -wise infusion protocol. However it was recognised 
that increased ventilation can alter blood gas tensions 
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rapidly so the effects of such alterations could not be 
completely prevented with this approach. Use of an 
intermittent infusion protocol would also facilitate 
substitution of adenosine by placebo at any point in the 
protocol. 
A full understanding of the mechanisms of the 
observed cardiovascular and respiratory effects of 
exogenous adenosine and the possible relevance of these 
effects could only come with an understanding of the 
concentrations of adenosine producing these effects at 
its sites of action. Measurement of plasma adenosine 
concentrations was considered the first step in providing 
that understanding. In this study changes in the 
peripheral venous plasma concentration of adenosine 
during exogenous infusion were measured. However it was 
recognised that, because of the short half -life of 
adenosine in blood, plasma and interstitial 
concentrations of adenosine were unlikely to be identical 
and also that plasma concentrations at steady state might 
differ at different sites in the circulation. 
Nevertheless it was considered that changes in venous 
plasma adenosine concentrations might provide a useful 
index and lower limit of changes elsewhere. 
5.2 - METHODS 
5.2.1 - SUBJECTS AND INFUSIONS 
The subjects were 10 normal volunteers (9 male), aged 23 
to 55 years (mean: 33) and weighing 55 to 89 kg (mean: 
71, SD: 12) (Appendix 3). A single patient known to 
suffer from asthma also completed the same protocol, as a 
pilot study of the effects of adenosine infusion in such 
patients. 
Each subject was studied on two occasions which are 
referred to subsequently in this chapter as the "placebo 
leg" and the "aminophylline leg ". Adenosine was 
administered on each occasion after prior infusion over 
10 min, in randomised single -blind manner, of either 
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aminophylline (6 mg /kg in total volume of 30 ml sterile 
water) or placebo (30 ml of 0.9% sodium chloride). These 
initial infusions are referred to in this discussion as 
"pretreatment ". Aminophylline was preferred to 
theophylline alone since it is more soluble and is the 
preparation of theophylline for injection normally used 
in clinical practice. The dose of aminophylline was 
chosen on the basis of previous work suggesting that a 
loading dose of 6mg /kg is likely to cause peak serum 
concentrations of 10 gg /ml, i.e. in the "therapeutic 
range ", with a low likelihood of causing serious toxicity 
(Hendeles et el., 1978). In view of the expected duration 
of each study (no more than 21/2 hours for the adenosine 
infusions) and the reported half -life of theophylline of 
approximately 4 to 9 h (Hendeles et ál., 1978) a 
continuous maintenance infusion of aminophylline was not 
considered necessary. 
Adenosine was infused in 5 min stages at each dose 
with recovery periods of at least 15 min between stages. 
Adenosine was given at an initial rate of 2.3 mg /min with 
increments, until limited by symptoms, to 4.3, 8.5, 11.9, 
16.8 and 23.4 mg /min. A control infusion (0.9% sodium 
chloride) was also given, single blind, instead of 
adenosine usually after at least one adenosine infusion 
stage causing definite subjective and objective changes. 
The protocol for the infusions and the measurements made 
is illustrated in Fig. 5.1. 
5.2.2 - MEASUREMENTS AND SAMPLES 
A single -lead electrocardiogram (ECG) was recorded 
throughout and used to determine heart rate. Arterial 
blood pressure was recorded using an electrical 
sphygmomanometer (Programmed Electrosphygmomanometer 
PE -300, Narco Biosystems Inc., Houston, Texas). This had 
an internal calibration of 100 mmHg which was found to be 
accurate to within ± 10% by comparison with a mercury 
manometer. Respiration was recorded using a respiratory 
inductance plethysmograph as described in Chapter 2. 
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Fig. 5.1 - Protocol for the infusions and measurements 
made. Resp, respiration; CO2, end -tidal PCO2; HR, heart 
rate; BP, blood pressure; A, plasma adenosine 
concentration; S, spirometry; Aminoph., aminophylline. 
* indicates the "pretreatment ". 
During the study exhaled gas was sampled continuously by 
a fine bore catheter taped to each subject's cheek with 
its tip just inside the left nostril and PCO2 was 
measured using a high speed response CO2 analyser (Type 
901 MK 2. P.K. Morgan Ltd.). The respiratory and PCO2 
traces were recorded on a chart recorder (Rikadenki). 
Respiratory variables and PETCO2 were subsequently 
derived from the traces obtained. Mean values for 40 s 
periods at each time point were used for analysis. 
Spirometry was performed using a rolling seal 
spirometer (Vitalograph Ltd) connected to an Apple IIc 
microcomputer which utilised a programme (Spirotrac II) 
to process the signal and derive various indices of the 
expiratory flow volume curve which were recorded by a 
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printer. The mean differences between values obtained 
from this programme and values obtained manually from the 
spirometer tracings were found to be -0.02 (SD:0.05) 1, 
-0.003 (SD: 0.04) 1 and -0.10 (SD: 0.19) 1/s for FEV1, 
FVC and forced expiratory flow between 25 and 75% of FVC 
(FEF25_75 %) respectively (n = 9 in each case). 
Blood was sampled before and during the final minute 
of each stage in 6 subjects (including the patient with 
asthma) for measurement of venous plasma adenosine 
concentrations. These samples were drawn from a separate 
intravenous plastic cannula in the arm opposite to that 
used for infusions. The method of blood sampling and the 
assay used are described in Chapter 2. 
Blood samples (5 ml) were also taken for measurement 
of serum theophylline concentrations just before the 
first adenosine /control infusion stage (15 min following 
the aminophylline or placebo pretreatment) and following 
the final stage. Assays for theophylline were kindly 
performed by Mr. D. C. Buss using a reversed phase HPLC 
method which has previously been described (Buss, 1990). 
Subjects were asked to report any symptoms every 
minute during and for 2 min after each stage. 
5.2.3 - STATISTICAL ANALYSIS 
For baseline values comparisons were made of values for 
different infusion stages, rather than infusion rates, to 
facilitate detection of any trends during the study, e.g. 
due to aminophylline. All subjects received at least five 
infusion stages (including the control infusion) during 
each leg. Therefore baseline values for the first 5 
infusion stages were compared with values before and 
after the pretreatment by ANOVA. Values before the 
pretreatment were also compared with values before the 
final infusion stage for each subject by Student's paired 
t test. 
All subjects received adenosine at infusion rates up 
to at least 8.5 mg /min. Therefore for changes during 
infusions data for the control infusion and adenosine 
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infusions at 2.3, 4.3, 6.1 and 8.5 mg /min were also 
compared by ANOVA. Data for the control infusion and 
adenosine infusion at the maximum dose for each subject 
were also compared using the paired t test. 
To simplify the analysis the peak minute ventilation 
and the trough PETCO2 for each subject during each 
infusion were used for these comparisons. For VT and fR 
the values at the time of peak minute ventilation were 
used. Since previous work had shown an increase in heart 
rate and systolic blood pressure and a decrease in 
diastolic blood pressure during adenosine infusion the 
peak heart rate and systolic blood pressure and trough 
diastolic blood pressure were used. Data for minute 
ventilation were log- transformed prior to analysis. 
The slopes of dose -response curves obtained after 
placebo and aminophylline pretreatment were compared 
using the following method. For every subject for any 
given variable the differences between the values 
obtained following aminophylline and placebo pretreatment 
at each dose of adenosine up to and including 8.5 mg /min 
were calculated. ANOVA was then performed. The sum of 
squares for doses (SD) can be regarded as consisting of 
two components, SDL and SDR, where SDL relates to the 
difference due to a linear increase (or decrease) with 
dose and SDR to the difference not accounted for by the 
linear change. Since: 
SD = SDL + SDR 
it follows that: 
SDR = SD - SDL 




(Armitage & Berry, 1987) where: 






where 5 is the number of doses, yi are the differences 
between responses during the placebo and aminophylline 
leg for each subject at dose level i, i is the mean 
value for all the subjects at dose level i and d is the 
mean dose given. 
5 
(2) A = 1 x E (di - a)2 
n i=1 
(Eq. 5.5) 
where n is the number of subjects (in this case 10). 
A test for the linear dose -response comes from comparing 
SDL /Residual Mean Square with an F- distribution on 1 and 
(residual df) degrees of freedom. 
To simplify the analysis of changes in spirometric 
variables so that any changes occurring over the course 
of each study or acutely following adenosine infusion 
would be detected data for the following times were 
compared by analysis of variance: before and following 
the pretreatment, following adenosine infusion at 2.3 and 
4.3 mg /min (since all subjects received at least these 
two doses before the control infusion), following the 
control infusion and following adenosine infusion at the 
maximum dose (which in all subjects was after the control 
infusion). 
For analysis of changes in FRC (see below) the means 
of the values during adenosine infusion, i.e. minutes 1 
to 5, were calculated for each subject. The resultant 
values for the control infusion and adenosine infusion at 
the maximum dose were compared using the paired t test. 
5.3 - RESULTS 
Full results are presented for the 10 normal subjects. 
The analysis of changes in venous plasma adenosine 
concentrations includes values from the single subject 
with asthma. Since this subject developed 
bronchoconstriction, which is important, during adenosine 
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Fig. 5.2 - Baseline heart rate and blood pressure at the 
time points and for the infusion stages shown. 
Fre, prior to the pretreatment; Post, immediately following the pretreatment; Final, 
the final infusion stage for each subject on the respective leg. Baselines 1 to 5 
represent the first five infusion stages (including control in most cases). *P < 
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Fig. 5.3 - Effect of aminophylline on changes in heart 
rate and blood pressure during adenosine infusion. Max 
(P), the maximum dose received by each subject following 
placebo pretreatment. 0 mg /min represents the control 
infusion. *P < 0.05; * *P < 0.01; * * *P < 0.001 for 
comparisons with control. n = 10 except where shown. 
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5.3.1 - DOSE OF ADENOSINE 
The maximum dose of adenosine was 12.3 (SD: 3.4) mg /min 
(mean: 175, SD: 41 µg /kg /min; range: 109 to 236) 
following placebo pretreatment and significantly higher 
at 15.6 (SD: 4.0) mg /min (mean: 224, SD: 61 µg /kg /min; 
range 109 to 330) following aminophylline (P < 0.01). 
5.3.2 - THEOPHYLLINE CONCENTRATIONS 
The theophylline concentrations following aminophylline 
infusion were 10.4 (SD: 2.1) mg /1 immediately before the 
first adenosine infusion stage and 7.8 (SD: 1.3) mg /1 
following the final stage (n = 9). Basal theophylline 
concentrations on the placebo leg were all < 0.6 mg /1 (n 
= 9) . 
5.3.3 - CHANGES IN HEART RATE AND BLOOD PRESSURE 
Baseline heart rate did not vary following placebo 
pretreatment but increased significantly following 
aminophylline (P < 0.05 for ANOVA and paired t analyses; 
Fig. 5.2a). During the placebo leg adenosine increased 
heart rate in a dose -dependent manner (P < 0.001 for 
ANOVA; Fig. 5.3a). At the maximum dose of adenosine mean 
peak heart rate was 35 beats /min higher than during the 
control infusion (P < 0.001). Aminophylline caused a 
significant flattening of the dose -response curve for 
this effect (P < 0.05; Fig. 5.3a). 
Baseline systolic blood pressure did not change 
following either placebo or aminophylline pretreatment 
(Fig. 5.2b). Baseline diastolic blood pressure did not 
change following aminophylline (Fig. 5.2b). Following 
placebo pretreatment the baseline diastolic blood 
pressure before infusions i to 5 did not change 
significantly but before the final infusion stage the 
mean diastolic blood pressure, 67 mmHg, was significantly 
higher than the value, 60 mmHg, before the placebo 
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Fig. 5.4 - Baseline minute ventilation and end -tidal PCO2 
at the time points and for the infusion stages shown. 
Abbreviations as in Figs. 5.2 and 5.3. *P < 0.05; * *P < 
0.01; * * *p < 0.001 for comparisons with values before the 
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Fig. 5.5 - Effect of aminophylline on changes in minute 
ventilation and end -tidal PCO2 during adenosine infusion. 
Abbreviations as in Fig. 5.3. *P < 0.05; * *P < 0.01; * * *P 
< 0.001 for comparisons with control (0 mg /min). n = 10 
except where shown. 
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Following placebo pretreatment adenosine increased 
peak systolic blood pressure (P < 0.001 for ANOVA; Fig. 
5.3b). At the maximum dose of adenosine mean peak 
systolic blood pressure was 16 mmHg higher than during 
the control infusion (P < 0.002; Fig. 5.3b). 
Aminophylline caused significant flattening of the 
dose -response curve for this effect (P < 0.01). Trough 
diastolic blood pressure was unaffected by adenosine both 
after placebo and aminophylline pretreatment (Fig. 5.3b). 
5.3.4 - CHANGES IN RESPIRATION 
Baseline minute ventilation and PETCO2 did not change 
following the placebo pretreatment (Fig.5.4). Following 
aminophylline baseline minute ventilation increased (P < 
0.01 for ANOVA). This increase was most marked just 
before the first adenosine infusion (Baseline 1), when 
minute ventilation, 7.6 (SD: 3.1) 1 /min, was 1.4 1 /min 
higher than the value before aminophylline, 6.3 (SD: 2.1) 
1 /min (Fig. 5.4a). PETCO2 decreased following aminophyll- 
ine and remained lower than the pre -aminophylline value 
for the duration of that leg (P < 0.001; Fig. 5.4b). 
Following placebo, peak minute ventilation increased 
from 6.6 (SD: 1.8) 1 /min during the control infusion to 
14.6 (SD: 4.3) 1 /min during adenosine infusion at 8.5 
mg /min (P < 0.001) and 17.6 (SD: 3.7) 1 /min during the 
maximum dose (P < 0.001; Fig. 5.5). This was primarily 
due to an increase in tidal volume, from 0.45 (SD: 0.24) 
1 during the control infusion to 0.85 (SD: 0.18) 1 during 
adenosine infusion at 8.5 mg /min (P < 0.001) and 1.10 
(SD: 0.35) 1 at the maximum dose (P < 0.001). Respiratory 
rate during adenosine infusion at the maximum dose, 17.2 
breaths /min, was not significantly different from the 
control value, 16.0 breaths /min. Trough PETCO2 decreased 
during adenosine infusion from 35.3 (SD: 3.2) mmHg during 
the control infusion to 28.6 (SD: 3.8) mmHg during 
adenosine infusion at 8.5 mg /min (P < 0.001) and 27.4 
(SD: 4.4) mmHg at the maximum dose (P < 0.001; Fig. 5.5). 
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Fig. 5.6 - Time course of changes in minute ventilation 
and end -tidal PCO2 during adenosine or control infusion 
following placebo pretreatment. n = 10 for minute 
ventilation and n = 8 for PCO2 except where shown. 
Adenosine infusion at 2.3 mg /min omitted for clarity. 
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Table 5.1 - Time to peak minute ventilation (min) during 
adenosine infusion, according to dose (placebo leg). *n = 
9; * *n = 8: otherwise n = 10. 
Dose (mg /min) 







dose -response curves for the increase in peak minute 
ventilation and decrease in trough PETCO2 during 
adenosine infusion (P < 0.001 and P < 0.001, 
respectively; Fig. 5.5). 
The relationship between the onset of symptoms and of 
respiratory stimulation was examined. During the placebo 
leg 8 subjects received at least one dose of adenosine 
without symptoms. Peak minute ventilation at the highest 
such dose for each subject, 7.4 (SD: 2.3) 1 /min, was not 
significantly different from the value during the control 
infusion, 6.6 (SD: 2.1) 1 /min. Similarly for the 
aminophylline leg there was no significant difference 
between peak minute ventilation during the maximum dose 
of adenosine without symptoms, 9.2 (SD: 3.1) 1 /min, and 
the value during the control infusion, 7.4 (SD: 2.2) 
1 /min (n = 9) . 
Inspection of the time course of ventilatory changes 
within infusions at each dose showed that in the majority 
of subjects minute ventilation increased to a peak and 
then decreased. This effect was most marked at the higher 
doses. There was some inter -subject variability in the 
time to peak response and the peaks tended to be earlier 
with higher doses (Table 5.1). 
For the group mean minute ventilation reached a peak 
1 or 2 min after the onset of infusion at each dose (Fig. 
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Fig. 5.7 - Changes in functional residual capacity (FRC) 
during adenosine infusion following placebo pretreatment. 
a) Changes during adenosine infusion at the maximum dose 
compared with changes during the control infusion. b) 
Respiratory trace from a single subject showing an 
increase in FRC occurring simultaneously with an increase 
in tidal volume. 
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5.6a). Comparison of values at 1 and 5 minutes showed a 
significant change only at the maximum dose (P < 0.05). 
PETCO2 decreased initially then seemed to plateau towards 
the end of each infusion (Fig. 5.6b). 
Upward movement of the baseline of the respiratory 
tracing was seen in most subjects during adenosine 
infusion, suggesting that they were breathing at a higher 
FRC. This effect was most marked at the maximum dose and 
parallelled the increase in minute ventilation (Fig. 
5.7a). In a few subjects a marked increase in tidal 
volume developed over a few breaths. In these subjects a 
shift in the respiratory trace clearly occurred 
simultaneously (Fig. 5.7b). During the placebo leg at the 
maximum dose of adenosine the peak shift was greater than 
0.2 1 in 7 subjects and in one subject was 0.96 1. For 
the 8 subjects who completed 5 minutes at the maximum 
dose the mean shift during minutes 1 to 5 was 0.16 (SD: 
0.24) 1, which was significantly different from the 
shift, - 0.04 (SD: 0.09) 1, during the control infusion 
(Fig. 5.7a). 
5.3.5 - CHANGES IN SPIROMETRY 
During the placebo leg FEV1 and FEF25_75% decreased 
significantly (P < 0.001 for ANOVA for both) between the 
measurements before the pretreatment and following the 
first adenosine infusion (Fig. 5.8). There were no other 
significant changes following this. FVC and FEV1 /FVC were 
unchanged. 
Following aminophylline there were slight increases 
in FEV1 and FVC which did not reach statistical 
significance. FEV1 /FVC and FEF25 _75% were unchanged (Fig. 
5.9) . 
In the subject with asthma adenosine infusion caused 
bronchoconstriction during the placebo leg but this was 
not seer} with the same maximum dose of adenosine during 
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Fig. 5.8 - Changes in spirometric variables during the 
placebo leg. n = 10 except where shown. 
Pre & Post, prior to and following the placebo pretreatment respectively; Max (P), 
the maximum dose received by each subject. Times 2.5, 5, 10 represent 2.5, 5 and 10 
minutes following an infusion. a, greater than all except "Post" value (P: < 0.001 to 
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Fig. 5.10 - Changes in spirometric variables in a patient 
with asthma. Spirometry was performed 2.5, 5 and 10 min 
after each infusion and also at 15, 20 and 25 min 
following adenosine infusion at 8.5 mg /min during the 
placebo leg, because of evidence of bronchoconstriction 
following that infusion. Abbreviations as in Fig. 5.8. 
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5.3.6 - CHANGES IN PLASMA ADENOSINE CONCENTRATION 
There was no significant difference between the venous 
plasma adenosine concentrations before placebo, 0.07 (SD: 
0.04) AM, and before aminophylline, 0.08 (SD: 0.02) µM (n 
= 6) . 
During the placebo leg there was no significant 
difference between the adenosine concentrations measured 
in the absence of adenosine infusion (mean of 3 baseline 
values and control infusion value), 0.07 (SD: 0.04) MM, 
and during infusion at the maximum dose, 0.09 (SD: 0.07) 
µM (n = 5) . 
During the aminophylline leg there was no significant 
difference in adenosine concentration before, 0.07 (SD: 
0.03) MM, and following, 0.08 (SD: 0.03) gM (using means 
of up to 3 values for each subject), aminophylline 
infusion in the absence of adenosine infusion (n = 6). 
However there was a significant increase in adenosine 
concentration from 0.08 (SD: 0.02) gM (using means of up 
to 4 values for each subject) in the absence of adenosine 
infusion to 0.10 (SD: 0.03) µM during adenosine infusion 
at the maximum dose (P < 0.02, n = 6). 
5.3.7 - SYMPTOMS CAUSED BY ADENOSINE 
Symptoms occurred in all subjects on both study days. 
Following aminophylline symptoms were fewer despite the 
higher maximum dose of adenosine (Table 5.2). The onset 
of first symptoms occurred at 4.9 (SD: 1.9, range: 2.3 to 
6.1) mg /min (70 (SD: 28) µg /kg /min) following placebo 
pretreatment and at 8.0 (SD: 4.3, range: 2.3 to 16.8) 
mg /min (112 (SD: 58) µg /kg /min) following aminophylline. 
5.4 - DISCUSSION 
This study examined the effects of aminophylline on the 
responses to adenosine infusion in normal volunteers. As 
in the study described in Chapter 3, adenosine caused 
significant increases in minute ventilation , tidal 
volume, heart rate and systolic blood pressure and a 
significant decrease in end -tidal PCO2. However in this 
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Table 5.2 - Symptoms during adenosine infusion. 
Symptom 
Number of subjects with symptom 
Placebo leg Aminophylline leg 
Epigastric discomfort 8 4 
Dyspnoea 7 5 
Flushing (subjective) 6* 4 
Chest discomfort 4 5 
Throat, jaw discomfort 4 1 
Paraesthesiae 4 1 
Shoulder pain 2 0 
Nausea 2 1 
Headache 1 2 
Palpitations 2 1 
Dizziness 1 1 
Eye irritation 0 1 
Altered taste 0 1 
Sweating 1 0 
Exhaustion 0 1 
Wheeze 1 0 
Total 43 28 
* 3 further subjects were visibly flushed during the 
placebo leg 
study diastolic blood pressure was unchanged. 
5.4.1 - AMINOPHYLLINE ANTAGONISM OF ADENOSINE EFFECTS 
A single infusion of aminophylline of 6 Ag /kg /min over 10 
min was sufficient to achieve mean serum theophylline 
concentrations of approximately 8 to 10 mg /1 for the 
duration of the relevant leg. There were few side -effects 
attributable to aminophylline, which caused significant 
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antagonism of the effects of adenosine on ventilation and 
PETCO2, heart rate and systolic blood pressure. 
Furthermore following aminophylline symptoms due to 
adenosine began at a higher mean dose and were fewer 
despite the higher maximum infusion rate of adenosine 
given. 
Since in vitro studies have shown that theophylline 
at a concentration of approximately 10 mg /1 causes signi- 
ficant antagonism of adenosine at cell -surface receptors 
(see Chapter 1) the findings of this study suggest that 
the direct effects of adenosine may be mediated by cell - 
surface receptors. As discussed in Chapter 1 antagonism 
by theophylline at such concentrations is unlikely to be 
due to phosphodiesterase inhibition. 
Other workers have examined the effects of 
methylxanthines on the cardiorespiratory responses to 
adenosine in animals and man. As discussed in Chapter 1 
methylxanthines have been shown to antagonise the 
respiratory depressant effects of adenosine and its 
analogues within the central nervous system (eg. 
Kattwinkel & Darnall, 1982; Wessberg et el., 1985). 
Antagonism of the ventilatory stimulation caused by 
intracarotid injections of an adenosine analogue in 
anaesthetised rats was reported by Monteiro and Ribeiro 
in 1987. In anaesthetised dogs aminophylline antagonises 
the coronary and systemic haemodynamic effects of 
adenosine (Afonso, 1970; Afonso & O'Brien 1970). 
In man, Routledge and Watt (1986) reported 
preliminary findings that aminophylline antagonized the 
adenosine - induced bradycardia but did not significantly 
affect the subsequent tachycardia or respiratory 
stimulation produced by adenosine boluses. However, 
consistent with the present results, Jonzon et al. (1989) 
reported that theophylline does antagonise the 
ventilatory effect of bolus injections of adenosine. 
Furthermore Smits et el. (1987) reported that caffeine 
significantly reduced the adenosine - induced changes in 
minute ventilation, tidal volume, respiratory frequency, 
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venous PCO2 and pH. Similarly Maxwell et al. (1987) 
observed antagonism of the effects of adenosine on 
ventilation and estimated arterial PCO2 by theophylline. 
They also showed that theophylline reduced symptoms 
caused by adenosine allowing higher infusion rates to be 
given. Both Smits et ál. (1987) and Maxwell et al. (1987) 
observed no reduction of adenosine effects by 
enprofylline a xanthine which does not antagonize 
adenosine in vitro (Persson et ál., 1982). 
Further confirmation that the cardiorespiratory 
effects of adenosine are mediated by cell- surface 
receptorscomes from reports that such effects are 
potentiated by dipyridamole, which increases 
extracellular concentrations of adenosine by inhibiting 
its transport into cells. Watt et al. (1986a) observed 
potentiation of the effects of adenosine on the sinus 
node by dipyridamole. Watt and Routledge (1987d) reported 
that dipyridamole potentiated the initial bradycardia and 
the ventilatory stimulation caused by intravenous bolus 
injections of adenosine. Biaggioni et ál. (1986) showed 
that after dipyridamole 4 -fold lower infusion rates of 
adenosine were required to produce a given increase in 
heart rate and systolic blood pressure and fall in 
diastolic blood pressure. 
5.4.2 - EFFECTS OF AMINOPHYLLINE PER SE ON RESPIRATION 
In this study aminophylline caused an increase in resting 
minute ventilation and decrease in PETCO2. It has long 
been known that methylxanthines can increase minute 
ventilation in man (Edsall & Means, 1914) and such 
compounds have been used to treat Cheynes Stokes 
respiration (Vogl, 1927) and neonatal apnoea (Kuzemko & 
Paala, 1973). Morice et al. (1986) reported that 
aminophylline potentiates the ventilatory response to 
hypercapnia although some earlier workers had been unable 
to show this (Stroud et ál., 1955; Lakshminarayan et ál., 
1978). Lakshminarayan et ál. (1978) and Sanders et ál. 
(1980) showed that aminophylline potentiates the 
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ventilatory response to hypoxia. Aubier (1981) reported 
that theophylline increased contractility and reduced 
fatigue in the diaphragm of normal subjects and suggested 
that increased diaphragmatic efficiency caused the 
theophylline- induced increase in ventilation which they 
observed in anaesthetised, spontaneously breathing dogs 
(Aubier et ál., 1983). However not all workers have been 
able to demonstrate effects of theophylline on 
diaphragmatic contractility in normal subjects (Moxham et 
al., 1985). 
Since adenosine and its analogues depress ventilation 
by an action within the central nervous system (see 
Chapter 1) and since such effects are antagonised by 
theophylline it has been proposed that methylxanthines 
may stimulate respiration by antagonism of the action of 
endogenous adenosine (Millhorn et al., 1984). Therefore 
the intriguing possibility exists that in the present 
study aminophylline influenced the adenosine -ventilation 
dose response curve by antagonism of two opposing effects 
of adenosine, one mediated peripherally the other exerted 
directly within the central nervous system. 
5.4.3 - CHANGES IN SPIROMETRY 
The cause of the initial fall in FEV1 and FEF25 -75% 
during the placebo leg is uncertain. It seems unlikely 
that this was due to an effect of the first, and lowest, 
dose of adenosine since subsequent infusions at higher 
rates caused no further change. Since these measurements 
were made semi -recumbent it is possible that a change 
occurred in subjects' posture early in the study although 
a foot board was used to prevent subjects slipping down 
the bed. If fatigue or bronchoconstriction, due to 
subjects performing multiple forced expirations, were the 
cause a progressive fall during the study would have been 
expected. Aminophylline caused an increase in FEV1 
suggesting that it may have caused bronchodilation. It 
therefore offset or possibly antagonised the mechanism of 
the fall noted during the placebo leg. Persson (1980) 
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showed in vitro that theophylline causes relaxation of 
airways from non -obstructed patients and in vivo 
theophylline has been shown to increase airway 
conductance in normal subjects by some, but not all, 
workers (Mackay et al., 1983; Estenne et al., 1980), a 
response possibly in part due to stimulation of 
catecholamine release (Higbee et al., 1982). 
The lack of an effect of adenosine on the indices of 
airway calibre suggests that bronchoconstriction was not 
responsible for the changes in breathing. Fuller et al. 
(1987) also assessed airway calibre by a forced 
expiratory flow volume curve. They found no significant 
change in air flow at 30% of a reference vital capacity 
during adenosine infusion up to 100 Ag /kg /min. Larsson 
and Sollevi (1988) found no change in expiratory flow 
volume curves, specific airway conductance (a more 
sensitive measure of airway calibre), or bronchial 
reactivity during adenosine infusion in asthmatic 
subjects. However their maximum infusion rate was only 50 
µg /kg /min. 
Although the bronchoconstriction observed in the 
single patient with asthma in this study might have been 
caused by the adenosine - induced hyperventilation (Deal et 
ál., 1979) it might have been due to a direct 
bronchoconstrictor effect of adenosine, as has been 
observed with the inhaled compound (see Chapter 1). 
Intravenous adenosine has been reported to cause 
bronchoconstriction in rats (Pauwels & Van Der Straeten, 
1983) and a case of bolus injections of adenosine 
exacerbating asthma in man has been reported (Taviot et 
ál., 1986). These observations suggest that caution 
should be used in administering adenosine to patients 
with asthma. 
5.4.4 - TIME COURSE OF ADENOSINE - INDUCED CHANGES 
Analysis of the time course of changes in ventilation 
confirms that, although there is some inter -subject 
variability in the time to peak response, it is 
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reasonable to use mean values 1 or 2 minutes after a 
change in infusion rate to construct dose -response curves 
as was done in Chapter 3. However a better approach may 
be to use areas under the curve or, as was done here, the 
peak response, provided comparison is made with the 
equivalent measurement during the control infusion. 
Antagonistic effects on the chemoreceptors of the 
reduced arterial PCO2 will have contributed to the 
reduction of minute ventilation towards the end of 
infusions at the higher doses. Whether this was the only 
mechanism is uncertain. However there was no evidence of 
a return towards normal of end -tidal PCO2 which might 
have been seen had tachyphylaxis occurred. 
The significance of the shift upwards in the baseline 
of the respiratory trace during adenosine infusion and 
the reasons why this was probably due to an increase in 
FRC will be discussed in Chapter 8. 
5.4.5 - CHANGES IN PLASMA ADENOSINE CONCENTRATION 
These results show that aminophylline has no effect on 
basal peripheral venous plasma concentrations of 
adenosine. That the concentration of adenosine was only 
increased during infusion at the higher maximum dose 
possible after aminophylline is consistent with in vitro 
studies which suggest that the half -life of adenosine in 
human blood is only a few seconds (Klabunde 1983; Möser 
et al., 1989). Furthermore in vivo vascular epithelium 
probably also avidly takes up adenosine. The peripheral 
venous concentration is therefore not a useful index of 
concentrations pertaining much more proximally in the 
circulation during intravenous infusion of adenosine. 
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CHAPTER 6 - CHANGES IN ARTERIAL PLASMA ADENOSINE 
CONCENTRATION DURING ADENOSINE- INDUCED RESPIRATORY 
STIMULATION 
6.1 - INTRODUCTION 
Watt & Routledge (1985) proposed that adenosine may be a 
physiological mediator or modulator of the ventilatory 
response to hypoxia in the carotid bodies. This 
hypothesis has gained support from the observation that 
intravenous infusion of adenosine potentiates the 
ventilatory response to hypoxia (Maxwell et al., 1986). 
However whether the effects of adenosine occur at 
concentrations likely to be achieved in vivo is unknown 
and was therefore investigated in this study. Since 
adenosine has a very short half -life in blood (Möser et 
al., 1989) and since the recirculating plasma venous 
adenosine concentration changes little during exogenous 
infusion, as discussed in Chapter 5, in the present study 
blood was sampled from a location as close as practicable 
to the putative site of action in the carotid bodies. 
6.2 - METHODS 
6.2.1 - SUBJECTS 
The subjects were 7 patients (5 male) aged 46 to 65 years 
(mean 57) scheduled to undergo investigation of chest 
pain by cardiac catheterisation (Table 6.1). This 
afforded an opportunity to sample blood from a site close 
to the carotid circulation. Six of the patients had 
coronary artery disease. None had clinical evidence of 
heart failure or a history of asthma or other chronic 
chest disease. All continued their usual medications 
(Table 6.1) and received diazepam 10 mg orally 1 hour 
prior to catheterisation. 
Prior to the study, which was performed before 
angiography, a pigtail catheter (8F) was inserted via a 
femoral artery sheath (8F) and positioned with its tip in 
the aorta just distal to the origin of the left common 
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Table 6.1 - Patient characteristics. 





1 55 M 1.78 92 B N 3-VD 
2 58 M 1.71 80 B N 2-VD 
3 63 F 1.59 63 BCNA 2-VD 
4 46 M 1.75 69 B A 1-VD 
5 52 M 1.80 96 N 2-VD 
6 65 M 1.72 78 B N 2-VD 
7 60 F 1.50 49 BC No CAD 
Mean 57 1.69 75 
SD 7 0.11 16 
M, male; F, female; CAD, coronary artery disease; 1-VD, 1 vessel coronary artery 
disease; 2 -VD, 2 vessel disease; 3 -VD, 3 vessel disease; B, B- adrenoceptor 
antagonist; C, calcium antagonist; N, long- acting nitrate; A, aspirin. 
carotid artery. A femoral venous sheath (7F) was also 
inserted and following an equilibration period the study 
was begun. 
6.2.2 - INFUSION PROTOCOL 
Following baseline measurements and samples adenosine was 
infused via the femoral venous sheath using a protocol 
similar to that employed in the study described in 
Chapter 3. The initial infusion rate, 4.3 mg /min, was 
followed by stepwise increments every 2 min (to 6.1, 8.5, 
11.9 and 16.8 mg /min) until limited by symptoms. This 
duration of the infusion stages was considered sufficient 
because of the findings discussed in Chapter 5 that mean 
minute ventilation reaches its maximum value 1 to 2 
minutes following the commencement of infusion at a given 
dose and that there is no significant difference between 
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values at 1 and 2 minutes. Symptoms were recorded at the 
end of each stage. 
6.2.3 - MEASUREMENTS AND SAMPLES 
Heart rate, blood pressure and respiration were monitored 
continuously (except for a few seconds during arterial 
blood sampling in the case of blood pressure) and 
recorded prior to the infusion (baseline), during the 
last 45 s of each infusion stage and 2 min after stopping 
the infusion. 
An electrocardiogram (modified standard lead 2) was 
used to determine heart rate. Blood pressure was measured 
via the arterial catheter using a Bell and Howell strain 
gauge transducer, a Cambridge amplifier and a Mingograph 
multichannel recorder. Respiration was recorded as 
described in Chapter 2 using a respiratory inductance 
plethysmograph connected to a chart recorder (Rikadenki). 
Blood was sampled from the aortic arch via the 
catheter at baseline, 15 s before the end of each stage 
and 2 min post- infusion for measurement of plasma 
adenosine concentration. The sampling technique and assay 
are described in Chapter 2. 
6.2.4 - STATISTICAL ANALYSIS 
Baseline data (log- transformed in the case of minute 
ventilation, tidal volume and plasma adenosine 
concentration) were compared with values obtained during 
the last complete infusion stage and 2 min following the 
infusion using repeated measures analysis of variance and 
the Student -Newman -Keuls test. 
6.3 - RESULTS 
The maximum dose of adenosine administered was limited in 
all patients by symptoms and during the final complete 
stage, ranged from 6.1 to 16.8 mg /min (mean 10.8 mg /min) 
(88 to 182 µg /kg /min, mean: 130 µg /kg /min). In 4 patients 
the final infusion stage was stopped prematurely at the 
patients request. In these cases, data from the last 
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complete stage were used in the analysis. 
6.3.1 - CHANGES IN PLASMA ADENOSINE CONCENTRATION 
The mean plasma adenosine concentration increased from 
0.07 (range: 0.04 to 0.12) gM at baseline to 1.20 (range: 
0.42 to 2.04) µM during the final complete stage (P < 
0.001) (Fig. 6.1). There was a threshold infusion rate, 
which varied between patients, below which aortic plasma 
adenosine concentration did not change. The adenosine 
concentration 2 min post infusion was 0.07 (range: 0.03 
to 0.10, n = 6) µM which was not different from the 
baseline value (Fig. 7.1). 
6.3.2 - CHANGES IN RESPIRATION 
Minute ventilation increased from 5.5 (SD: 1.9) 1 /min at 
baseline to 10.9 (SD: 3.3) 1 /min at the maximum dose of 
adenosine (P < 0.001) (Fig 2). This was almost entirely 
due to a 101% increase in tidal volume from 0.33 (SD: 
0.12) 1 to 0.66 (SD: 0.25) 1 (P < 0.005). There was no 
significant change in respiratory frequency which was 17 
(SD: 3) breaths /min at baseline and 18 (SD: 4) 
breaths /min at the maximum dose of adenosine. Two minutes 
following the infusion minute ventilation was 5.0 (SD: 
1.6) 1 /min which was not different from the baseline 
value, but tidal volume, although less than during the 
infusion (P < 0.05), remained 74% higher than the 
baseline value (P < 0.05), and respiratory rate fell to 
12 (SD: 5) breaths /min (P < 0.025) indicating a change in 
breathing pattern. 
6.3.3 - CHANGES IN HEART RATE AND BLOOD PRESSURE 
Heart rate increased from 61 (SD: 12) beats /min at 
baseline to 72 (SD: 14) beats /min at the maximum dose (P 
< 0.01) and following the infusion fell to 67 (SD: 15) 
beats /min which was not significantly different from the 
baseline value. There were no significant changes in 
systolic, diastolic or mean blood pressure (138 (SD: 20), 
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Fig. 6.2 - Changes in minute ventilation during adenosine 
infusion. B, baseline. 
and 135 (SD: 21), 71 (SD: 20) and 98 (SD: 21) mmHg 
respectively at the maximum dose). 
6.3.4 - INDIVIDUAL RESPONSES 
In 3 patients (numbers 1,2,3) an initial increase in 
minute ventilation (of 69% by the end of the third 
infusion stage, 46% during the second stage and 33% 
during the first stage respectively) was accompanied by 
little change in the plasma adenosine concentration (0.12 
to 0.14 µM, 0.10 to 0.06 gM and 0.09 to 0.09 gM 
respectively) or heart rate (62 to 62, 56 to 56 and 70 to 
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64 beats /min respectively) although all subsequently 
showed increases in heart rate and adenosine 
concentration. In the remaining patients minute 
ventilation, heart rate and adenosine concentration 
increased in concert. 
6.3.5 - SYMPTOMS CAUSED BY ADENOSINE 
Symptoms reported were similar to those experienced in 
the other studies described in this thesis and included 
dyspnoea in 5 patients, flushing, chest discomfort and 
throat discomfort each in 3 patients, headache and limb 
paraesthesiae each in 2 patients and drowsiness and 
altered taste each in 1 patient. All symptoms resolved 
within 1 to 2 min of discontinuing the infusion. 
6.4 - DISCUSSION 
In this study the relationship between the adenosine 
concentration in arterial plasma from the distal aortic 
arch and minute ventilation during intravenous infusion 
of adenosine were examined. An increase in mean adenosine 
concentration from 0.07 to 1.20 µM was associated with a 
doubling in minute ventilation, a slight increase in 
heart rate and symptoms similar to those reported 
previously, but no significant change in arterial blood 
pressure. 
6.4.1 - CHANGES IN RESPIRATION 
The present unexpected finding that ventilation increased 
in 3 subjects in the absence of a detectable increase in 
adenosine concentration in the aorta might have been due 
to spontaneous variation in respiration. Alternatively it 
suggests that adenosine might stimulate respiration by an 
intra- pulmonary effect. Blood cells and pulmonary 
endothelial cells avidly take up adenosine (Hellewell & 
Pearson, 1983; Catravas, 1984; Das & Steinberg, 1988) so 
it would be possible for increased concentrations to 
pertain in the pulmonary circulation while little change 
is detected more distally. Sylvén et ál. (1987) reported 
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that the onset of respiratory stimulation by bolus 
injections preceded the development of atrioventricular 
block consistent with an action of adenosine in the lung, 
although their observations contrasted with the earlier 
findings of Watt and Routledge (1985) that the longest 
R -R interval on the ECG, reflecting both sinus slowing 
and atrioventricular block (Watt & Routledge, 1986b), 
occurred up to 2 s before the onset of the increase in 
respiration. Preliminary observations in the 
anaesthetised cat showed that adenosine stimulates 
intra- pulmonary vagal afferents (Cherniack et al., 1987) 
and increases respiration by an action unaffected by 
sino- aortic denervation (Runold et al., 1987). This 
however contrasts with the findings that respiratory 
stimulation by adenosine in the rabbit and rat is 
abolished by section of the nerve supply to the carotid 
body (Buss et al., 1986; Monteiro & Ribeiro, 1987). 
Symptoms or psychogenic factors might have 
contributed to the respiratory changes in the present 
study. That ventilation was increased largely by an 
increase in tidal volume is consistent with a 
chemoreceptor- mediated effect (Jennett et el., 1974; 
Newsom Davis and Stagg, 1974). However anxiety or 
unpleasant sensations have been reported to affect 
breathing in different ways (Cunningham & Gardiner, 1972; 
Hugelin, 1986) so it is difficult to predict the possible 
effects of combinations of such stimuli. Nevertheless as 
described in Chapter 4 adenosine infusion into the 
descending thoracic aorta was not associated with 
increased ventilation although the majority of subjects 
experienced chest or epigastric discomfort. Furthermore, 
as discussed in Chapter 3, while a single -blind infusion 
of adenosine caused a degree of respiratory stimulation 
in normal volunteers similar to that observed in the 
present study, a single -blind infusion of inosine caused 
no significant change, suggesting that the response to 
adenosine was not due to subjects' expectations. For 
these reasons a placebo was not used in the present 
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study. 
Other factors might have affected the ventilatory 
responses observed. Changes in blood gas tensions will 
have antagonised the increases in ventilation as 
discussed in Chapter 5. Other factors which might have 
affected the responses to adenosine, such as changes in 
cardiac output and left ventricular filling pressure and 
the other medications patients received, will be 
discussed in Chapter 7. 
6.4.2 - CHANGES IN PLASMA ADENOSINE CONCENTRATION 
Sampling of blood through a catheter for measurement of 
adenosine concentration poses particular problems as 
discussed in Chapter 2. Nevertheless the measured values 
during adenosine infusion are likely to have been 
sufficiently good estimates of the true values to allow 
an answer to be given to the main question posed by this 
study, i.e.: "Are the concentrations of adenosine which 
cause respiratory stimulation likely to be achieved 
physiologically ?" 
There is considerable variation amongst previously 
reported values of plasma adenosine concentration in man, 
probably largely due to differences in sampling and assay 
techniques (Table 2.1). Recently reported values for 
resting levels of adenosine in man range from 0.02 gM 
(Mann et al., 1986) to 0.15 µM in venous blood (Sollevi, 
1986), and 0.36 µM in arterial blood from patients with 
ischaemic heart disease (Sollevi, 1986), i.e. of a 
similar order of magnitude to the present data. It is of 
interest that Lönnroth et al. (1989) recently found, 
using a microdialysis technique, similar basal 
concentrations of adenosine (0.025 to 0.3 AM) in 
interstitial fluid of subcutaneous adipose tissue in 
humans. 
During adenosine infusion radial artery plasma 
concentrations, which are probably lower than central 
arterial concentrations, have been measured by 2 groups. 
During hypotension induced by adenosine infusion at 140 
110 
(SD: 40) µg /kg /min into the superior vena cava in 
anaesthetised patients, Sollevi et al. (1984b) observed 
an increase in radial artery adenosine concentration from 
0.15 (SD: 0.02) to 2.45 (SD: 0.65) AM. Their patients 
were pre- treated with dipyridamole, which probably 
increased plasma adenosine concentrations (Sollevi et 
al., 1984c). Biaggioni et al. (1986) observed an increase 
in radial artery adenosine concentration from 0.16 (SD: 
0.07) to 0.41 (SD: 0.19) µM during peripheral intravenous 
infusion at 129 (SD: 8) pg /kg /min in conscious subjects. 
The increase in aortic plasma concentration observed in 
the present study, from 0.07 (SD: 0.03) to 1.2 (SD: 0.53) 
pM, during infusion at 130 (SD: 30) pg /kg /min is 
consistent with those results. 
6.4.3 - ADENOSINE AND THE CONTROL OF BREATHING 
Monteiro and Ribeiro (1987) showed that the adenosine - 
induced increase in ventilation in the rat is probably 
due to an effect at A2 adenosine receptors, which 
generally mediate stimulation of adenylate cyclase (van 
Calker et al., 1979). The affinity of A2 receptors shows 
wide variation with half -maximal effects reported at 
adenosine concentrations varying from less than 1 pM to 
over 10 pM depending on the tissue and species studied 
(Daly, 1983). 
Due to rapid cellular uptake and metabolism of 
adenosine the maximum concentrations pertaining in the 
pulmonary circulation in this study may have been of the 
order of 10 to 20 pM, assuming a circulation time to the 
sampling point of 4 s (Treves et el., 1974) and a 
half -life of 1.5 s. Similarly the maximum concentrations 
in the carotid bodies may have been less than 1 pM. These 
results would therefore be consistent with an A2- mediated 
intra- pulmonary effect of adenosine but do not exclude an 
effect in the carotid bodies. 
Stimuli such as hypoxia which induce ATP degradation 
have been shown, predominantly in animals, to cause 
several -fold increases in adenosine concentration in a 
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number of tissues (Tables 6.2 and 6.3). In humans Sollevi 
(1986) reported plasma adenosine concentrations in 
umbilical arterial blood of hypoxic neonates ranging up 
to 2µM (mean 0.61 MM), i.e. several -fold higher than in 
normoxic adults. Concentrations in tissue interstitial 
fluid in that instance might have been even higher than 
plasma concentrations. These reports suggest that 
concentrations of adenosine similar to those observed in 
the present study may be achieved in vivo during states 
such as hypoxia. 
In conclusion these results are consistent with the 
suggestion (Watt and Routledge, 1985) that adenosine 
released during hypoxia may mediate or modulate the 
resultant ventilatory stimulation. However, despite 
previous evidence suggesting that adenosine - induced 
respiratory stimulation is mediated by the carotid 
bodies, the finding that ventilation increased in 3 
subjects without a detectable increase in plasma 
adenosine concentration suggests that an intra- pulmonary 
effect might also contribute. 
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Table 6.2 - Examples of increased tissue adenosine 
content in situations of increased ATP breakdown. 
Species 
Increase in 
Tissue Stimulus adenosine Reference 
content 
Rat Brain Hypoxia: 
Fi02 10.7% x3 






5 s x2 
60 s x6 Winn et al., 1979 
Heart: Ischaemia: 
ventricle 15 s x6 Olsson, 1970 
Heart: Cardioplegia: 
ventricle 15 °C for 10 min x4 Sollevi, 1986 
Hindlimb: Ischaemic 
muscle contraction: 
5 min x2 Dobson et al., 1971 
Dog Lung Hypoxia: 
95% N2 and 
5% CO2 for 
3 min x9 Mentzer et al., 1975 
Rat Kidney Ischaemia: 
30 s x3 
60 s x6 Osswald et al., 
1977 
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Table 6.3 - Examples of increased adenosine 











for 10 min 
a) Frontal 
cortex 
0.68 to 1.60 
b) Thalamus 1.03 to 2.60 Park et al., 1987 







plasma ligation 0.06 to 0.22 Sollevi, 1986 
Dog Hindlimb: Exercise: 
venous stimulated 





plasma 5 min 0.04 to 0.22 Dobson et el., 1971 
Rat Liver: 
perfusate 
Hypoxia 0.05 to 1.1 Arnold & Cysyk, 1986 
*The left hand figure represents the basal value and the right hand figure the value 
in response to the stimulus indicated. 
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CHAPTER 7 - ACUTE HAEMODYNAMIC CHANGES DURING INTRAVENOUS 
INFUSION OF ADENOSINE 
7.1 - INTRODUCTION 
The studies described so far in this thesis have shown 
that infusion of adenosine in conscious subjects produces 
haemodynamic as well as respiratory changes. Although 
often considered separately the cardiovascular and 
respiratory systems are intimately related both 
anatomically and physiologically. Changes in one system 
can affect the other. It would therefore be expected 
that, in view of its marked effects on ventilation, 
however caused, adenosine infusion would produce 
haemodynamic changes. Furthermore adenosine has been 
shown to cause local changes in the cardiovascular system 
including potent vasodilation in many tissues as 
discussed in Chapter 1. Such changes and their systemic 
haemodynamic consequences might affect respiration. 
Whether and in what circumstances adenosine could be 
useful as a respiratory stimulant depends in part on the 
nature and magnitude of its cardiovascular effects. 
Adenosine has been used to induce hypotension in 
patients undergoing intracranial surgery (Sollevi et el., 
1984b; Öwall et al., 1987) and detailed studies of its 
haemodynamic effects in anaesthetised patients have been 
performed. Sollevi (1986) suggested that adenosine might 
be useful for reducing afterload in patients with heart 
failure. However, as shown in this thesis, infusion of 
adenosine into conscious subjects produces effects not 
seen during anaesthesia, eg) marked stimulation of 
respiration and various symptoms. In addition the 
patterns of change in heart rate and blood pressure in 
conscious subjects differ from those reported in 
anaesthetised patients. 
Since the haemodynamic effects of adenosine infusion 
and their relationship to the respiratory changes in 
conscious subjects had not previously been fully defined 
they were the subject of this study. 
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7.2 - METHODS 
7.2.1 - PATIENTS AND INFUSIONS 
The subjects were 16 patients (11 men), aged 37 to 64 
(mean: 52) years and weighing 63 to 95 (mean: 78) kg, 
undergoing cardiac catheterisation for investigation of 
chest pain (Table 7.1). Patients with unstable angina or 
heart failure were excluded. Some patients suspected of 
having non -cardiac chest pain who nevertheless required 
coronary arteriography were included: 9 patients had 
normal coronary arteriograms. Exercise stress tests which 
had been performed in 8 of these patients were negative. 
Although microvascular angina was not specifically 
excluded, all 9 patients with normal arteriograms were 
ultimately considered to have non -cardiac pain. The other 
7 patients had coronary artery disease (Table 7.1). 
Patients were receiving a variety of medications as 
shown in Table 7.1. In 3 patients treatment with a 
ß- adrenoceptor antagonist (atenolol) had been 
discontinued 30 - 45 h previously. All patients received 
diazepam 10mg orally one hour before catheterisation. All 
had abstained from caffeine -containing beverages for at 
least 6 h. 
After baseline measurements solutions were infused 
single blind via the femoral venous sheath. Placebo (0.9% 
sodium chloride) was given for 5 min, followed by 
adenosine with dosage increments every 5 min except in 
the case of the first adenosine stage which was continued 
for 6 min to ensure clearing of the dead -space of the 
venous sheath. An initial dose of adenosine of 4.3 mg /min 
was used because studies previously described in this 
thesis suggested that such a dose would produce mild 
effects. Subsequent doses were 6.1, 8.5, 11.9 mg /min as 
tolerated. At the end of each stage, patients were asked 
to report any symptoms and if they were willing to 
continue to the next dose. 
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Table 7.1 - Patient characteristics. 
Patient Age 
(years) 
Sex Height Weight Treatment Diagnosis 
(m) (kg) 
1 56 M 1.73 85 Z 3 -VD 
2 63 M 1.69 72 B C N 3 -VD 
3 45 M 1.75 80 B C 1-VD 
4 60 M 1.71 90 B CON 2-VD 
5 50 M 1.73 72 Z Musculoskeletal pain 
6 39 F 1.64 62 Oesophageal spasm 
7 37 F 1.63 71 B Musculoskeletal pain 
8 52 F 1.61 80 Musculoskeletal pain 
9 51 M 1.77 94 Musculoskeletal pain 
10 64 M 1.69 71 B *C NE Oesophageal spasm 
11 62 F 1.60 70 B* L Hyperventilation 
12 54 M 1.87 95 C 2 -VD 
13 55 M 1.63 78 Hyperventilation 
14 44 F 1.52 60 B* 1 -VD 
15 55 M 1.84 83 A Musculoskeletal pain 
16 47 M 1.70 85 B C 1 -VD 
Mean 52 1.69 78 
SD 8 0.09 10 
M, male; F, female; 1 -VD, 1 vessel coronary artery disease; 2 -VD, 2 vessel disease; 
3 -VD, 3 vessel disease; B, B- adrenoceptor antagonist; *withdrawn at least 30 h before 
the study; C, calcium antagonist; D, diuretic; N, long- acting nitrate; A, amiodarone; 
E, etrinate; L, lederfen; Z, benzodiazepine. 
7.2.2 - MEASUREMENTS AND SAMPLES 
The study was performed following an equilibration period 
of at least 10 min after insertion of catheters and 
before any angiograms. Except as indicated below measured 
variables were recorded following the equilibration 
period (baseline), during the final 3.5 min of each 
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infusion stage and 5 min following the end of the final 
infusion stage. The first adenosine stage was continued 
for 2.5 min prior to measurements being made to allow 
clearing of the deadspace of the infusion sheath. It was 
reasoned that steady -state concentrations of adenosine 
would be achieved quickly because of its very short 
half -life and because at the doses used recirculating 
venous concentrations are unchanged as shown in Chapter 
5. 
An ECG was recorded throughout using a single bipolar 
lead (modified standard lead 2) and was used to determine 
heart rate and PR interval. 
A pigtail catheter (7F gauge) was inserted through an 
8F sheath in the right femoral artery for measurement of 
systemic and, in some patients, left ventricular 
pressures. A balloon tipped catheter (Swan -Ganz, 7F 
gauge) was inserted via a 9F sheath in the right femoral 
vein and positioned for measurement of right atrial 
pressure, pulmonary artery pressure and pulmonary 
capillary wedge pressure (Swan et ál., 1970). Pressures 
(mean of at least five non -ectopic beats) were recorded 
via the catheters which were connected to Bell and Howell 
strain gauge transducers, a Cambridge amplifier, and a 
Mingograph multichannel recorder (8 patients), or to 
Hewlett Packard quartz transducers and amplifier and a 
Gould recorder (8 patients). Patients were supine and the 
zero reference level was at the sternal angle. Arterial 
blood pressure was not measured in 2 patients (nos. 6 and 
7) because of a transducer fault. In the last 8 patients 
(3 with coronary disease) left ventricular end -diastolic 
pressure was also measured at baseline and during the 
final infusion stage. 
Cardiac output (mean of at least 3 estimations) was 
measured by the thermodilution technique (Ganz et ál., 
1971). Ten ml of ice -cold 5% dextrose solution was 
rapidly injected via the lumen of the Swan -Ganz catheter 
which terminated in the right atrium. The temperature 
transient was detected by a thermistor at the tip of the 
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catheter which was situated in the pulmonary artery. 
Cardiac output was calculated on -line using an 
Instrumentation Laboratories computer. 
Respiration was recorded using a respiratory 
inductance plethysmograph in the first 12 patients. 
Isovolume manoeuvres performed by each patient were used 
to determine the relative contributions of the abdominal 
and ribcage signals. Volume calibration was then 
performed using a spirometer (Micro Medical Instruments). 
A spirometer fault prevented this in the first case. 
Respiratory rate, tidal volume and minute ventilation 
were determined from the respiratory trace, recorded on a 
chart recorder. 
Blood (1ml) was sampled from the pulmonary artery and 
aorta at each stage for determination of oxygen 
saturation (OSM2 Hemoximeter, Radiometer, Copenhagen). 
Samples (2ml) were also obtained in the last 8 patients 
at baseline, during the final infusion stage, and 5 min 
post- infusion, for determination of arterial blood gas 
tensions and pH (Ciba- Corning Model 178 Blood Gas 
Analyser). 
Derived haemodynamic indices were calculated using 
standard formulae (WHO /ISFC Task Force on Haemodynamics, 
1985), as follows: 
Mean PAP - Mean PCWP 
PVR - x 80 
CO 
Mean BP - Mean RAP 
SVR - x 80 
CO 
SVI = 





Where PVR and SVR are pulmonary and systemic vascular 
resistances respectively (dyne.s.cm -5), PAP is pulmonary 
artery pressure, PCWP is pulmonary capillary wedge 
pressure, BP is systemic blood pressure and RAP is right 
atrial pressure (mmHg), CO is cardiac output (1 /min), CI 
is cardiac index (1 /min /m2), SVI is stroke volume index 
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(ml /beat /m2) and HR is heart rate (beats /min). 
Total body oxygen consumption (VO2; ml /min) was 
calculated from arteriovenous oxygen content difference 
(AV- O2cont; m1/1) and cardiac output (CO; 1 /min) as 
follows (Rubin et el., 1982): 
VO2 = CO x AV-O2cont (Eq. 7.4) 
AV- O2cont was calculated from the arteriovenous 
difference in oxygen saturation (AV- O2sat; %) and 
haemoglobin concentration (Hb; g /dl) as follows (WHO /ISFC 
Task Force on Haemodynamics, 1985): 
AV-O2cont = 1.34 x AV-O2sat x Hb (Eq. 7.5) 
where 1.34 is the empirical value of oxygen capacity of a 
gram of haemoglobin. 
7.2.3 - STATISTICAL ANALYSIS 
Repeated measures analysis of variance and the Student - 
Newman -Keuls test, or the paired t -test, where 
appropriate, were used to analyse changes in measured 
variables. Differences between subgroups according to 
diagnosis and treatment were compared using the unpaired 
t -test, the Mann -Whitney u -test or the Kruskal- Wallis 
test for non -parametric analysis of variance, as 
appropriate. Correlations were examined using the 
product- moment or Spearman rank correlation coefficients. 
7.3 - RESULTS 
The maximum dose of adenosine given ranged from 6.1 to 
11.9 (mean: 8.5,(SD: 2.3) mg /min, equivalent to 107.9 
(SD: 24.3) gg /kg /min)and correlated with both body 
weight (r = 0.60, P < 0.02) and body surface area (r = 
0.74, P < 0.001). All patients received at least two 
doses, 4.3 and 6.1 mg /min, equivalent to 56.5 (SD: 7.8) 
and 79.3 (SD: 10.9) gg /kg /min. 
7.3.1 - EFFECTS OF PLACEBO 
There were no significant changes during the placebo 
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saline infusion (Figs. 7.1 to 7.5 and Table 7.2). 
7.3.2 - HAEMODYNAMIC AND RESPIRATORY EFFECTS OF ADENOSINE 
a) Lowest Dose 
At the lowest dose of adenosine pulmonary vascular 
resistance fell by 20% (Fig. 7.3), but there were no 
other significant haemodynamic changes (Fig. 7.1 to 7.3). 
Minute ventilation, however, increased by 44% (Fig. 7.5). 
b) Maximum Dose 
Changes during the maximum dose are summarised in Table 
7.2. At the maximum dose adenosine infusion increased 
heart rate by 34% but did not affect systolic, diastolic 
or mean systemic blood pressure (Fig. 7.1). PR interval 
was unchanged. Cardiac index increased by 52% and stroke 
index by 12% (Fig. 7.1). Mean pulmonary capillary wedge 
pressure and pulmonary artery pressure both increased by 
6 (SD: 5) mmHg to 10 (SD: 5) and 16 (SD: 5) mmHg 
respectively. Mean right atrial pressure did not change 
significantly (Fig. 7.2). Pulmonary and systemic vascular 
resistances fell, by 38% and 34% respectively (Fig. 7.3). 
Total oxygen consumption showed no significant change 
(Fig. 7.4). The product of systolic blood pressure and 
heart rate, an approximate index of myocardial work 
(Gobel et al., 1978), increased by 28% (Fig. 7.4). 
Left ventricular end -diastolic pressure, measured in 
8 patients, increased by 9 (SD: 8) mmHg to 14 (SD: 10) 
mmHg. The change in pulmonary capillary wedge pressure in 
this group, 3 (SD: 2) to 9 (SD: 6) mmHg (P < 0.05), was 
similar to the change in the 8 patients (4 with coronary 
artery disease) in whom left ventricular end -diastolic 
pressure was not measured directly: 3 (SD: 3) to 10 (SD: 
5) mmHg, P < 0.001. 
Minute ventilation increased by 84 %, due largely to a 
60% increase in tidal volume (Fig. 7.5). The arterial 
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Fig. 7.1 - Changes in heart rate, blood pressure, cardiac 
index and stroke volume index during adenosine infusion. 
B, baseline; C, control infusion; I, adenosine infusion at 4.3 mg /min; II, adenosine 
infusion at 6.1 mg /min; M, maximum dose of adenosine for each subject; 5', 5 min 
following adenosine infusion; * *P < 0.01, * * *P < 0.001 for comparisons with baseline. 
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Fig. 7.2 - Changes in mean right atrial, pulmonary artery 
and pulmonary capillary wedge pressures during adenosine 
infusion. Symbols and abbreviations as in Fig. 7.1. n = 
16. 
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Fig. 7.3 - Changes in systemic and pulmonary vascular 
resistance during adenosine infusion. *P < 0.05. Other 
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Fig. 7.4 - Changes in oxygen consumption and double 
product during adenosine infusion. Symbols and 
abbreviations as in Figs. 7.1 and 7.3. n = 16 except 
where shown. 
3) mmHg and arterial pH increased from 7.39 (SD: 0.03) to 
7.45 (SD: 0.02). The arterial oxygen tension increased 
slightly (by 2 mmHg), but this was not statistically 
significant (Fig. 7.5). 
There was a significant correlation between the 
percentage increases in heart rate and minute ventilation 
(rs = 0.615, P < 0.05, n = 12), but neither of these 
correlated significantly with the percentage decrease in 
either pulmonary vascular resistance (rs = 0.165, n = 16 
and rs = -0.406, n = 12, respectively) or systemic 
vascular resistance (rs = 0.297, n = 14 and rs = -0.091, 
n = 10, respectively). 
c) Highest Dose Without Symptoms 
Ten patients received at least 1 dose of adenosine 
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Fig. 7.5 - Changes in respiration, blood gas tensions and 
pH during adenosine infusion. Symbols and abbreviations 
as in Figs. 7.1 and 7.3. 
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Table 7.2 - Changes during the placebo infusion and 
adenosine infusion at the maximum dose. 
Baseline Placebo Adenosine 




HR (beats/min) 69 (21) 67 (19) 92 (24) < 0.001 < 0.001 
PR interval (s)(n=14) 0.18 (0.02) 0.18 (0.02) 0.19 (0.02) NS NS 
SBP (mmHg)(n=13) 127 (20) 134 (16) 124 (16) NS NS 
DBP (mmHg)(n=13) 70 (8) 73 (6) 67 (8) NS NS 
MBP (mmHg)(n=14) 94 (12) 96 (9) 92 (11) NS NS 
CI 0/minim') 3.4 (0.8) 3.3 (0.8) 5.1 (1.7) < 0.001 < 0.001 
SVI (ml/beat/m') 52 (17) 52 (17) 58 (21) < 0.01 < 0.001 
RAP (mmHg) 1 (3) 2 (2) 2 (3) NS NS 
PAP (mmHg) 10 (3) 12 (3) 16 (5) < 0.001 < 0.001 
PCWP (mmHg) 3 (2) 4 (3) 10 (5) < 0.001 < 0.001 
LVEDP (mmHg)(n=8) 5 (6) 14 (10) < 0.05 
SVR (dyne.s.cm-5)(n=14) 1209 (299) 1270 (319) 794 (267) < 0.001 < 0.001 
PVR (dyne.s.cm-5) 93 (32) 94 (30) 58 (18) < 0.001 < 0.001 
RPP (mmHg.beats/min) 8647 (4018) 8640 (3261) 11048 (3248) < 0.001 < 0.001 
fR (breaths/min)(n=11) 18 (4) 16 (3) 20 (4) < 0.05 < 0.01 
VT (l)(n=11) 0.28 (0.11) 0.30 (0.14) 0.45 (0.15) < 0.001 < 0.001 
V (l/min)(n=11) 4.9 (2.1) 4.8 (2.1) 9.9 (2.9) < 0.001 < 0.001 
V02 (ml/kg/m') 3.4 (1.1)# 3.5 (1.0) 3.7 (1.2) NS NS 
Pa02 (mmHg)(n=8) 83 (13) 85 (12) NS 
PaCO2 (mmHg)(n=8) 39 (5) 31 (3) < 0.001 
Arterial pH (n=8) 7.39 (0.03) 7.46 (0.02) < 0.001 
Data are mean (SD). *P values refer to: (a) adenosine vs. baseline and (b) adenosine 
vs. placebo. NS, not significant; HR, heart rate; SBP, systolic arterial blood press- 
ure; DBP, diastolic blood pressure; MBP, mean arterial blood pressure; CI, cardiac 
index; SVI, stroke volume; RAP, mean right atrial; PAP, mean pulmonary artery 
pressu- 
re; PCWP, mean pulmonary capillary wedge pressure; SVR, systemic vascular 
resistance; 
PVR, pulmonary arteriolar resistance; RPP, rate - pressure product; fR, respiratory 
frequency; VT, tidal volume; V, minute ventilation; V02, total oxygen 
consumption; 
Pa02, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; 
#n = 15. 
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Table 7.3 - Changes during adenosine infusion at the 
maximum dose given without causing symptoms. 
Baseline Placebo Adenosine 
(n = 10 except where indicated) a 
P* 
b 
HR (beats/min) 61 (8) 59 (7) 62 (8) NS NS 
CI (l/min/m2) 3.4 (0.9) 3.3 (0.8) 3.6 (1.4) NS NS 
PAP (mmHg) 10 (2) 12 (3) 10 (3) NS NS 
PCWP (mmHg) 3 (3) 4 (3) 4 (3) NS NS 
PVR (dyne.s.cm-5) 96 (30) 99 (28) 76 (28) < 0.05 < 0.05 
SVR (dyne.s.cm-5) (n=9) 1,104 (280) 1,173 (306) 1,168 (400) NS NS 
V (l/min)(n=8) 5.4 (2.4) 5.2 (2.3) 6.7 (2.2) NS NS 
Data are mean (SD). *P values refer to: (a) adenosine vs. baseline and (b) adenosine 
vs. placebo. NS = not significant. Abbreviations as in Table 7.2. 
maximum dose without symptoms, 4.7 (SD: 0.7, range: 4.3 
to 6.1) mg /min, caused a 21% fall in pulmonary vascular 
resistance but no other significant changes (Table 7.3). 
7.3.3 - SYMPTOMS CAUSED BY ADENOSINE 
The dose of adenosine at which symptoms were first 
reported varied (Fig. 7.6). Precordial discomfort was 
reported by 14 patients: 6 of the 7 with coronary disease 
and 8 of the 9 with normal angiography. Ten patients 
compared the character of the discomfort with their usual 
chest pain: 6 (3 with coronary disease, 3 without) 
thought it was the same and 4 (2 with coronary disease, 2 
without) thought it was different. Two patients who 
experienced their usual chest pain developed 1 mm ST 
segment depression. One had normal angiography, the other 
two -vessel disease. 
Dyspnoea was reported by 11 patients and usually 
first occurred at higher doses than precordial discomfort 
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Fig. 7.6 - Onset of symptoms during the study. III, 
adenosine infusion at 8.5 mg /min; IV, adenosine infusion 
at 11.9 mg /min. Other symbols as in Fig. 7.1. 
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or neck in 6 patients (with another 6 visibly flushed), 
headache in 4, lightheadedness in 3 and epigastric 
discomfort in 1. 
7.3.4 - CHANGES FOLLOWING ADENOSINE INFUSION 
Most variables were returning towards baseline values 5 
min after the infusion (Figs. 7.1 to 7.3). Minute 
ventilation tended to fall below the baseline value (by 
28 %) and this was associated with a fall in arterial 
oxygen tension to 74 (SD: 9.5) mmHg, but these changes 
were not statistically significant (Fig. 7.5). Oxygen 
consumption increased to 121% of the baseline value 5 min 
after the infusion (P < 0.01 ) (Fig. 7.4). 
All symptoms resolved completely within 1 to 2 min of 
stopping the infusion. 
7.3.5 - EFFECTS OF DIAGNOSIS ON RESPONSES TO ADENOSINE 
There were no significant differences, in baseline 
values, or changes during adenosine infusion, of any 
variable, between patients with and without coronary 
artery disease. 
7.3.6 - EFFECTS OF TREATMENT WITH ß- ADRENOCEPTOR 
ANTAGONISTS ON RESPONSES TO ADENOSINE 
In the 3 patients whose B- adrenoceptor antagonist 
treatment, atenolol, was discontinued between 30 and 45 h 
before the study, baseline heart rate, 93 (SD: 28) 
beats /min, was significantly higher than the value, 55 
(SD: 8) beats /min, in those continuing treatment (P < 
0.05), and tended to be higher than the value, 69 (SD: 
17) beats /min, in those who had never received such 
treatment (NS). There were no other differences in 
baseline variables between these three groups. 
The rise in left ventricular end -diastolic pressure, 
during adenosine infusion, in patients in whom atenolol 
was recently withdrawn, 2 (SD: 4) mmHg (n = 3), was 
significantly smaller than the change, 14 (SD: 6) mmHg (n 
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Fig. 7.7 - Change in left ventricular end -diastolic 
pressure in 8 subjects during adenosine infusion at the 
maximum dose. N, not treated with ß- adrenoceptor 
blockers; T, treated with ß- adrenoceptor blockers: open 
symbols indicate patients in whom the treatment was 
discontinued at least 30 hours prior to the study. 
(Fig. 7.7). The adenosine - induced increase in pulmonary 
capillary wedge pressure in those patients in whom 
atenolol had recently been withdrawn, 2.0 (SD: 4.4) mmHg 
(n = 3), was likewise smaller, though not significantly 
so, than the changes, 7.9 (SD: 4.9) mmHg (n = 8) and 6.6 
(SD: 2.6) mmHg (n = 5), in those patients who had never 
received such a drug or who continued treatment 
respectively. There were no other significant differences 
during adenosine infusion between the three groups. In 
particular there were no differences in the heart rate 
increment between patients not receiving a ß- adrenoceptor 
antagonist, those who were ß- blocked and those in whom 
such treatment had recently been withdrawn (24 (SD: 9, n 
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= 8), 21 (SD: 7, n = 5) and 26 (SD: 8, n = 3) beats /min 
respectively). 
7.4 - DISCUSSION 
This study demonstrates that in conscious subjects 
intravenous infusion of adenosine causes both systemic 
and pulmonary vasodilation. At the lowest dose used, 
there was a selective effect on the pulmonary 
circulation. At higher doses, adenosine also increased 
left ventricular filling pressure, an effect not 
previously described. 
Results of some previous detailed studies of the 
haemodynamic effects of adenosine in anaesthetised 
animals and man are summarised in Tables 7.4 and 7.5. 
Universal findings have been that adenosine causes 
systemic vasodilation, a reduction in systemic blood 
pressure, little change in right atrial, pulmonary artery 
or pulmonary capillary wedge pressures and increased 
coronary flow. Heart rate and cardiac output responded 
variably in animals, but both were increased in man, 
although the changes in heart rate were small. Pulmonary 
vascular resistance was consistently reduced in man (see 
below), albeit not always to a statistically significant 
degree. Stroke work, where measured, has been shown to 
fall. Myocardial oxygen consumption increased in two 
animal studies in both of which adenosine caused 
substantial increases in heart rate. Responses in man 
have been variable. Changes in total oxygen consumption 
have been small. Where measured Pa02 has been shown to 
decrease. 
Compared with the findings in anaesthetised patients 
the main differences observed in this study in conscious 
subjects were: greater increases in heart rate and 
cardiac output, no change in systemic blood pressure and 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.5 - Haemodynamic changes during adenosine 
infusion in anaesthetised patients. 
Sollevi et Öwall et al. ÖwaLl et al. Öwall et al. Zäll et al. 




10 47 5 6 
intracranial intracranial intracranial abdominal 
































B-blockers phenoperidine phenoperidine phenoperidine 
pancuronium pancuronium pancuronium 
mannitol mannitol mannitol 
N20 
Dipyridamole 
Adenosine dose 140 (40)2 
(µg /kg /min)1 
HR (beats /min) +9 
** 
BP (mmHg) -36 ** 
CO or CI ( %) 
** 
SVI ( %) 
CSBF ( %) 
RAP (mmHg) +0.4 
PAP (mmHg) +2.1 
PCWP (mmHg) +1.4 
SVR or SVRI ( %) -63 ** 
PVR or PVRI ( %) 15 
CVR ( %) 
LVSWI ( %) 
RVSWI ( %) 
MV02 ( %) 
Vol ( %) -12* 



























































Haemodynamic variables are expressed as the change in the mean value compared with 
control. HR, heart rate; BP, mean systemic arterial blood pressure; CO, cardiac 
output; CI, cardiac index; SVI, stroke volume index; CSBF, coronary sinus blood flow; 
RAP, mean right atrial or central venous pressure; PAP, mean pulmonary artery 
pressure; PCWP, mean pulmonary capillary wedge pressure; SVR(I), systemic vascular 
resistance (index); PVR(I), pulmonary vascular resistance (index); CVR, coronary 
vascular resistance; LVSWI, left ventricular stroke work index; RVSWI, right 
ventricular stroke work index; MV02, myocardial oxygen consumption; V02, total oxygen 
consumption; Pa02, arterial oxygen tension. linfused into superior vena cava or right 
atrium, mean (SEM); 2patients pretreated with dipyridamole; 3n = 7; 4n = 21; P < 
0.05; * *P < 0.01. 
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7.4.1 - EFFECTS OF ADENOSINE ON SYSTEMIC AND PULMONARY 
VASCULAR RESISTANCE 
Although adenosine has been used as a systemic 
vasodilator during anaesthesia (Sollevi et al., 1984; 
Öwall et ál., 1987), the present study showed that in 
conscious subjects infusion rates of adenosine sufficient 
to reduce peripheral vascular resistance usually cause 
symptoms. This may limit the clinical use of adenosine as 
a systemic vasodilator. Bush et al. (1989) recently 
reported that adenosine infusion at 70 µg /kg /min 
increased effective pulmonary blood flow and reduced 
estimated systemic vascular resistance whereas infusion 
at 30 µg /kg /min was without effect. Most of their 
subjects experienced side -effects at 70 µg /kg /min and six 
said they would not have tolerated a higher dose. Edlund 
et al. (1990) showed in healthy volunteers that adenosine 
infusion into a central vein at rates up to 80 µg /kg /min 
caused reduction of more than 50% in systemic vascular 
resistance associated with a doubling of cardiac output. 
They also observed a 28 %, but not significant, reduction 
in pulmonary vascular resistance. All of their subjects 
developed side -effects and only 5 were willing to receive 
the maximum infusion rate. 
The selective effect of adenosine on the pulmonary 
circulation at lower doses observed in the present study 
might be due to lower concentrations reaching the 
systemic circulation because of rapid uptake of adenosine 
by endothelial (Catravas, 1984) and red blood cells 
(Klabunde, 1983). 
Previous reports of the effects of adenosine on the 
pulmonary vasculature have been conflicting. Drury and 
Szent -Györgyi (1929) observed that adenosine increased 
pulmonary artery pressure in a dog heart -lung prepara- 
tion. Bennet and Drury (1931) inferred that adenosine 
caused pulmonary vasoconstriction from rather crude exp- 
eriments in perfused rabbit lungs. Gaddum & Holz (1933) 
showed that in isolated perfused cat lungs small doses of 
adenosine produced transient vasodilation while larger 
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doses produced initial dilation followed by vasoconstr- 
iction. Green and Stoner (1950) observed that intravenous 
injections of adenosine increased pulmonary artery press- 
ure in cats. More recently Hyman et al. (1971) reported 
that intra -lobar infusion of adenosine had no effect in 2 
dogs but Wiklund et al. (1987) reported that adenosine 
(approximately 1 to 100 AM) enhanced basal tone and 
contractile responses to transmural nerve stimulation and 
noradrenaline in isolated strips of guinea pig pulmonary 
artery. Furthermore Biaggioni et al. (1989) found that 
intravenous infusions of adenosine caused pulmonary 
vasoconstriction in unanaesthetised sheep. These changes 
were associated with a slight fall in cardiac output so 
they are of doubtful relevance to humans. 
In contrast to most of the previous observations 
Mentzer et al. (1975) showed that adenosine infusion in 
the dog caused pulmonary vasodilation during normoxia and 
prevented the pulmonary pressor response to hypoxia. The 
latter effect has also been shown recently in isolated 
perfused rat lungs (Jolin et el., 1989). The cause of the 
discrepancies in these observations is not clear but 
there are probably species differences. In addition 
adenosine might exert contrasting effects at different 
concentrations or at different sites in the pulmonary 
artery wall. A further possibility is suggested by the 
recent observations in the cat by Neely et el. (1989) 
that at low pulmonary vascular tone adenosine was 
vasoconstrictor whereas when pulmonary vascular tone was 
increased it was vasodilator. 
Recently, several studies have shown a fall in 
pulmonary vascular resistance of approximately 30% during 
adenosine infusion in anaesthetised patients (see Table 
7.5), and Barnes et al. (1988) reported that adenosine 
relaxed pre- constricted human pulmonary arteries in 
vitro. Although patients with pulmonary hypertension were 
not studied in the present work, the results suggest that 
the effects of adenosine on the pulmonary circulation in 
such patients merit investigation. Gaba et el. (1986) 
136 
reported that adenosine did not alter pulmonary vascular 
resistance in patients with chronic obstructive pulmonary 
disease. However the highest dose of adenosine given was 
equivalent to only 27 Ag /kg /min, compared with the mean 
lowest dose in the present study of 57µg /kg /min, and all 
of their patients were also treated with the potent 
adenosine antagonist theophylline. 
7.4.2 - EFFECTS OF ADENOSINE ON HEART RATE AND BLOOD 
PRESSURE 
This study confirmed the findings discussed in earlier 
chapters that adenosine infusion in conscious subjects 
increases heart rate but does not affect mean arterial 
blood pressure, although it may increase pulse pressure. 
The mechanisms of the increase in heart rate are not 
clear. A response to symptoms may contribute. Some but 
not all workers have shown sympathetic activation during 
adenosine infusion in conscious subjects (Biaggioni et 
ál., 1986; Biaggioni et ál., 1987; Fuller et ál., 1987; 
Conradson et al., 1987; Edlund et ál., 1990). However 
Conradson et al. (1987) suggested that the increase in 
heart rate is mediated predominantly by reduced cardiac 
vagal tone. This is supported by the present finding that 
the increase was not modulated by treatment with a ß- 
blocker. However this finding contrasts with the observ- 
ation that ß- blockade did seem to reduce the increase in 
heart rate caused by adenosine in the study discussed in 
Chapter 4, suggesting that at least in that study sympa- 
thetic activation contributed to the heart rate changes. 
A major component of the increase may be secondary to 
the augmentation of ventilation, mediated in a similar 
way to the increase in heart rate caused by hypoxic 
stimulation of the carotid body in dogs (Daly & Scott, 
1958) or systemic hypoxia in man (Kimura it el., 1988). 
Consistent with this suggestion is the finding that the 
increase in heart rate correlated with the increase in 
minute ventilation, but not with the changes in systemic 
or pulmonary vascular resistance, which might have been 
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expected to cause reflex effects. Furthermore, injection 
of adenosine in the aortic arch proximal to the carotid 
circulation has been shown to cause an initial increase 
in heart rate and systolic blood pressure before the 
onset of peripheral vasodilation, whereas more distal 
injection does not (Biaggioni et al., 1987). Against this 
explanation is the finding in the present study that at 
the lowest dose causing a significant increase in 
ventilation heart rate was unchanged. 
That a smaller increase in heart rate has been 
observed in anaesthetised subjects may be partly due to 
pharmacological (Zimpfer et ál., 1981) or mechanical 
attenuation of the ventilatory changes. However other 
factors such as a greater direct negative chronotropic 
action due to the larger doses of adenosine used or 
attenuation of baroreceptor effects cannot be excluded. 
The present results suggest that the bigger increase in 
heart rate in conscious subjects contributes 
substantially to the larger rise in cardiac index and 
consequently the unchanged mean blood pressure despite 
peripheral vasodilation. 
As discussed in Chapter 1 adenosine can depress 
conduction in the atrioventricular node. Although a 
slight increase in mean PR interval and occasional first 
degree heart block have been observed with adenosine 
infusion during anaesthesia (Öwall et ál., 1988a), no 
such changes were observed in the present study, where 
lower doses of adenosine were used. 
7.4.3 - EFFECTS OF ADENOSINE ON LEFT VENTRICULAR FILLING 
PRESSURE 
An unexpected finding in this study was an acute increase 
in left ventricular end -diastolic pressure and its 
indirect measure pulmonary capillary wedge pressure at 
the higher doses of adenosine. 
Ischaemia might have caused these changes. Occasional 
cases of ischaemia have been observed during 
adenosine - induced hypotension (Öwall et ál., 1988a). 
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However in those cases the hypotension would have reduced 
coronary perfusion pressure. Edlund et al. (1989) 
reported that adenosine infusion caused typical anginal 
pain in 6 patients with known ischaemic heart disease, 
with the development of associated ST segment depression 
suggestive of ischaemia on the ECG in 5. These workers 
suggested that the changes might be due to an adenosine - 
induced coronary steal, since they occurred with only 
minor increases in cardiac work, as judged by the small 
alterations in heart rate and unchanged blood pressure. 
However Belvedere et al. (1990) reported that during 
adenosine infusion at 140 µg /kg /min chest pain was 
equally common in normal volunteers (22/41) and patients 
with coronary disease (15/26). Furthermore whilst 8/26 
patients developed "non- specific" ECG changes none showed 
changes diagnostic of ischaemia. 
A coronary steal phenomenon has been described during 
adenosine infusion in dogs (Gallagher et ál., 1980; 
Patterson & Kirk, 1983; Gewirtz et ál., 1983) but may be 
more likely to occur when coronary perfusion pressure is 
reduced (Buffington et al., 1987). The increase in 
myocardial work suggested by the increase in the 
rate -pressure product in the present study might also 
have contributed to the development of ischaemia. However 
the change in end -diastolic pressure occurred equally in 
patients with and without coronary artery disease, with 
and without chest pain (discussed below) and, except in 2 
patients, without ECG changes consistent with ischaemia. 
The rise in end -diastolic pressure might represent 
the consequence of a negative inotropic effect, 
consistent with the known ability of adenosine to 
antagonise both the release of noradrenaline and the 
ß- receptor mediated responses to catecholamines in the 
myocardium as discussed in Chapter 1. This might also 
explain the further observation, albeit in small numbers, 
that the rise in end -diastolic pressure was smaller in 
patients investigated 30 to 45 h after stopping atenolol, 
a time when rebound ß- receptor hypersensitivity has been 
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demonstrated (Schwartz et el., 1981). However, it is 
difficult to implicate a negative inotropic effect when 
the rise in left ventricular end -diastolic pressure was 
associated with an increase in stroke output. 
A further possible explanation is that adenosine 
might have reduced ventricular compliance by increasing 
turgor through its coronary dilator action (Watt et al., 
1987c), as has been described in experimental animals 
(Vogel et ál., 1982). Limitation of such an increase in 
turgor by hypotension and reduced coronary perfusion 
pressure could explain the apparent absence of an 
adenosine - induced increase in left ventricular filling 
pressure during anaesthesia. 
7.4.4 - EFFECTS OF ADENOSINE ON RESPIRATION 
In this study ventilation was first increased at a dose 
of adenosine that caused no haemodynamic changes apart 
from a fall in pulmonary vascular resistance. Wasserman 
et el. (1974) showed in dogs that an increase in cardiac 
output causes an increase in pulmonary ventilation, 
so- called "cardiodynamic hyperpnea ". Such a mechanism 
might contribute to the ventilatory changes associated 
with adenosine infusion at the higher doses used in this 
thesis but could not explain the changes seen at the 
lowest dose in this study, when cardiac output was 
unchanged. Furthermore in the study described in Chapter 
4 the site -dependent changes in heart rate, a major 
component of the changes in cardiac output caused by 
adenosine, and ventilation during intra- aortic adenosine 
infusion were not parallel. 
The increase in left ventricular filling pressure 
might also contribute to changes in ventilation via 
stimulation of stretch receptors in the left atrium or 
pulmonary circulation. That this mechanism is unlikely to 
be quantitatively important is indicated by the 
observations in Chapter 4 that adenosine infusion into 
the ascending aorta immediately proximal to the carotid 
circulation, which is unlikely to have changed left 
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ventricular filling pressure, caused a similarly large 
increase in ventilation. 
The changes in arterial gas tensions and pH are 
likely to have antagonised the effects of adenosine on 
ventilation. 
7.4.5 - EFFECTS OF ADENOSINE ON OXYGEN CONSUMPTION 
The increase in oxygen consumption following adenosine 
infusion is surprising. During adenosine infusion in 
anaesthetised subjects slight falls in whole body oxygen 
consumption have been observed in some studies, possibly 
due to shunting of blood away from metabolically active 
tissues or inhibition of metabolic demands (Sollevi et 
al., 1984b; Lagerkranser et ál., 1984). In the present 
study such effects might have offset the increased oxygen 
consumption demanded by the greater cardiac and 
respiratory work during adenosine infusion. A rebound 
phenomenon after withdrawal of such mechanisms may have 
contributed to the increase in oxygen consumption 
following the infusion. 
7.4.6 - SYMPTOMS CAUSED BY ADENOSINE 
Symptoms described in this study were similar to those 
reported in the studies described in earlier chapters. 
Sylvén et el. (1986) suggested that adenosine release 
during myocardial ischemia might mediate the symptom of 
angina. There is however evidence that adenosine may have 
a more generalised algogenic effect (Bleehen & Keele, 
1977; Watt et al., 1987b; Sylvén et el., 1988). This is 
supported by the present observations that, although in 
some patients with coronary disease adenosine appeared to 
reproduce their typical pain, it also did so in some 
patients thought to have non -cardiac pain, while in 
others with coronary disease it produced a discomfort 
different from their angina. These observations differ 
from those of Crea et el. (1990) who reported that in 20 
patients with angina who developed chest pain during 
adenosine infusion the pain was similar to their angina 
141 
in each case. The mechanism of adenosine - induced pain 
remains to be fully elucidated but the pain does not seem 
to be secondary to vasodilation in either the brachial or 
coronary arteries (Sylvén et ál., 1988; Sylvén et al., 
1989; Crea et al., 1990). 
7.4.7 - INTERACTIONS OF PATIENTS' MEDICATION WITH 
ADENOSINE 
Some patients were receiving a variety of drugs during 
this study and the studies described in Chapters 4 and 6 
but, apart from ß- adrenoceptor antagonists, there is no 
clear evidence that these drugs affected the responses to 
adenosine. However the absence of an increase in systolic 
and reduction in diastolic blood pressure caused by 
adenosine, as have been found previously (Biagionni et 
ál., 1986; this thesis Chapters 3 and 5), might have been 
due to effects of patients' medications. 
Conradson et al. (1987) and Jonzon et al. (1989) 
found that ß- adrenoceptor antagonists such as atenolol 
had no significant effect on the changes in ventilation 
or simple haemodynamic variables produced by adenosine 
infusion. As discussed above the only interaction 
observed in this study was a possible modulation of the 
effect of adenosine on left ventricular filling pressure 
following withdrawal of ß- adrenoceptor antagonists. Why 
attenuation by ß- blockade of the heart rate changes was 
only seen in the study described in Chapter 4 is 
unexplained, but it might relate to the different site of 
infusion of adenosine used in that study. 
Based on an uncontrolled study Ikram et ál. (1973) 
suggested that at therapeutic doses diazepam can increase 
coronary blood flow in man. Furthermore Clanachan and 
Marshall (1980a) showed that diazepam potentiated the 
coronary vasodilator response to adenosine in dogs, but 
large doses (1 to 4 mg /kg) of diazepam were required. 
However there is evidence that at low micromolar 
concentrations diazepam can inhibit the cellular uptake 
of adenosine and potentiate its actions in a variety of 
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tissues including the heart (Clanachan & Marshall, 1980b; 
Kenakin, 1982; Mehta and Kulkarni, 1984; Ruiz et al., 
1988) and it has been suggested that benzodiazepines may 
exert some of their therapeutic actions by potentiating 
the effects of endogenous adenosine (Phillis & O'Regan, 
1988). Even at 0.1 gM diazepam caused at least 20% 
inhibition of adenosine uptake in rat brain synaptosomes 
(Phillis et el., 1980). Hopkins (1973) showed that such a 
degree of inhibition in guinea pig atria was enough to 
cause a 2 -fold potentiation of the actions of adenosine. 
During the present study the mean plasma diazepam 
concentration is likely to have been less than 1 gM 
(Hillestad et al., 1974; Gamble et ai., 1975) but, since 
the concentration of diazepam in some tissues might have 
exceeded that in plasma (Friedman et ál., 1986), tissue 
concentrations of diazepam might have been sufficient to 
influence the responses to adenosine, although this is 
uncertain. Diazepam has been shown by some workers to 
depress ventilation (Dalen et el., 1969) and the 
ventilatory responses to hypoxia (Lakshminarayan et el., 
1976) and hypercapnia (Catchlove & Kafer, 1971) and cause 
minor haemodynamic changes (Dalen et el., 1969). However 
the symptoms and heart rate and ventilatory changes in 
this study were similar to those observed at similar 
doses of adenosine in healthy volunteers who had not 
received diazepam (see Chapter 3). 
Merrill et al. (1982) reported that nifedipine 
inhibited the coronary vasodilator response to adenosine 
in anaesthetised dogs. The mechanism was uncertain. 
However in vitro studies have been unable to demonstrate 
antagonism of adenosine - induced vascular relaxation by 
concentrations of nifedipine at the lower end of the 
range encountered with usual therapeutic doses (Young & 
Merrill, 1983; Mustafa & Askar, 1986; Sorkin et ál., 
1985). Furthermore Rooney et el. (1989) reported that 
nifedipine had no effect on the dose -requirement or the 
associated systemic haemodynamic changes during 
adenosine - induced hypotension in anaesthetised dogs. 
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Nifedipine has been reported to antagonise the binding of 
the adenosine analogue R -PIA to Al receptors (Cheung et 
al, 1987; Hu et ál., 1987), providing a possible basis 
for antagonism of some actions of adenosine. However 
nifedipine can also inhibit cellular uptake of adenosine, 
thereby potentiating its actions (Marangos et ál., 1984; 
Hammond et el., 1985). Half -maximal effects for both 
interactions require nifedipine concentrations at least 
several -fold greater than are encountered with usual 
therapeutic doses in man, i.e. less than approximately 
150 µg /1 (0.4 LM) (Sorkin et al., 1985). 
I know of no evidence of a direct interaction between 
adenosine and organic nitrates. Concentrations of isosor- 
bide dinitrate sufficient to relax vascular smooth muscle 
do not cause changes in the concentration of cyclic AMP, 
which mediates many of the effects of adenosine (Matlib 
et al., 1985). Nitrates such as isosorbide dinitrate 
generate nitric oxide which stimulates the production of 
cyclic guanosine monophosphate (GMP) resulting in smooth 
muscle relaxation (Ignarro & Kadowitz, 1985). Since 
vascular smooth muscle relaxation by adenosine might also 
be mediated by cyclic GMP (see Chapter 1) the possibility 
exists of an interaction of the effects of adenosine and 
nitrates. Deussen et al. (1986) showed that increasing 
coronary flow with isosorbide dinitrate had no effect on 
the effluent perfusate concentration of adenosine in 
isolated perfused guinea pig hearts. 
7.4.8 - IMPLICATIONS FOR THE POSSIBLE THERAPEUTIC USE OF 
ADENOSINE 
This study shows that in conscious subjects adenosine is 
a pulmonary and systemic vasodilator as well as a 
respiratory stimulant. However side effects may limit its 
sustained use in conscious subjects to infusion rates <_ 
60 to 80 µg /kg /min. Nevertheless at such rates adenosine 
can reduce pulmonary vascular resistance without causing 
symptoms suggesting that its effects in patients with 
pulmonary hypertension merit further study. 
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CHAPTER 8 - THE EFFECTS OF ADENOSINE INFUSION IN PATIENTS 
WITH CHRONIC HYPO %IA 
8.1 - INTRODUCTION 
As discussed in previous chapters adenosine causes marked 
stimulation of respiration in normal subjects and in 
patients with ischaemic heart disease. There is fairly 
good evidence that this effect is mediated at least in 
part via an action in the carotid bodies. These 
observations raise two questions: firstly, whether the 
effects of adenosine are similar in patients with 
respiratory failure and, secondly, whether adenosine may 
be useful in treating that condition. In the study 
described in this chapter the effects of adenosine 
infusion were studied in patients with chronic hypoxia 
secondary to chronic obstructive airways disease. 
8.2 - METHODS 
8.2.1 - SUBJECTS 
Six patients (1 female), aged 57 to 70 years (mean 65) 
were studied. All had been heavy smokers and suffered 
from chronic hypoxia secondary to chronic bronchitis and 
chronic obstructive airways disease. Although in most an 
arterial P02 of less than 60 mmHg (the cutoff point for 
the definition of oxygenation failure) had previously 
been documented when they were clinically stable, four 
had an arterial P02 slightly greater than this at the 
time of the study. All were stable at the time of the 
study. Patients with a history of asthma or previously 
documented reversibility of airways obstruction ( >_ 20% 
improvement in FEV1 following a bronchodilator) were 
excluded since inhaled adenosine may cause 
bronchoconstriction in such patients (Cushley et ál., 
1983). Details of the patients and their treatment are 
shown in Table 8.1. 
Patients receiving theophylline preparations 
discontinued these at least 24 hours prior to the 
study 
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Table 8.1 - Patient characteristics. 
Subject Age 
(years) 
Sex Treatment FEV1 










1 65 M OTS D 0.73 (26) 2.09 (58) 0.35 61 51 7.37 
2 65 F SIB D 0.47 (23) 1.05 (41) 0.45 61 45 7.37 
3 66 M TSIB 0.46 (19) 1.35 (44) 0.34 64 40 7.39 
4 57 M SI PDiD 0.54 (18) 1.27 (34) 0.42 58 49 7.34 
5 70 M OTSI D 0.60 (24) 1.55 (44) 0.39 48 58 7.36 
6 65 M TSI DiD 1.04 (33) 3.26 (80) 0.32 64 36 7.45 
Mean 65 0.64 (24) 1.76 (50) 0.38 59 46 7.38 
SD 4 0.22 (5) 0.81 (17) 0.05 6 8 0.04 
FEV1, forced expiratory volume in 1s; %, % of predicted; FVC, forced vital capacity; 
Pa02, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; pH, arterial 
pH; 0, long term oxygen therapy; I, theophylline; S, inhaled salbutamol; I, inhaled 
ipratroprium bromide; 8, inhaled beclomethasone; P, oral prednisoLone; Di, digoxin; 
D, diuretics. 
and blood was sampled from these patients at the time of 
the study for measurement of theophylline concentration. 
No restriction was placed on the use of inhaled drugs 
prior to the study. No subject needed to use them during 
the study. 
8.2.2 - INFUSIONS 
Adenosine was infused single blind via a plastic cannula 
in an ante -cubital vein. An infusion protocol similar to 
that described in Chapter 5 was used: stages of 5 min at 
each dose were used with recovery periods of at least 15 
min between stages. Adenosine was given at an initial 
rate of 2.3 mg /min with increments, as tolerated, to 
4.3, 
8.5, 11.9 and 16.8 mg /min. A control infusion (0.9% 
sodium chloride) was also given, single blind, instead 
of 
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adenosine usually after at least one adenosine infusion 
stage causing definite subjective and objective changes. 
Subjects were aware that doses of adenosine would 
increase at each new infusion stage during the study but 
also that at any stage the control infusion might be 
substituted. Subjects were asked to report any symptoms 
every minute during and for 2 min after each stage. Prior 
to each new stage subjects were asked if they were 
willing to receive a further infusion. The protocol for 
the infusions and measurements made is illustrated in 
Fig. 8.1. 
8.2.3 - MEASUREMENTS 
Respiration was recorded using a RIP as described in 
Chapter 2. A 20- breath volume calibration was performed 
over a range of tidal volumes at the start of the study 
and a 10- breath check calibration at the end of the 
study. The two curves were combined and linear regression 
analysis using the method of least squares was performed 
to obtain the calibration factor used. At each time point 
respiratory and haemodynamic variables were averaged over 
at least 40 s. 
The peak minute ventilation during each infusion and 
the simultaneous respiratory rate and tidal volume were 
used in the initial comparisons of the effects at 
different doses. For reasons discussed below a separate 
analysis of changes occurring during adenosine infusion 
at the maximum dose was performed. For this analysis 
ventilation during the final minute of the infusion was 
used for comparison. 
A plastic cannula inserted under local anaesthetic 
into a radial artery was used for blood sampling and 
direct recording of arterial pressure with a Gould 
T4812AD transducer connected to a Physio- Control VSM1 
monitor. Systolic and diastolic blood pressure were 
obtained from a mean of 5 to 10 beats. Heart rate was 
determined from an electrocardiogram which was monitored 
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Fig. 8.1 - Protocol for infusions and measurements. 
HR, heart rate; BP, systemic blood pressure; blood gases, 
arterial blood gas tensions; S, spirometry. 
blood pressures the values during infusion were taken as 
the mean of the 2 min and 5 min values. Mean blood 
pressure was calculated 
as: 
Systolic BP + 2 x Diastolic BP 
Mean BP - (Eq. 8.1) 
3 
Spirometry was performed in the posture maintained 
during the study using the same system as described in 
Chapter 5. Apart from the initial baseline test where 3 
recordings were made only one recording was made at each 
time point to prevent fatigue and provocation of 
bronchospasm. For similar reasons every subject did not 
perform tests at 3 separate time points following each 
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infusion. The means of the values obtained were therefore 
used for analysis. Arterial blood samples were analysed 
for oxygen and carbon dioxide tensions (PaO2 and PaCO2) 
and pH using an Instrumentation Laboratories Blood Gas 
Manager Model 1312. 
8.2.4 - STATISTICAL ANALYSIS 
Since all patients received adenosine infusion at 2.3 and 
4.3 mg /min, variables at those doses and during placebo 
infusion were compared using repeated measures analysis 
of variance and, where appropriate, Student -Newman -Keuls 
test. Values during placebo infusion were also compared 
with values during the maximum dose for each patient by 
the paired t -test. For spirometric variables comparisons 
included baseline values, in order to detect any change 
occurring during the first one or two adenosine infusion 
stages which would therefore have occurred before the 
placebo stage. Log transformation of blood pressures was 
performed before analysis. Except where indicated n = 6. 
8.3 - RESULTS 
In the 4 patients who had discontinued treatment with a 
theophylline preparation the serum theophylline 
concentration ranged from 0.9 to 2.0 mg /l. The maximum 
dose of adenosine infused was limited in all patients by 
symptoms and ranged from 4.3 to 16.8 mg /min (73 to 248 
µg /kg /min; mean: 137 gg /kg /min). In 2 patients the final 
infusion was stopped after less than 5 min at the 
patients request because of symptoms. 
8.3.1 - BASELINE VALUES 
Baseline heart rate before the placebo infusion was 
significantly higher than the values before adenosine 
infusion at 2.3 and 4.3 mg /min (P < 0.025), but was not 
different from the value before the maximum dose. There 
were no other differences in baseline values (Table 8.2). 
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Table 8.2 - Baseline data for haemodynamic variables, 
minute ventilation, blood gas tensions and pH. 
Placebo Adenosine Infusion 
2.3 mg/min 4.3 mg /min Maximum 
Heart rate (beats /min) 87 (7) 82 (5) 84 (6) 85 (6) 
Systolic blood pressure (mmHg) 133 (20) 138 (21) 132 (14) 133 (14) 
Diastolic blood pressure (mmHg) 65 (13) 66 (12) 65 (10) 65 (10) 
Minute ventilation (l /min) 7.5 (2.9) 7.3 (2.1) 6.9 (1.6) 7.9 (3.1) 
Pa02 (mmHg) 59* (6) 60* (7) 61* (5) 60 (6) 
PaCO2 (mmHg) 46* (10) 46* (9) 46* (9) 47 (9) 
pH 7.38* (0.04) 7.39* (0.04) 7.38* (0.04) 7.38 (0.04) 
Data are mean (SD). *n = 5, otherwise n = 6. Abbreviations as in Table 8.1. 
8.3.2 - CHANGES IN VENTILATION AND BLOOD GAS TENSIONS 
The changes in tidal volume and respiratory rate at peak 
minute ventilation at each infusion rate were not 
statistically significant. Nevertheless initial analysis 
showed that, compared with placebo, peak minute 
ventilation increased by 20% during adenosine infusion at 
the maximum dose (P < 0.05) (Table 8.3). However 
comparison of volume calibration curves for the RIP 
performed at the beginning and end of the study in the 5 
subjects for whom both were available showed that there 
were differences between the slopes of more than 10% for 
3 subjects. Since such changes may have contributed to 
the apparent increase in minute ventilation, a separate 
comparison was performed of minute ventilation at 
baseline immediately before adenosine infusion at the 
maximum dose with the value during the final minute of 
that infusion. The increase in minute ventilation from 
7.9 (SD: 3.1) 1 to 8.8 (SD: 3.3) 1 was not significant. 
Four patients (Numbers 1,4,5,6) received at least 
one 
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Table 8.3 - Haemodynamic and ventilatory changes during 
adenosine infusion. 
Placebo Adenosine infusion 
2.3 mg/min 4.3 mg /min Maximum 
Heart rate (beats /min) 81 (7) 84 (5) 86 (8) 90 (20) 
Systolic blood pressure (mmHg) 130 (19) 138 (18) 140 * ** (20) 156 ** (27) 
Diastolic blood pressure (mmHg) 62 (12) 66 (12) 72 (23) 75 (23) 
Mean blood pressure (mmHg) 85 (14) 90 (14) 95* (22) 101* (24) 
Peak minute ventilation (l /min) 8.0 (2.6) 8.3 (2.1) 8.2 (1.7) 9.5* (2.6) 
Tidal volume (l)# 0.36 (0.10) 0.37 (0.06) 0.37 (0.07) 0.43 (0.15) 
Respiratory rate (breaths /min)# 22 (6) 22 (3) 23 (5) 23 (7) 
Pa02 (mmHg) 59 (6) 59 (8) 60 (8) 58 (8) 
PaCO2 (mmHg) 46 (9) 44 (10) 45 (9) 45 (7) 
pH 7.39 (0.04) 7.39 (0.04) 7.40 (0.03) 7.39 (0.03) 
Data are mean (SD). n = 6. For comparisons with data during placebo infusion: *P < 
0.05; * *P < 0.01; * * *P < 0.001. #, measured at time of peak minute ventilation. Other 
abbreviations as in Table 8.1. 
dose of adenosine without symptoms. At the highest such 
dose the peak minute ventilation, 9.0 (SD: 2.2) 1 /min, 
was not significantly different from the value during 
placebo, 8.6 (SD: 2.7) 1 /min. 
For the group there were no significant changes in 
PaO2, PaCO2 or pH during adenosine infusion at any dose 
(Table 8.3). Furthermore comparison of blood gas tensions 
during the final minute of adenosine infusion at the 
maximum dose with the baseline value for that infusion 
showed no significant change (Table 8.4). However 
individual responses were variable and 4 patients showed 
an increase in both tidal volume and minute ventilation 
and a slight improvement in blood gas tensions (Table 
8.4) . 
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Table 8.4 - Changes during the final minute of adenosine 
infusion at the maximum dose. 
Subject Dose Changes 
(pg /kg 
/min) HR SBP DBP MBP FRC VT V PaO2 PaCO2 pH 
(beats (mmHg) (mmHg) (mmHg) (l) (l) (l /min) (mmHg) (mmHg) (units) 
/min) 
1 175 -13 21 1 9 0.34 0.09 2.0 1 -2 0.03 
2 97 10 20 13 16 0.22 0.04 1.2 5 -3 0.02 
3 94 60 69 47 63 0.41 -0.09 0.9 -7 1 -0.01 
4 73 6 14 6 8 0.34 0.08 1.9 2 -7 0.02 
5 131 8 23 6 10 0.22 0.01 1.2 1 -3 0.03 
6 248 -9 20 3 12 0.77 -0.14 -1.6 -10 2 -0.02 
Mean 137 10 28 13 20 0.38 0.00 0.9 -1 -2 0.01 
SD 65 26 20 17 21 0.20 0.09 1.3 6 3 0.02 
Changes are calculated with respect to the baseline values before infusion at the 
maximum rate. Positive values represent an increase, negative values a decrease. HR, 
heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean 
blood pressure; FRC, functional residual capacity; VT, tidal volume; V, minute 
ventilation. Other abbreviations as in Table 8.1. 
In all patients a shift upwards in the baseline of 
the respiratory trace occurred during adenosine infusion 
suggesting that they were breathing at a higher FRC. 
During adenosine infusion at the maximum dose, where this 
shift was most marked, the mean increase in FRC was 0.28 
(SD: 0.14) 1 which was significantly different from the 
mean change of -0.02 (SD: 0.08) 1 during placebo infusion 
(P < 0.05) (Fig. 8.2). Inspection of the respiratory 
traces showed that in all patients the baseline shift 
occurred predominantly in the compartment which 
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Fig. 8.2 - Changes in functional residual capacity (FRC) 
during adenosine and placebo infusions. n = 6 except 
where shown. 
was seen only or predominantly in the abdominal 
compartment, and in 2 only or predominantly in the 
thoracic compartment. Of the 4 patients who received at 
least one dose of adenosine which did not cause symptoms, 
2 (numbers 4,6) showed an obvious increase in FRC at the 
highest such dose. These changes were 0.24 and 0.36 1, 
compared with -0.01 and -0.02 1 respectively during 
placebo. 
The 2 patients who showed the largest increase in FRC 
(numbers 3,6) both showed reduced tidal volume and 
worsened blood gas tensions. One also showed a decrease 
in minute ventilation (Table 8.4). 
8.3.3 - CHANGES IN SPIROMETRY 
There were no significant changes in FEV1, FVC, FEV1 /FVC 
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Table 8.5 - Spirometry in semi -recumbent position. 
Baseline Placebo Adenosine Infusion 
2.3 mg/min 4.3 mg/min Maximum 
FEV1 (l) 0.45* (0.15) 0.40 (0.17) 0.40 (0.13) 0.39 (0.16) 0.37 (0.16) 
FVC (l) 1.28* (0.51) 1.13 (0.57) 1.11 (0.47) 1.17 (0.59) 1.04 (0.53) 
FEV1/FVC (%) 36.4* (6.6) 36.6 (4.9) 37.6 (6.3) 34.9 (4.6) 37.1 (5.5) 
FEF25-75% (l/s) 0.23** (0.07) 0.15 (0.06) 0.17 (0.05) 0.16 (0.06) 0.15 (0.05) 
Data are mean (SD). n = 6 except where shown. *n =5; * *n =4. FEV1, forced expiratory 
volume in 1s; FVC, forced vital capacity; FEF25 -75 %, forced expiratory flow rate at 
25 -75% of FVC. 
or FEF25_75% following adenosine infusion at any dose 
(Table 8.5). 
8.3.4 - CHANGES IN HEART RATE AND BLOOD PRESSURE 
For the group as a whole heart rate showed no significant 
change during adenosine infusion (Table 8.3) but 
individual responses were variable. One patient showed a 
marked increase in heart rate at the maximum dose, by 60 
beats /min during the infusion, but the two patients who 
received the highest doses of adenosine showed decreases 
in heart rate at the maximum dose (Table 8.4). 
Systolic blood pressure increased significantly 
during adenosine infusion at 4.3 mg /min (P < 0.001) and 
at the maximum dose (P < 0.01) (Table 8.3). Changes in 
diastolic blood pressure were not significant but 
calculated mean blood pressure increased significantly 
during adenosine infusion at 4.3 mg /min (P < 0.05) and 
at 
the maximum dose (P < 0.05). 
8.3.5 - SYMPTOMS CAUSED BY ADENOSINE 
Symptoms experienced during adenosine infusion 
were 
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similar to those reported by normal subjects and patients 
with ischaemic heart disease. Dyspnoea occurred in 6 
patients, central chest discomfort and headache each in 3 
patients, flushing in 2 patients and throat discomfort in 
1 patient. All symptoms resolved within 1 to 2 minutes of 
discontinuing the infusion. The dose at which any new 
symptom was first reported ranged from 2.3 to 16.8 mg /min 
(35 to 248 pg /kg /min). 
8.4 - DISCUSSION 
8.4.1 - CHANGES IN VENTILATION 
This study investigated the effects of symptom- limited 
adenosine infusion in patients with chronic hypoxia 
secondary to chronic obstructive airways disease. 
Adenosine caused variable responses with only modest 
improvements at best in minute ventilation. 
As discussed in Chapter 2 respiratory inductance 
plethysmography has been evaluated in patients with 
chronic obstructive airways disease and been shown to 
provide estimates of tidal volume within 10% of values 
obtained simultaneously using a spirometer, provided that 
calibration is carefully performed (Gonzalez et ál., 
1984; Dadzie et al., 1988). Even were the errors greater 
than this in the present study they are unlikely to have 
been large enough to invalidate the above conclusion 
concerning the magnitude of the ventilatory stimulation 
in these patients. Furthermore this conclusion is 
supported by the observed changes in the blood gas 
tensions. 
The results of this study contrast with the previous 
findings in subjects without pulmonary disease, where 
maximal doses of adenosine caused a mean increase of 
approximately 80 to >100% in minute ventilation and falls 
in PETCO2 of approximately 8 to 10 mmHg. 
The smaller ventilatory stimulation by adenosine in 
the present patients might have been due to decreased 
sensitivity of the peripheral chemoreceptors. Since 
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endogenous adenosine concentrations have been shown to 
increase in a variety of tissues in various species 
during hypoxia, as discussed in Chapter 6, the endogenous 
adenosine concentrations might have already been 
increased in these patients. Whether this does occur in 
such patients is unknown, but increased plasma adenosine 
concentrations have been found in patients with sleep 
apnoea and severe nocturnal hypoxaemia (Findley et al., 
1988). If a chronic increase in adenosine concentrations 
were present, the adenosine -dependent mechanisms might 
have already been substantially activated and 
down -regulation of adenosine receptors might have 
occurred. 
While it is possible that a centrally- mediated 
respiratory depressant effect of adenosine opposing the 
peripherally- mediated stimulation of respiration 
contributed to the changes we observed, there is no 
evidence that such an effect should be greater in the 
present patients than in healthy volunteers. 
It is possible that the adenosine - induced worsening 
of hypoxia in 2 patients was caused by increased 
ventilation /perfusion mismatching due to pulmonary 
vasodilation (Chapter 7, this thesis; Mentzer et el., 
1975). However the fall in PaO2 in these patients was 
associated with an increase in PaCO2 and fall in tidal 
volume suggesting that reduced ventilation was 
responsible. 
Theophylline is a competitive antagonist of the 
actions of adenosine at cell- surface receptors and at a 
concentration of approximately 10 pg /ml attenuates the 
cardiorespiratory effects of adenosine in man (Maxwell et 
Al., 1987). In vitro studies have shown that half maximal 
effects of theophylline on responses to adenosine occur 
at concentrations ranging from approximately 1 to 10 
µg /ml depending on the tissue and species studied (Daly, 
1983). Therefore the concentrations of theophylline found 
in 4 patients in the present study might have caused 
weak 
antagonism of the effects of adenosine, but it seems 
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unlikely that this should have qualitatively affected the 
responses observed. 
A further possible explanation of the absence of a 
marked respiratory stimulant effect of adenosine is that 
ventilation was limited by mechanical factors in these 
patients with severe chronic obstructive airways disease. 
It is possible that an acute increase in FRC contributed 
to this. In support of this suggestion is the finding 
that the apparent increase in FRC was greatest in two 
patients who showed a fall in tidal volume and worsening 
of blood gas tensions. 
8.4.2 - CHANGES IN FUNCTIONAL RESIDUAL CAPACITY 
The apparent change in FRC is unlikely to have been due 
to altered posture since its major component was from the 
compartment contributing most to tidal volume in each 
patient. It might have been due to an increase in 
intrathoracic blood volume (Sjöstrand, 1951) caused by 
pulmonary vasodilation. However a similar change observed 
in healthy volunteers (Chapter 5) developed in concert 
with increased ventilation suggesting that it is most 
likely a reflection of altered control of breathing. 
Furthermore an increase in FRC can be seen in spirograms 
obtained invasively during adenosine administration 
(Jonzon et á1.,l989). 
Although symptoms experienced may have been partly 
responsible for the change, an increase in FRC was also 
seen in some patients at doses of adenosine not causing 
symptoms. The time course of the change, with a rapid 
recovery following the infusion, in both healthy 
volunteers and patients, suggests that it was not due to 
airways obstruction (Cushley et ál., 1983). Furthermore 
spirometry did not change in the present subjects or in 
the healthy volunteers (see Chapter 5). It is of interest 
that some, although not all, workers have reported that 
FRC increases during ventilatory stimulation by hypoxia 
in normal subjects (Garfinkel et ál., 1978; Saunders 
et 
ál., 1977; Kellogg & Mines, 1975; Cotes et ál., 1977). 
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Similar changes in dogs or rats are abolished by carotid 
body blockade or denervation (Bouverot & Fitzgerald, 
1969; Barer et ál., 1978). Ventilatory stimulation by 
hypercapnia also increases FRC in normal subjects 
(Garfinkel et ál., 1978) and in patients with chronic 
airflow limitation (Gribbin et al., 1983). In the latter 
case Garrard and Lane (1979) suggested that the increase 
in FRC is responsible for the diminished tidal volume 
response seen during hypercapnia in such patients. 
8.4.3 - CHANGES IN HEART RATE AND BLOOD PRESSURE 
In the present study adenosine produced variable changes 
in heart rate, with no significant change for the group, 
and significant increases in systolic and mean blood 
pressure. These responses differ from those observed in 
normal volunteers, in whom heart rate is consistently 
increased by maximal infusion rates of adenosine infusion 
and mean blood pressure usually remains constant due to a 
fall in diastolic pressure offsetting a rise in systolic 
blood pressure as discussed in Chapter 3. 
As discussed in Chapter 7 reflexes secondary to 
peripheral chemoreceptor stimulation may contribute 
substantially to the haemodynamic effects of adenosine 
infusion. Studies in dogs have shown that, compared with 
animals in whom ventilation is mechanically restrained, 
the haemodynamic effects of hypoxic stimulation of the 
carotid bodies are opposite in direction in animals in 
whom ventilation is allowed to increase (Daly & Scott, 
1963). The haemodynamic effects in the latter group 
probably occur as a reflex secondary to stimulation of 
pulmonary stretch receptors and reduced arterial PCO2. 
The different effects of adenosine on ventilation and 
PaCO2 in the present subjects compared with normal 
volunteers might therefore partly explain the differences 
in haemodynamic response. 
The fall in heart rate seen in the patients who 
received the highest doses of adenosine might be due to 
the well -recognised direct negative chronotropic effect 
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of adenosine (see Chapter 1), unopposed by reflexes which 
in healthy volunteers cause heart rate to increase. A 
contribution of a baroreceptor reflex secondary to the 
increased blood pressure cannot however be excluded. 
Blood pressure increased even in patients in whom 
heart rate fell indicating that either stroke volume or 
peripheral vascular resistance increased. Myocardial 
contractility is unlikely to have increased since in 
vitro studies have shown that adenosine antagonises the 
cardiac effects of catecholamines, as discussed in 
Chapter 1, and exerts little direct positive inotropic 
effect (Bruckner, 1985). In most tissues the direct 
arterial effect of adenosine is vasodilation. However 
reflex arterial constriction increasing systemic vascular 
resistance or venoconstriction increasing venous return 
to the heart might have been responsible for the increase 
in blood pressure observed. 
8.4.4 - IMPLICATIONS FOR THE POSSIBLE THERAPEUTIC USE OF 
ADENOSINE 
The inter -individual variability in ventilatory and 
haemodynamic responses observed in the present study 
suggests that further work is required to identify which 
patient subgroups, if any, are most likely to derive 
benefit from the use of adenosine as a ventilatory 
stimulant. Adenosine might be more efficacious in 
patients with less mechanical limitation of breathing 
than those in the present study, e.g. patients with 
drug- induced respiratory depression, although there are 
as yet no data to support this speculation. Further 
studies will need to examine whether and to what extent 
the symptoms produced by adenosine contribute to the 
ventilatory changes seen and the degree to which such 
symptoms might limit the compound's possible therapeutic 
use. In any further studies caution should be used in 
interpreting indices of ventilatory drive which may be 
affected by changes in FRC, eg. mouth occlusion pressure 
(Fitzgerald et al., 1976). 
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CHAPTER 9 - SUMMARY 
1. Diverse biological effects of the nucleoside 
adenosine have been described. This thesis takes as its 
starting point the observations of Watt and Routledge 
(1985) that intravenous bolus injections of adenosine 
cause transient stimulation of respiration in man. It 
discusses the results of studies undertaken to further 
characterise the respiratory and concomitant 
cardiovascular effects of adenosine in man and in so 
doing to answer some of the questions raised by the 
previous observations. In all studies respiration was 
measured non -invasively using either a respiration 
transducer (Lectromed, Type 4320) or a respiratory 
inductance plethysmograph (Respitrace). 
2. To determine whether the respiratory stimulation by 
adenosine is sustained during continuous infusion, 
whether it is caused directly by adenosine or one of its 
metabolites and whether it is secondary to hypotension, 
due to the known vasodilator effect of adenosine, the 
cardiorespiratory effects of symptom -limited intravenous 
infusions of adenosine and its deaminated metabolite, 
inosine, administered in random order, single -blind, were 
compared in 6 healthy volunteers. 
3. Adenosine infusion at rates of 6.1 mg /min and above 
increased mean minute ventilation (by191% at the maximum 
dose, 13.5 (SD: 5.7) mg /min), principally due to an 
increase in tidal volume, and reduced end -tidal PCO2 
(PETCO2) (from 38 (SD: 3) mmHg to 27 (SD: 5) mmHg at the 
maximum dose). Mean inspiratory flow rate increased and 
expiratory duration decreased, by 179% and 23% 
respectively at the maximum dose, but there was no change 
in inspiratory duration. Adenosine also increased heart 
rate by 57% and systolic blood pressure from 120 (SD: 10) 
mmHg to 134 (SD: 15) mmHg at the maximum dose, without a 
significant change in diastolic blood pressure. 
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4. Infusion of inosine at dose rates up to 16.8 mg /min 
produced no pharmacological effects. 
5. This study shows that infusion of adenosine produces 
sustained respiratory stimulation in man which does not 
depend on prior conversion of adenosine to inosine or 
related metabolites and is not secondary to systemic 
hypotension. 
6. Since in animals adenosine has been shown to 
stimulate the peripheral chemoreceptors, the effects of 
infusion of adenosine at different sites in the aorta 
were investigated in 12 patients undergoing cardiac 
catheterisation for investigation of chest pain, to 
determine whether adenosine might stimulate respiration 
via an action in the carotid bodies in man. 
7. Respiration was stimulated when adenosine was infused 
proximal to the carotid circulation, but not when it was 
infused distal to the head and neck vessels. Since 
previous studies in animals suggest that respiratory 
stimulation by adenosine is unlikely to be mediated 
within the central nervous system, these results support 
the hypothesis that adenosine -induced respiratory 
stimulation in man is mediated in the carotid body. 
8. In order to determine whether the cardiorespiratory 
effects of adenosine are mediated by cell -surface 
adenosine receptors, the effects of aminophylline, a 
competitive antagonist of adenosine at such receptors, on 
the responses to symptom- limited intravenous infusion of 
adenosine were investigated in 10 healthy volunteers. 
9. Aminophylline (6 mg /kg infused over 10 min at the 
start of the study) alone increased heart rate by 13% and 
minute ventilation by 25 %, but reduced the symptoms and 
antagonised the increases in heart rate, systolic blood 
pressure and minute ventilation and the reduction in 
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PETCO2 caused by adenosine. This suggests that such 
effects of adenosine are mediated by stimulation of 
cell- surface receptors. 
10. There was no significant adenosine - induced change in 
FEV1, FVC, FEV1 /FVC or FEF25 -75% suggesting that the 
adenosine - induced changes in respiration are unlikely to 
be secondary to bronchoconstriction. Adenosine caused a 
significant increase in functional residual capacity 
(FRC) which developed in concert with the changes in 
minute ventilation suggesting that it was due to altered 
control of breathing. 
il. The peripheral venous plasma adenosine concentration 
was measured, after conversion of adenosine to 
1,N6- ethenoadenosine, using high performance liquid 
chromatography with fluorometric detection. A significant 
change during adenosine infusion was detectable only at 
the higher maximum dose possible after aminophylline, 
consistent with the very short half -life of adenosine 
(less than 10 s) as previously demonstrated by others in 
vitro. This shows that a change in the peripheral venous 
concentration of adenosine cannot be used as an index of 
a change at sites much more proximal in the circulation. 
12. Whether the respiratory stimulant effect of adenosine 
occurs at concentrations likely to be achieved 
physiologically was investigated in a further 7 patients 
undergoing cardiac catheterisation, in whom it was 
possible to sample blood via a catheter from a site close 
to the putative site of action in the carotid bodies. 
13. During symptom- limited intravenous infusion of 
adenosine (mean maximum dose per minute: 130 gg /kg /min) 
mean minute ventilation increased by 98% while mean 
plasma adenosine concentration in the aortic arch 
increased from 0.07 (range: 0.04 to 0.12) gM to 1.2 
(range: 0.4 to 2.0) µM. In three patients ventilation 
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first increased without a detectable increase in aortic 
adenosine concentration, suggesting a possible 
intra- pulmonary effect of adenosine, although increased 
concentrations were apparent at higher doses. 
14. Previous work suggests that micromolar concentrations 
of adenosine are probably achieved in tissues during 
hypoxia, secondary to increased hydrolysis of adenine 
nucleotides. This study shows that at such concentrations 
adenosine stimulates respiration. These results are 
consistent with the suggestion that endogenous adenosine 
release may mediate or modulate the ventilatory response 
to hypoxia. A possible intra- pulmonary effect of 
adenosine merits further study. 
15. Since the cardiovascular and respiratory systems are 
intimately related and since adenosine has been shown to 
have various effects within the cardiovascular system, 
including dilation of most vascular beds, which may have 
therapeutic application, the acute haemodynamic effects 
of symptom- limited intravenous infusion of adenosine were 
studied in 16 patients (7 with coronary artery disease, 9 
with normal coronary arteries) undergoing cardiac 
catheterisation for investigation of chest pain. 
Pressures were measured via fluid -filled catheters and 
cardiac output by thermodilution using a balloon- tipped 
(Swan -Ganz) pulmonary artery catheter. 
16. At the lowest dose used (4.3 mg /min) adenosine 
increased minute ventilation by 44% (n = 11) and reduced 
pulmonary vascular resistance by 20% without causing 
other significant haemodynamic changes. 
17. At the maximum dose (8.5 (SD: 2.3) mg /min) adenosine 
reduced pulmonary and systemic vascular resistance, by 
38% and 34% respectively, and increased heart rate by 
34 %, stroke index by 12% and cardiac index by 52 %. 
Systemic blood pressure and right atrial pressure did not 
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change. Unexpectedly, adenosine increased left 
ventricular end -diastolic pressure, from 5 (SD: 6) mmHg 
to 14 (SD: l0) mmHg (n = 8), pulmonary capillary wedge 
pressure, from 3 (SD: 2) mmHg to 10 (SD: 5) mmHg (n = 16) 
and consequently mean pulmonary artery pressure, from 10 
(SD: 2) mmHg to 16 (SD: 5) mmHg. Minute ventilation 
increased by 84% (n = 11), resulting in hypocapnia 
(PaCO2: 31 (SD: 3) mmHg. n = 8) and alkalosis (arterial 
pH: 7.46 (SD: 0.02). n = 8). Oxygen consumption was 
unchanged during the infusion but increased by 21% 5 min 
post infusion. All effects were similar in patients with 
and without coronary artery disease. 
18. Adenosine therefore causes pulmonary and systemic 
vasodilation and increased cardiac output in addition to 
respiratory stimulation. Symptoms and the increase in 
left ventricular end -diastolic pressure which occurred at 
the higher doses, may limit the use of adenosine as a 
systemic vasodilator or respiratory stimulant in 
conscious subjects. However at low infusion rates (< 60 
to 80 µg /kg /min) adenosine causes selective pulmonary 
vasodilation which merits further study. 
19. Since adenosine might be useful in treating 
respiratory failure the effects of symptom- limited 
intravenous infusion of adenosine were studied in 6 
patients with chronic hypoxia secondary to severe chronic 
obstructive airways disease. 
20. The ventilatory responses to adenosine were variable. 
During maximum tolerated infusion rates 4 patients showed 
an increase in minute ventilation ranging from 1.2 to 2.0 
1 /min with a slight improvement in arterial blood gas 
tensions, while 2 patients showed a fall in tidal volume 
(of 0.09 and 0.14 1) and arterial PO2 (of 7 and 10 mmHg 
respectively). All patients showed an increase in FRC 
ranging from 0.2 to 0.8 1, which did not seem to be due 
to bronchoconstriction and probably resulted from altered 
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control of breathing. The increase in FRC was greatest in 
the 2 patients who showed a fall in arterial PO2. Changes 
in heart rate were variable but all patients showed an 
increase in mean blood pressure ranging from 9 to 52 mmHg 
(mean: 18 mmHg). 
21. The magnitude of the effects of adenosine on 
ventilation contrasts with the prominent stimulation of 
respiration observed in healthy volunteers. Mechanical 
limitation of breathing, possibly exacerbated acutely by 
the increase in FRC, was probably at least partly 
responsible for the smaller and variable responses, but 
down -regulation of adenosine receptors in these 
chronically hypoxic patients cannot be excluded. The 
improvement in ventilation in some patients suggests that 
further evaluation of adenosine as a respiratory 
stimulant is indicated. 
22. In all studies the higher doses of adenosine caused 
symptoms including: chest and epigastric discomfort, 
dyspnoea, flushing and paraesthesiae. Although 
significant group changes in minute ventilation were not 
observed in the absence of symptoms, a dissociation 
between the occurrence of chest and epigastric discomfort 
and respiratory stimulation was seen when adenosine was 
infused at different sites in the aorta. This suggests 
that the respiratory changes are not just a response to 
the symptoms caused by adenosine. Further work will be 
necessary to clarify the relationships between symptoms 
and other effects caused by adenosine and the extent to 
which such symptoms may limit any therapeutic use of 
adenosine in conscious subjects. 
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APPENDIX 1 - MAIN INDIVIDUAL DATA FOR CHAPTER 3 
SUBJECTS AND DOSES 
Subject Sex Maximum dose received (mg /min) 
Adenosine Inosine 
1 M 16.8 23.4 
2 F 8.5 16.8 
3 M 11.9 23.4 
4 M 8.5 23.4 
5 M 23.4 23.4 
6 M 11.9 16.8 
7 M (11.9) (23.4) 
8 M (8.5) 
Mean (n = 6) 13.5 21.2 




Adenosine infusion rate (mg /min)* 
3.1 4.3 6.1 8.5 Maximum 
Respiratory rate (breaths /min) 
1 13 12 12 13 12 14 16 
2 13 13 17 23 21 19 39 17 17 
3 17 11 11 11 9 14 15 15 19 
4 15 17 15 15 11 14 15 16 19 
5 9 12 9 9 9 9 10 8 9 
6 13 13 10 13 11 11 13 15 18 
Mean 13 13 12 14 12 13 17 14 16 
SD 3 2 3 5 4 3 11 3 4 
Tidal volume (l) 
1 0.69 0.64 0.73 0.70 0.62 1.36 1.15 
2 0.10 0.25 0.36 0.38 0.14 0.35 0.21 0.41 0.41 
3 0.07 0.27 0.33 0.31 0.49 0.24 0.82 0.84 1.55 
4 0.51 0.51 0.47 0.48 0.75 0.48 0.86 0.78 0.53 
5 0.86 0.62 0.56 0.74 0.67 0.82 1.00 0.89 1.57 
6 1.00 0.93 1.20 1.13 1.21 1.20 1.49 1.35 2.00 
Mean 0.54 0.52 0.58 0.61 0.67 0.63 0.83 0.94 1.20 
SD 0.39 0.28 0.36 0.30 0.35 0.35 0.42 0.36 0.63 
Minute ventilation (l /min) 
1 9.2 7.4 8.5 8.8 7.1 18.6 18.2 
2 1.3 3.2 6.2 8.8 2.9 6.6 8.2 7.1 7.1 
3 1.2 3.1 3.7 3.4 4.6 3.4 12.3 12.6 29.5 
4 7.6 8.4 6.9 7.3 8.3 6.9 12.7 12.3 10.2 
5 7.5 7.3 5.2 6.4 5.7 7.6 9.5 6.9 14.6 
6 12.6 12.4 11.6 14.7 13.0 13.7 20.0 20.5 35.8 
Mean 6.6 6.9 6.7 8.0 7.1 7.8 11.6 13.0 19.2 
SD 4.5 3.9 3.0 3.7 3.6 3.4 4.6 5.7 11.2 
End -tidal PCO2 (mmHg) 
1 37 39 34 31 36 32 25 
2 34 29 32 31 28 26 26 25 25 
3 41 37 39 39 38 37 31 31 22 
4 40 39 40 39 40 38 36 35 
36 
5 34 36 35 35 36 35 34 34 
26 
6 40 39 40 38 38 38 36 35 
28 
Mean 38 36 37 37 36 34 33 32 
27 
SD 3 4 3 3 5 5 4 
4 5 






TE (s) TTOT (s) TI'TTOT VT /TI (L /min) 
B Max B Max B Max B Max 
1 2.0 1.6 2.6 2.2 4.5 3.8 0.43 0.43 21 43 
2 1.0 1.0 3.8 2.5 4.7 3.5 0.20 0.28 6 25 
3 1.1 1.3 2.4 1.8 3.5 3.2 0.32 0.43 4 70 
4 1.7 1.2 2.4 2.0 4.0 3.1 0.41 0.37 19 28 
5 2.2 2.4 4.7 4.1 6.9 6.5 0.32 0.37 23 40 
6 2.1 1.6 2.6 1.8 4.8 3.4 0.45 0.48 28 76 
Mean 1.7 1.5 3.1 2.4 4.8 3.9 0.36 0.39 17 47 
SD 0.5 0.5 1.0 0.9 1.2 1.3 0.09 0.07 10 21 
B, baseline; Max, adenosine infusion at the maximum dose. 
Subject Base- 
line 
Adenosine infusion rate (mg /min)* 
3.1 4.3 6.1 8.5 Maximum 
Heart rate (beats /min) 
1 75 72 73 77 77 100 120 
2 69 71 76 76 97 84 114 103 103 
3 73 66 72 67 87 73 81 85 100 
4 64 68 64 63 66 66 86 71 93 
5 57 60 58 65 59 61 58 66 109 
6 63 63 68 65 67 70 86 90 105 
Mean 67 66 68 68 75 72 84 86 105 
SD 7 4 7 5 14 8 18 15 9 
Systolic blood pressure (mmHg) 
1 124 134 131 124 144 134 124 
2 112 108 110 110 112 115 118 124 124 
3 106 108 112 112 114 112 124 132 134 
4 116 114 114 122 120 122 126 122 120 
5 125 120 125 128 125 123 120 123 138 
6 134 144 146 140 140 150 148 150 162 
Mean 120 
SD 10 
119 121 124 124 





Diastolic blood pressure (mmHg) 
1 90 92 91 104 86 84 76 
2 72 74 72 72 80 74 72 68 68 
3 54 56 56 56 62 58 62 58 64 
4 60 60 70 80 80 80 70 60 42 
5 73 80 75 80 78 79 75 65 52 
6 86 86 86 84 86 82 94 96 96 
Mean 73 71 72 77 80 80 77 72 66 
SD 14 13 11 12 10 15 12 15 19 
*Two columns for any dose represent data for the first and second minutes. 
Subjects FEY/ (l) FVC (L) PEFR (L/min) 
Pre Post Pre Post Pre Post 
4 3.54 3.44 4.46 4.48 636 613 
5 4.68 4.26 5.86 5.74 603 541 
6 4.45 4.13 5.63 5.55 726 650 
7* 4.33 4.55 5.00 5.29 576 570 
Mean 4.25 4.10 5.24 5.27 635 594 
SD 0.50 0.47 0.63 0.56 65 48 
*subject whose other data were not included because of a poor respiratory trace. 
Pre, prior to adenosine; Post, following adenosine. 
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INOSINE INFUSION 
Subject Base- Inosine infusion rate (mg /min)* 
line 
0 3.1 4.3 6.1 8.5 11.9 16.8 
Respiratory rate (breaths /min) 
1 10 11 10 12 13 13 
2 15 16 17 20 18 15 11 
3 12 18 20 18 19 18 15 
4 16 18 16 14 15 14 14 
5 14 13 11 10 13 13 11 
6 9 11 6 9 9 12 9 
Mean 13 15 14 14 14 14 12 
SD 3 3 5 5 4 2 2 
Tidal volume (t) 
1 0.83 0.85 0.59 0.81 
2 0.17 0.10 0.18 0.15 0.15 
3 0.12 0.07 0.08 0.12 0.21 
4 0.52 0.43 0.58 0.63 0.58 
5 0.78 0.65 0.89 0.63 0.57 
6 1.11 0.98 0.98 0.91 0.92 
Mean 0.59 0.45 0.59 
SD 0.39 0.38 0.38 
0.51 0.54 
0.31 0.31 
Minute ventilation (l /min) 
1 8.4 9.1 6.1 9.5 
2 2.6 1.6 3.1 3.0 2.7 
3 1.5 1.2 1.6 2.2 4.1 
4 8.1 7.7 9.3 9.0 8.6 
5 10.7 8.6 9.8 6.3 7.6 
6 10.0 10.8 6.2 8.3 8.5 
Mean 6.9 6.0 



















End -tidal PCO2 (mmHg) 
1 33 36 40 36 37 37 
2 33 33 30 30 33 33 29 
3 41 43 43 43 43 42 40 
4 40 40 41 40 39 40 41 
5 35 39 38 36 37 38 37 
6 38 38 40 40 40 34 38 
Mean 37 39 38 38 38 37 37 
SD 3 4 4 4 4 4 4 
For clarity only the 2 minute value at each dose is shown. 
Subject TI (s) TE (s) TTOT (s) TI- TTOT VT/TI (l/min) 
B 16.8 B 16.8 B 16.8 B 16.8 B 16.8 
1 2.2 1.9 3.7 2.9 5.9 4.8 0.37 0.39 23 18 
2 1.1 1.1 2.8 4.2 3.9 5.3 0.28 0.20 10 19 
3 0.8 1.9 4.1 2.1 4.8 4.0 0.16 0.48 10 5 
4 1.4 1.4 2.5 2.8 3.9 4.3 0.36 0.33 23 21 
5 1.4 1.4 3.0 4.1 4.4 5.5 0.32 0.25 34 24 
6 2.4 2.6 4.2 3.9 6.7 6.6 0.36 0.40 28 24 
Mean 1.5 1.7 3.4 3.3 4.9 5.1 0.31 0.34 21 19 
SD 0.6 0.5 0.7 0.9 1.1 0.9 0.08 0.10 10 7 




Inosine infusion rate (mg /min)* 
3.1 4.3 6.1 8.5 11.9 16.8 
Heart rate (beats /min) 
1 80 77 80 80 80 80 
2 67 71 73 71 75 70 70 
3 73 78 78 76 75 76 84 
4 63 59 62 65 64 65 68 
5 58 57 58 55 59 65 63 
6 61 58 60 60 57 58 64 
Mean 67 65 68 68 68 69 72 
SD 8 9 9 10 10 8 9 
Systolic blood pressure (mmHg) 
1 110 124 134 128 132 133 
2 105 110 109 100 112 110 110 
3 106 110 106 110 108 106 106 
4 108 108 114 116 106 110 106 
5 125 123 125 125 123 125 125 
6 136 140 140 136 138 140 140 
Mean 115 118 120 120 120 121 120 
SD 13 14 13 14 13 14 15 
Diastolic blood pressure (mmHg) 
1 92 93 84 82 84 84 
2 68 68 74 72 70 72 74 
3 44 52 48 52 48 42 54 
4 70 70 74 70 70 68 70 
5 70 
6 86 90 88 84 88 82 84 
Mean 72 70 74 73 71 71 75 
SD 17 14 16 12 14 15 12 
For clarity only the 2 minute value at each dose is shown. 
Subjects FEV1 (I) FVC (L) PEFR (l/min) 
Pre Post Pre Post Pre Post 
4 3.46 3.48 4.29 4.45 616 592 















Mean 4.12 4.19 5.20 5.30 572 588 
SD 0.45 0.49 0.72 0.63 60 73 
* *subject whose other data were not included because of a poor respiratory trace. 
Pre, prior to inosine; Post, following inosine. 
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APPENDIX 2 - MAIN INDIVIDUAL DATA FOR CHAPTER 4 
Patient details are shown in Chapter 4. 
Subject Baseline Site 1 Site 2 Site 3 Site 4 Site 5 
Respiratory rate (breaths /min) 
1 13 15 11 13 13 16 
2 13 15 13 13 13 17 
3 16 15 18 15 14 
4 11 10 12 15 14 12 
5 19 21 24 13 18 21 
6 17 17 20 17 7 19 
7 16 14 12 15 14 13 
9 22 22 24 13 14 20 
10 14 16 13 19 14 16 
11 21 19 18 19 19 19 
Mean 16 16 17 15 14 17 
SD 4 4 5 2 3 3 
Tidal volume (l) 
1 0.31 0.57 0.64 0.65 0.61 0.54 
2 0.44 0.54 0.40 0.38 0.23 0.42 
3 0.39 0.63 0.55 0.47 0.33 
4 0.55 1.25 0.84 0.56 0.41 1.55 
5 0.41 0.77 1.44 0.69 0.38 1.03 
6 0.29 0.37 0.25 0.37 0.25 0.27 
7 0.14 0.38 0.53 0.68 0.55 1.07 
9 0.27 0.35 0.31 0.25 0.15 0.22 
10 0.54 0.63 0.62 0.37 0.54 0.55 
11 0.17 0.22 0.38 0.21 0.18 0.22 
Mean 0.35 0.57 0.60 0.46 0.38 0.62 
SD 0.14 0.57 0.34 0.18 0.18 0.45 
Minute ventilation (l /mín) 
1 3.9 8.4 7.2 8.1 8.0 8.8 
2 5.6 8.1 5.4 5.0 2.9 7.2 
3 6.1 9.1 9.9 7.2 4.8 
4 5.9 12.6 9.9 8.4 5.6 18.2 
5 7.8 16.2 35.1 9.1 6.8 21.7 
6 5.0 6.1 5.1 6.3 1.7 5.1 
7 2.3 5.3 6.2 10.2 7.4 14.1 
9 5.8 7.7 7.3 3.2 2.1 4.4 
10 7.2 9.9 8.3 6.9 7.6 8.8 
11 3.6 4.3 6.9 3.9 3.4 4.1 
Mean 5.3 8.8 10.1 6.8 5.1 9.7 

















































































Subject Baseline Site 1 Site 2 Site 3 Site 4 Site 5 
Right femoral artery blood pressure (systolic /diastolic; mmHg) 
7 122/64 116/57 121/60 116/57 120/60 124/62 
8 140/76 140/75 155/83 160/84 150/78 158/84 
9 115/83 136/96 135/90 110/78 100/73 124/86 
11 117/55 130/60 136/66 130/62 150/75 144/70 
Mean 123/70 131/72 137/75 129/70 130/72 138/76 
SD 11/12 11/18 14/14 22/13 24/8 17/11 
Subject Pre -adenosine Post -adenosine 
Intra -aortic blood pressure (systolic /diastolic (mean); mmHg) 
3 110/60 (80) 100/50 (64) 
4 112/62 (84) 116/60 (76) 
5 122/70 (92) 125/70 (96) 
6 110/70 (88) 125/60 (90) 
7 125/75 (96) 110/60 (80) 
8 135/75 (104) 125/65 (92) 
9 140/65 (92) 140/65 (98) 
10 120/50 (80) 110/48 (76) 
Mean 122/66 (89) 119/60 (84) 
SD 11/8 (8) 12/7 (12) 
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Maximum adenosine dose (mg /min) 
Placebo leg Aminophylline leg 
1 33 M 70 11.9 16.8 
2 23 M 84 16.8 16.8 
3 36 M 55 11.9 16.8 
4 43 F 57 11.9 11.9 
5 55 M 85 11.9 16.8 
6 26 M 59 8.5 11.9 
7 27 M 89 16.8 16.8 
8 27 M 71 16.8 23.4 
9 33 M 63 8.5 16.8 
10 25 M 75 8.5 8.5 
Mean 33 71 12.3 15.6 




Pre Post 1 2 3 4 5 Final 
Heart rate (beats /.in) 
1 51 55 57 57 54 54 54 55 
2 68 72 71 75 73 69 65 64 
3 61 65 67 63 63 58 61 
4 63 65 67 64 69 71 68 76 
5 66 67 78 75 79 81 80 78 
6 63 68 59 69 68 57 68 68 
7 79 69 66 75 73 63 62 71 
8 55 57 60 62 60 60 64 54 
9 80 74 73 68 76 80 80 80 
10 62 63 66 66 66 60 60 
Mean 65 66 66 68 68 66 66 67 
SD 9 7 7 6 8 9 9 9 
Systolic blood pressure (mmHg) 
1 100 102 108 108 110 110 106 108 
2 124 126 126 125 121 120 126 129 
3 102 94 98 98 94 88 100 
4 100 106 102 94 104 98 106 104 
5 142 145 145 145 144 150 147 156 
6 86 84 84 86 92 86 90 90 
7 130 118 116 122 124 112 110 
8 114 120 115 112 122 120 122 123 
9 106 110 106 95 99 108 106 106 
10 100 122 112 136 120 114 114 
Mean: 110 113 112 109 115 113 112 
114 




Pre Post 1 2 3 4 5 Final 
Diastolic blood pressure (mmHg) 
1 56 60 55 59 58 54 56 62 
2 64 66 66 64 65 71 67 74 
3 60 54 60 54 56 56 60 
4 56 52 54 60 54 54 64 65 
5 78 84 92 91 78 87 81 94 
6 52 54 57 54 61 54 54 54 
7 58 62 54 70 69 60 64 
8 50 50 56 58 56 57 50 56 
9 68 66 66 60 70 71 74 74 
10 56 64 54 54 60 64 64 
Mean 60 62 63 61 62 63 63 67 
SD 8 12 11 11 8 11 10 12 
Minute ventilation (l /min) 
1 5.8 5.7 6.4 5.8 6.6 5.5 5.9 5.0 
2 8.6 9.3 8.1 9.2 8.5 8.1 9.0 8.7 
3 4.7 4.5 3.9 4.5 4.6 3.8 3.9 
4 3.4 3.8 4.0 3.1 3.5 3.4 3.3 3.5 
5 5.1 5.8 7.1 6.7 7.4 8.7 9.2 7.0 
6 5.0 3.6 5.0 3.6 3.9 4.2 3.7 3.7 
7 6.9 8.0 6.4 7.3 7.4 7.4 6.0 6.4 
8 6.2 6.2 6.5 6.1 5.3 6.1 5.1 5.2 
9 5.6 5.0 5.2 4.7 5.0 6.2 6.2 6.2 
10 8.3 8.4 9.0 9.8 9.5 9.0 9.0 
Mean 6.0 5.9 6.2 6.0 6.2 6.3 6.1 5.9 
SD 1.6 1.9 1.5 2.1 2.1 2.0 2.3 2.0 
End -tidal PCOZ (mmHg) 
1 28.4 28.7 28.1 29.7 29.3 32.2 31.8 32.0 
3 29.9 29.8 30.3 29.4 30.0 30.9 30.7 
4 38.0 37.5 37.5 39.4 38.0 38.1 37.2 37.0 
5 35.4 35.0 33.6 34.6 33.5 33.2 31.7 32.8 
6 43.8 43.7 41.3 40.8 40.1 38.2 40.9 40.9 
8 41.3 41.5 40.9 40.6 38.0 37.1 39.2 38.6 
9 38.3 39.8 39.8 40.4 39.4 36.5 37.6 37.6 
10 40.9 40.4 40.3 40.3 39.0 40.6 40.6 
Mean 37.0 37.7 36.4 37.0 36.0 35.5 36.2 36.3 
SD 5.5 5.4 5.2 4.8 4.6 3.3 4.2 4.0 
AMINOPHYLLINE LEG 
Subject Baseline 
Pre Post 1 2 3 4 5 Final 
Heart rate (beats /min) 
1 59 61 62 59 60 56 56 60 
2 65 62 71 66 68 70 66 63 
3 59 60 58 58 61 58 58 59 
4 72 77 83 87 82 86 91 97 
5 64 79 87 88 79 90 90 97 
6 66 74 68 64 61 64 69 71 
7 58 55 54 68 57 64 59 60 
8 62 63 79 83 79 79 83 74 
9 79 87 87 89 87 85 87 87 
10 67 66 62 68 64 69 69 
Mean 65 69 72 72 70 72 73 74 
SD 7 11 12 13 11 12 14 15 
202 
Subject Baseline 
Pre Post 1 2 3 4 5 Final 
Systolic blood pressure (mmHg) 
1 106 120 115 124 117 106 117 123 
2 128 128 124 128 140 130 128 127 
3 94 104 96 103 96 104 
4 106 110 110 111 110 110 116 98 
5 137 134 134 130 134 130 140 150 
6 82 94 94 86 90 88 90 90 
7 112 119 116 110 110 117 115 114 
8 120 124 124 126 116 125 119 122 
9 108 110 104 110 110 107 108 106 
10 112 124 120 126 130 
Mean 111 116 114 115 117 114 115 116 
SD 16 13 13 14 15 15 14 19 
Diastolic blood pressure (mmHg) 
1 61 72 73 72 65 63 74 73 
2 58 62 72 64 75 75 70 76 
3 50 48 54 50 58 53 60 
4 58 64 58 58 63 64 70 66 
5 81 74 84 82 78 80 83 90 
6 54 58 56 58 58 58 60 66 
7 80 69 70 77 72 71 74 70 
8 56 55 70 60 64 63 52 56 
9 72 78 80 76 74 73 72 71 
10 70 66 62 70 66 
Mean 64 64 68 66 68 67 68 71 
SD 11 10 10 10 7 8 9 10 
Minute ventilation (l /min) 
1 5.9 8.2 7.8 6.3 6.6 6.2 6.3 7.6 
2 9.7 10.7 13.9 10.5 9.3 11.8 10.4 8.8 
3 5.0 7.0 6.0 5.6 6.0 4.7 4.7 4.2 
4 3.6 5.1 4.1 4.8 4.4 5.1 4.6 4.4 
5 5.4 6.3 6.8 7.0 6.3 7.9 8.9 6.5 
6 6.3 9.0 6.6 7.4 4.2 6.5 5.1 6.2 
7 6.9 8.8 7.7 8.2 7.4 7.7 7.7 7.9 
8 4.7 5.7 4.8 4.8 5.0 6.1 5.1 3.8 
9 5.0 6.9 6.2 6.4 4.7 5.3 6.2 7.5 
10 10.0 12.2 7.7 9.3 9.2 8.3 8.3 
Mean 6.3 7.5 7.6 6.9 6.3 7.0 6.7 6.5 
SD 2.1 1.8 3.1 1.7 1.9 2.2 2.0 1.8 
End -tidal PCO2 (mmHg) 
1 39.9 34.8 35.0 35.2 35.9 35.8 34.6 34.3 
2 39.5 37.5 37.0 37.5 36.4 36.5 35.9 34.6 
3 39.1 35.0 34.6 34.9 34.9 35.8 36.4 35.1 
4 36.3 32.1 32.5 33.0 33.2 31.9 32.1 32.2 
5 36.2 31.5 31.2 31.9 32.0 31.4 31.2 31.8 
6 43.4 34.5 35.7 32.2 38.8 38.0 36.9 37.7 
7 37.6 34.3 33.7 32.1 32.6 33.5 33.2 33.5 
8 38.2 33.5 34.7 34.2 35.0 35.2 35.2 35.1 
9 37.9 31.6 33.1 33.1 33.8 33.1 34.0 31.1 
10 40.7 35.3 36.7 36.7 36.4 36.4 36.4 
Mean 38.9 33.9 34.3 34.1 34.9 34.8 34.6 
34.2 
SD 2.2 1.9 1.7 2.0 2.1 2.2 1.9 
2.1 
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CHANGES DURING ADENOSINE INFUSION 
PLACEBO LEG 
Subject Control Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 Max (P) 
Peak heart rate (beats /min) 
1 56 60 76 82 86 94 
2 75 74 76 79 74 101 
3 61 69 69 71 77 87 
4 75 73 99 110 116 125 
5 80 75 80 88 86 97 
6 64 70 76 95 114 114 
7 78 83 81 82 100 122 
8 66 68 74 89 105 114 
9 83 72 101 101 108 108 
10 69 68 80 93 93 93 
Mean 71 71 81 89 96 106 
SD 9 6 11 11 15 13 
Peak systolic blood pressure (mmHg) 
1 112 111 109 116 126 136 
2 122 136 128 134 127 152 
3 103 102 98 98 106 115 
4 108 106 116 122 126 132 
5 146 150 156 153 163 171 
6 86 98 90 106 102 102 
7 120 126 126 130 130 122 
8 122 128 136 137 128 130 
9 115 108 105 118 110 110 
10 120 123 142 140 142 142 
Mean 115 119 121 125 126 131 
SD 15 17 21 17 18 21 
Trough diastolic blood pressure (mmHg) 
1 52 51 50 50 50 52 
2 62 65 66 66 62 59 
3 52 48 48 50 44 55 
4 54 56 50 53 52 62 
5 82 84 83 82 82 82 
6 57 54 54 53 56 56 
7 66 58 60 60 46 56 
8 37 50 42 41 38 30 
9 66 60 58 62 66 66 
10 62 54 56 48 58 58 
Mean 59 58 57 57 55 58 
SD 12 10 11 12 13 13 
Peak minute ventilation (mmHg) 
1 6.1 6.8 8.3 12.7 11.8 15.4 
2 8.6 9.5 8.9 11.3 11.0 16.6 
3 6.0 6.1 6.8 5.9 11.3 16.5 
4 4.2 4.3 8.3 10.4 13.9 16.2 
5 8.9 6.4 9.7 15.2 12.9 19.6 
6 4.3 5.7 5.2 10.9 11.2 11.2 
7 6.6 8.0 7.9 10.3 15.1 21.7 
8 5.4 6.7 8.7 10.1 17.0 17.3 
9 6.0 5.5 8.9 11.8 16.8 16.8 
10 9.2 10.4 14.6 22.5 24.9 24.9 
Mean 6.6 6.9 8.7 12.1 14.6 17.6 
SD 1.8 1.9 2.4 4.3 4.3 3.7 
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Subject Control Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 Max (P) 
Trough end -tidal PCO2 (mmHg) 
1 32.5 28.7 27.3 26.0 26.8 
3 29.1 29.0 28.2 27.7 23.0 
4 38.0 36.5 33.5 31.7 30.4 
5 34.5 33.5 32.3 29.7 26.3 
6 38.0 41.4 36.8 34.2 33.0 
8 37.6 40.3 38.2 34.1 33.0 
9 35.1 40.1 35.2 31.1 30.9 

















Subject Pre Post Adenosine dose (mg /min) /time (min) 
2.3 4.3 Control Max (P) 
2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 
FEV1 (l) 
1 3.57 3.35 3.18 3.43 3.32 3.11 3.39 3.30 3.24 3.34 3.28 3.62 3.28 3.23 
2 3.52 3.83 3.54 3.42 3.76 3.67 3.53 3.62 3.46 3.17 3.36 2.95 3.13 3.59 
3 3.33 3.21 3.16 3.05 3.10 3.19 3.09 2.87 2.95 3.00 3.11 3.10 3.02 3.09 
4 4.89 4.87 4.76 4.79 4.85 4.77 4.74 4.80 4.72 4.62 4.61 4.41 4.32 4.42 
5 4.67 4.64 4.46 4.65 4.58 4.39 4.49 4.55 4.33 4.19 4.37 4.10 4.23 4.22 
6 4.11 3.99 3.84 3.87 3.88 3.90 3.79 3.74 4.06 3.87 3.81 3.92 3.86 3.88 
7 2.98 2.83 2.29 2.39 2.37 2.36 2.32 1.87 2.37 2.47 2.14 2.49 2.14 2.42 
8 3.06 3.04 2.94 3.07 3.11 2.95 2.96 3.03 3.06 2.98 2.85 2.97 2.76 2.98 
9 4.38 4.28 4.13 4.25 4.29 4.38 4.37 4.21 4.24 4.30 4.06 4.17 4.37 
10 2.90 2.84 2.74 2.84 2.80 2.76 2.94 2.97 2.83 2.94 2.95 2.95 2.68 
Mean 3.83 3.69 3.45 3.55 3.61 3.54 3.55 3.51 3.54 3.47 3.48 3.46 3.39 3.49 
SD 0.70 0.74 0.79 0.80 0.80 0.78 0.80 0.90 0.75 0.71 0.78 0.64 0.73 0.72 
FVC (l) 
1 5.07 4.86 4.68 4.78 4.60 4.79 4.87 4.91 4.79 4.84 4.80 5.26 4.89 4.78 
2 5.28 5.66 5.72 5.27 5.65 5.55 5.55 5.76 5.34 5.00 5.11 4.64 4.92 5.35 
3 3.93 3.87 3.87 3.70 3.73 3.83 3.73 3.50 3.56 3.64 3.78 3.79 3.68 3.77 
4 5.98 5.96 5.97 5.98 6.03 5.95 5.95 6.00 6.00 5.81 5.82 6.00 5.80 5.90 
5 5.78 5.76 5.58 5.70 5.65 5.53 5.57 5.64 5.34 5.38 5.49 5.25 5.37 5.38 
6 4.91 4.73 4.69 4.72 4.84 4.84 4.82 4.85 4.95 4.73 4.60 4.74 4.72 4.60 
7 3.50 3.47 3.30 3.42 3.46 3.40 3.40 3.41 3.47 3.36 3.37 3.19 3.13 3.28 
8 3.73 3.74 3.28 3.52 3.91 3.49 3.66 3.76 3.83 3.75 3.54 3.69 3.49 3.69 
9 5.44 5.48 5.23 5.38 5.48 5.61 5.55 5.44 5.44 5.48 5.30 5.35 5.49 
10 3.87 3.85 3.77 3.81 3.75 3.68 3.91 3.93 3.80 4.02 3.87 3.93 3.55 
Mean 4.85 4.74 4.55 4.61 4.71 4.66 4.68 4.73 4.67 4.58 4.60 4.57 4.53 4.58 
SD 0.91 0.95 1.04 0.95 0.94 0.97 0.98 1.00 0.90 0.87 0.88 0.90 0.91 0.95 
FEV1/FVC ( %) 
1 70 69 68 72 72 65 70 67 68 69 68 69 
67 68 
2 67 68 62 65 67 66 64 63 65 63 66 64 64 
67 
3 85 83 82 82 83 83 83 82 83 82 82 
82 82 82 
4 82 82 80 80 80 80 80 80 79 80 79 
74 74 75 
5 81 81 80 82 81 79 81 81 81 78 80 
78 79 78 
6 84 84 82 82 80 81 79 77 82 82 83 
83 82 84 
7 85 82 69 70 68 69 68 55 68 74 
64 78 68 74 
8 82 81 90 87 80 85 81 81 80 79 
81 80 79 81 
9 81 78 79 79 78 78 79 77 78 
78 77 78 80 
10 75 74 73 75 75 75 75 76 74 
73 76 75 75 
Mean 80 78 76 77 77 76 76 74 76 76 
75 76 75 76 
SD 7 6 9 7 6 7 6 9 
7 6 7 6 6 6 
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Subject Pre Post Adenosine dose (mg /min) /time (min) 
2.3 4.3 Control Max (P) 
2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 
1 2.49 2.41 2.22 2.51 2.60 1.96F .38 2.21/2.30 2.26 2.25 2.49 2.15 2.06 
2 5.25 4.37 2.22 2.20 2.50 2.50 2.24 2.25 2.20 2.01 2.21 1.88 1.97 2.44 
3 4.02 4.03 3.69 3.13 3.27 3.80 3.30 2.89 3.25 3.21 3.68 3.70 3.32 3.27 
4 4.32 4.34 4.16 4.18 4.23 4.13 4.12 4.20 4.07 4.09 4.05 3.30 3.31 3.70 
5 4.20 4.17 4.01 4.21 4.09 3.95 4.05 4.12 4.02 3.69 3.92 3.69 3.82 3.74 
6 4.79 4.33 4.33 4.15 4.08 3.98 4.00 3.85 4.10 3.97 4.04 4.17 4.12 4.26 
7 3.24 2.76 1.62 1.75 1.74 1.72 1.73 1.14 1.73 1.93 1.48 2.14 1.33 1.99 
8 3.13 3.27 3.90 3.80 2.87 3.21 2.91 2.88 2.80 2.81 2.71 2.75 2.44 2.79 
9 4.16 4.01 3.88 3.96 4.03 3.97 4.05 3.96 4.01 4.00 3.76 3.92 4.12 
10 2.33 1.99 1.81 2.05 2.04 2.00 2.21 2.25 1.99 1.98 2.31 2.15 2.04 
Mean 3.96 3.60 3.13 3.16 3.14 3.13 3.07 2.98 3.07 3.00 3.03 3.02 2.85 3.04 
SD 0.86 0.83 1.08 1.01 0.92 0.98 0.94 1.04 0.92 0.91 1.01 0.80 0.96 0.89 
Subject Pre Post Base- Control Adenosine dose (mg /min) 
line 1 
2.3 4.3 6.1 8.5 Max (P) 
Venous plasma adenosine concentration (IM) 
1 0.10 0.09 0.06 0.14 0.04 0.10 0.09 0.09 
2 0.10 0.10 0.13 0.08 0.08 0.07 0.08 0.07 0.20 
3 0.04 0.03 0.03 0.10 0.08 0.09 0.07 0.05 0.04 
7 0.03 0.05 0.05 0.04 0.09 0.03 0.04 0.04 0.07 
10 0.14 0.14 0.07 0.07 0.09 0.07 0.06 0.09 0.09 
* 0.02 0.02 0.04 0.03 0.03 0.04 0.08 0.04 0.04 
Mean 0.07 0.07 0.06 0.07 0.07 0.07 0.07 0.06 0.09 
SD 0.05 0.04 0.04 0.04 0.03 0.03 0.02 0.02 0.07 
*, patient with asthma. 
TIMECOURSE OF CHANGES (Maximum dose of adenosine) 
Subject Time (min) 
0 1 2 3 4 5 6 7 
Minute ventilation (l /min) 
1 5.0 15.4 8.1 6.1 9.3 6.4 3.5 3.4 
2 8.7 12.2 12.0 16.6 12.8 13.5 7.6 4.4 
4 3.5 13.3 10.7 16.2 12.2 9.4 3.9 2.7 
5 7.0 19.6 15.4 12.6 11.3 9.4 5.6 4.5 
6 3.7 6.8 11.2 9.3 7.3 5.1 6.5 4.7 
7 6.4 21.7 21.1 15.4 11.7 13.5 3.4 4.3 
8 5.2 14.8 17.3 11.9 8.8 8.8 2.9 1.3 
10 9.0 18.3 24.9 24.3 16.3 22.0 10.3 7.7 
Mean 6.1 15.3 15.1 14.0 11.2 11.0 5.5 4.1 
SD 2.1 4.7 5.7 5.5 2.8 5.4 2.6 1.8 



















26.2 27.3 26.3 27.7 
28.1 25.8 25.9 25.4 
29.7 28.1 27.2 
34.8 34.4 33.0 33.1 
32.8 31.9 32.6 32.2 




























CHANGE IN FRC (1) 
Subject Time (min) 
1 2 3 4 5 6 7 
Maximum dose of adenosine 
1 -0.04 0.12 0.21 0.18 0.18 0.12 0.07 
2 -0.08 -0.03 0.20 -0.03 0.00 0.17 0.03 
4 0.08 0.05 -0.11 0.02 -0.08 -0.20 -0.17 
5 0.92 0.96 0.48 0.52 0.48 -0.20 -0.48 
6 0.28 0.35 0.22 0.30 0.00 -0.10 -0.25 
7 0.23 0.36 0.33 0.17 0.13 0.00 0.10 
8 0.09 0.09 0.00 -0.03 0.00 -0.06 -0.12 
10 0.00 0.00 0.00 -0.09 -0.16 -0.19 -0.06 
Mean 0.19 0.24 0.17 0.13 0.07 -0.06 -0.11 
SD 0.32 0.33 0.19 0.21 0.20 0.14 0.19 
Control infusion. 
1 -0.05 -0.14 -0.25 -0.28 -0.37 -0.35 -0.33 
2 0.03 0.03 0.00 -0.03 -0.01 -0.03 -0.03 
4 -0.01 0.01 0.01 -0.01 0.01 -0.01 -0.05 
5 -0.04 0.02 0.04 0.04 0.04 0.04 -0.10 
6 -0.02 0.02 -0.06 0.05 -0.02 0.06 -0.03 
7 0.07 -0.03 -0.07 0.07 0.12 0.27 0.30 
8 0.03 -0.01 -0.01 -0.03 -0.06 -0.06 -0.03 
10 -0.13 -0.13 -0.13 -0.09 -0.13 -0.13 -0.09 
Mean -0.02 -0.03 -0.06 -0.04 -0.05 -0.03 -0.05 
SD 0.06 0.07 0.09 0.11 0.15 0.17 0.17 
AMINOPHYLLINE LEG 
Subject Control Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 Max (P) 
Peak heart rate (beats /min) 
1 60 64 64 73 85 
2 68 68 71 98 87 98 
3 62 62 61 60 62 75 
4 92 84 96 114 156 161 
5 90 88 91 89 98 99 
6 72 72 71 75 93 93 
7 63 64 69 71 82 109 
8 84 82 82 83 92 134 
9 90 92 98 102 107 107 
10 69 64 67 72 90 90 
Mean 75 75 77 83 94 105 
SD 13 11 14 18 25 25 
Peak systolic blood pressure (mmHg) 
1 122 118 118 119 117 
2 132 126 142 136 130 142 
3 104 105 103 102 100 110 
4 113 116 116 116 130 125 
5 144 144 142 140 144 138 
6 88 90 86 94 94 94 
7 118 122 117 124 122 130 
8 126 130 126 130 130 136 
9 108 111 109 114 112 112 
10 126 130 128 122 130 130 
Mean: 118 119 119 120 121 123 
SD: 16 16 17 14 15 15 
207 
Subject Control Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 Max (P) 
Trough diastolic blood pressure (mmHg) 
1 62 68 61 57 55 
2 72 64 64 62 68 60 
3 49 51 51 50 46 45 
4 52 60 55 54 60 62 
5 70 83 80 72 70 72 
6 55 44 56 50 40 40 
7 68 72 74 69 67 54 
8 48 57 54 52 54 43 
9 72 74 78 70 70 70 
10 54 58 64 58 64 64 
Mean 60 63 64 60 60 57 
SD 10 12 10 8 10 11 
Peak minute ventilation (l /min) 
1 7.6 8.2 7.5 10.2 10.9 
2 10.8 11.9 12.8 12.0 14.2 17.0 
3 5.7 6.5 6.8 6.4 7.2 7.8 
4 5.3 4.7 7.1 7.2 14.0 12.9 
5 7.4 7.6 7.7 9.9 11.4 12.1 
6 7.2 8.6 8.1 7.1 8.8 8.8 
7 8.6 9.9 9.0 10.8 11.1 18.0 
8 3.8 5.2 4.7 6.6 7.1 9.9 
9 7.5 7.4 5.3 9.6 8.7 8.7 
10 10.1 12.1 9.8 11.7 20.6 20.6 
Mean 7.4 8.2 7.9 8.9 11.3 12.7 
SD 2.1 2.7 2.3 2.2 4.1 4.4 
Trough end -tidal PCO, (mmHg) 
1 34.3 34.0 35.0 32.5 30.8 
2 36.1 37.1 36.6 35.6 34.3 30.8 
3 35.9 34.1 34.7 32.8 32.8 31.2 
4 31.1 31.1 30.5 31.0 28.2 27.6 
5 30.7 31.7 30.8 29.2 29.5 28.3 
6 37.1 34.3 31.6 37.5 31.9 31.9 
7 32.3 33.7 30.9 32.3 31.5 27.3 
8 34.8 34.2 34.4 34.5 32.6 30.8 
9 31.2 29.6 31.8 29.2 29.3 29.3 
10 35.3 36.0 35.2 33.6 29.5 29.5 
Mean 33.9 33.5 33.1 33.1 31.2 29.7 
SD 2.4 2.4 2.2 2.7 2.0 1.6 
Subject Pre Post Adenosine dose (mg /min) /time (min) 
2.3 4.3 Control Max (A) 
2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 
FEV (1) 
1 3.11 3.43 3.37 3.29 3.50 3.50 3.4 3.42 3.12 3.00 3.26 3.25 3.44 3.25 
2 3.54 4.04 3.71 4.00 4.20 4.00 3.83 4.07 3.60 3.60 3.48 3.95 3.70 3.86 
3 3.21 3.30 3.24 3.26 3.31 3.21 3.30 3.38 3.18 3.12 3.01 
4 4.60 4.80 4.77 4.79 4.77 4.71 4.60 4.89 4.93 4.96 4.89 5.03 4.96 5.09 
5 4.30 4.51 4.57 4.45 4.69 4.60 4.49 4.50 4.45 4.53 4.49 4.49 4.38 4.29 
6 4.04 4.20 4.02 4.14 4.19 4.17 4.19 4.22 4.21 4.18 4.06 3.85 3.81 4.13 
7 2.89 2.90 3.03 2.59 2.92 2.98 2.97 2.89 2.94 3.07 3.07 2.89 2.80 2.81 
8 3.15 3.18 3.09 3.09 3.21 3.22 3.18 3.20 3.21 3.20 3.16 3.07 3.06 2.88 
9 4.16 4.24 4.32 4.33 4.19 4.29 3.99 4.28 4.33 4.07 3.82 4.08 4.22 4.21 
10 2.86 3.05 3.01 2.84 2.98 3.03 3.08 3.08 3.18 3.23 3.17 3.17 3.18 3.12 
Mean 3.59 3.77 3.77 3.72 3.85 3.77 3.70 3.79 3.72 3.71 3.68 3.70 3.67 3.67 
SD 0.64 0.67 0.69 0.79 0.71 0.66 0.60 0.69 0.70 0.68 0.62 0.70 0.68 0.76 
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Subject Pre Post Adenosine dose (mg /min) /time (min) 
2.3 4.3 Control Max (A) 
2.5 5 10 2.5 5 10 2.5 5 10 2.5 5 10 
FVC (l) 
1 4.64 5.02 4.95 4.88 5.11 5.14 4.90 4.90 4.72 4.79 4.97 4.87 4.81 4.93 
2 5.25 5.72 5.38 5.80 5.82 5.87 5.73 6.04 5.09 5.47 5.15 5.93 5.58 5.58 
3 3.86 3.95 3.91 3.92 3.91 3.78 3.92 3.98 3.77 3.71 3.64 
4 5.74 5.85 5.91 5.84 5.87 5.80 5.62 5.88 5.81 5.95 5.83 6.04 6.05 6.10 
5 5.52 5.69 5.68 5.53 5.90 5.74 5.64 5.67 5.62 5.69 5.68 5.59 5.73 5.56 
6 4.99 5.01 4.84 4.89 5.09 4.95 4.82 4.92 4.85 4.81 4.72 4.40 4.65 4.96 
7 3.55 3.51 3.57 3.36 3.56 3.48 3.48 3.50 3.35 3.46 3.49 3.43 3.12 3.33 
8 3.62 3.87 3.73 3.72 3.95 3.84 3.72 3.77 3.56 3.95 3.91 3.47 3.66 3.21 
9 5.26 5.19 5.32 5.32 5.19 5.32 4.96 5.23 5.33 5.00 4.74 5.12 5.17 5.19 
10 3.86 4.05 4.00 3.80 3.87 3.99 3.97 3.93 4.25 4.28 4.24 4.20 4.14 4.17 
Mean 4.63 4.79 4.82 4.79 4.93 4.80 4.68 4.78 4.64 4.73 4.67 4.68 4.66 4.67 
SD 0.84 0.87 0.86 0.94 0.92 0.92 0.85 0.94 0.87 0.82 0.77 0.98 0.99 1.02 
FEV1/FVC (%) 
1 67 68 68 67 68 68 70 70 66 63 66 67 72 66 
2 67 71 69 69 72 68 67 67 71 66 68 67 66 69 
3 83 84 83 83 85 85 84 85 84 84 83 
4 80 82 81 82 81 81 82 83 85 83 84 83 82 83 
5 78 79 80 80 79 80 80 79 79 80 79 80 76 77 
6 81 84 83 85 82 84 87 86 87 87 86 88 82 83 
7 81 83 85 77 82 86 85 83 88 89 88 84 90 84 
8 87 82 83 83 81 84 85 85 90 81 81 88 84 90 
9 79 82 81 81 81 81 80 82 81 81 81 80 82 81 
10 74 75 75 75 77 76 78 78 75 75 75 75 77 75 
Mean 78 79 78 78 78 79 80 80 81 79 79 80 79 79 
SD 7 6 6 6 5 6 7 6 8 9 8 8 7 7 
FEF25_75x (l/s) 
1 2.32 2.40 2.33 2.27 2.49 2.44 2.44 2.13 1.85 2.11 2.02 2.79 2.13 
2 2.35 2.98 2.54 2.72 3.17 2.80 2.51 2.77 2.57 2.34 2.26 2.64 2.47 2.77 
3 3.86 4.00 3.97 4.04 4.08 3.89 4.02 4.09 3.88 3.85 3.19 
4 4.25 4.32 4.22 4.28 4.25 4.17 4.16 4.41 4.54 4.50 4.42 4.54 4.40 4.58 
5 3.87 4.04 4.18 4.05 4.22 4.08 4.03 4.07 3.96 4.05 3.97 4.02 3.75 3.70 
6 4.37 4.51 4.21 4.36 4.37 4.44 4.61 4.50 4.51 4.51 4.56 4.40 4.17 4.30 
7 2.98 3.09 3.27 3.86 3.10 3.25 3.69 2.92 3.93 3.88 3.20 3.98 4.05 2.72 
8 3.94 4.23 3.32 3.20 3.77 3.86 3.88 4.25 3.20 3.15 4.05 3.23 3.94 
9 4.17 4.28 4.21 4.15 4.06 4.11 3.90 4.17 4.22 4.05 3.95 3.93 4.15 4.07 
10 2.14 2.33 2.24 2.04 2.41 2.30 2.54 2.63 2.30 2.43 2.30 2.37 2.47 2.26 
Mean 3.42 3.62 3.40 3.45 3.47 3.53 3.58 3.71 3.63 3.48 3.40 3.58 3.53 3.37 
SD 0.88 0.83 0.91 0.90 0.77 0.78 0.78 0.73 0.93 0.96 0.93 0.89 0.73 0.87 
Subject Pre Post Base- Control Adenosine dose (mg /min) 
line 1 
2.3 4.3 6.1 8.5 Max (A) 
Venous plasma adenosine concentration (AM) 
1 0.03 0.05 0.04 0.06 0.04 0.04 0.04 0.08 
2 0.09 0.12 0.12 0.15 
3 0.06 0.05 0.04 0.08 0.07 0.09 0.05 0.05 0.09 
7 0.05 0.09 0.08 0.06 0.09 0.06 0.08 0.11 0.08 
10 0.09 0.11 0.09 0.09 0.10 0.10 0.30 0.11 0.11 
* 0.09 0.06 0.08 0.07 0.06 0.07 0.09 0.09 
Mean 0.07 0.07 0.07 0.07 0.09 0.07 0.11 0.08 0.10 
SD 0.03 0.03 0.03 0.01 0.02 0.03 0.11 0.03 0.03 
* patient with asthma. 
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Patient details are shown in Chapter 6. 
Subject Baseline Adenosine dose (mg /min) 2' Post 
4.3 6.1 8.5 11.9 16.8 Max 
Plasma adenosine concentration (µM) 
1 0.12 0.12 0.14 0.14 0.69 1.40 1.40 
2 0.10 0.06 0.06 0.73 2.04 2.04 0.10 
3 0.09 0.09 0.14 1.12 1.12 0.03 
4 0.05 0.28 1.24 1.24 0.06 
5 0.04 0.04 0.04 0.06 0.42 0.42 0.03 
6 0.07 0.08 0.36 1.48 1.48 0.09 
7 0.05 0.02 0.70 0.70 0.09 
Mean 0.07 0.10 0.38 1.20 0.07 
SD 0.03 0.08 0.44 0.53 0.03 
Respiratory rate (breaths /min) 
1 16 15 16 17 17 17 17 17 
2 18 19 14 17 17 17 9 
3 17 13 12 20 20 21 
4 14 17 18 18 9 
5 19 9 11 19 12 12 10 
6 14 14 14 14 14 5 
7 23 23 25 25 13 
Mean 17 16 16 18 12 
SD 3 4 5 4 5 
Tidal volume (l) 
1 0.40 0.48 0.53 0.64 0.69 0.71 0.71 0.40 
2 0.46 0.45 0.85 0.89 0.80 0.80 0.72 
3 0.24 0.44 0.54 0.29 0.29 0.17 
4 0.22 0.42 0.84 0.84 0.36 
5 0.38 0.56 0.59 0.59 0.85 0.85 0.69 
6 0.42 0.41 0.67 0.80 0.80 0.91 
7 0.16 0.16 0.31 0.31 0.28 
Mean 0.33 0.42 0.62 0.66 0.50 
SD 0.12 0.12 0.19 0.25 0.27 
Minute ventilation (l /min) 
1 6.4 7.2 8.7 10.8 11.9 11.8 11.8 6.7 
2 8.1 8.8 11.8 15.0 13.8 13.8 6.5 
3 4.1 5.5 6.4 5.9 5.9 3.5 
4 3.2 7.2 15.2 15.2 3.3 













Mean 5.5 6.2 9.4 10.9 
5.0 
SD 1.9 1.7 3.2 
3.3 1.6 
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Subject Baseline Adenosine dose (mg /min) 2' Post 
4.3 6.1 8.5 11.9 16.8 Max 
Systolic blood pressure (mmHg) 
1 133 136 137 137 139 145 145 147 
2 114 109 100 108 94 94 104 
3 156 145 149 148 148 151 
4 132 120 120 120 123 
5 158 157 160 147 154 154 165 
6 160 153 154 143 143 144 
7 115 139 140 140 137 
Mean 138 137 137 135 139 
SD 20 17 21 21 20 
Diastolic blood pressure (mmHg) 
1 76 77 75 73 77 79 79 80 
2 61 58 55 56 50 50 56 
3 77 70 73 74 74 69 
4 64 58 57 57 60 
5 107 108 111 99 109 109 115 
6 71 66 62 65 65 61 
7 55 64 61 61 65 
Mean 73 72 71 71 72 
SD 17 17 19 20 20 
Mean blood pressure (mmHg) 
1 94 98 97 100 102 107 107 109 
2 78 79 79 80 70 70 81 
3 102 103 102 102 102 106 
4 86 86 78 78 89 
5 124 129 132 118 135 135 142 
6 102 92 94 98 98 98 
7 85 92 94 94 103 
Mean 96 97 97 98 104 
SD 15 16 18 21 
19 
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Patient details are shown in Chapter 7. 
Subject Baseline Control Adenosine dose (mg /min) 5 min post 
4.3 6.1 Maximum 
Heart rate (beats /min) 
1 56 58 56 62 73 68 
2 58 56 55 84 84 59 
3 55 55 59 70 81 61 
4 49 47 50 55 61 53 
5 58 56 58 75 98 66 
6 100 101 122 136 136 104 
7 68 70 63 81 89 70 
8 87 85 93 106 106 88 
9 72 67 65 79 92 75 
10 72 64 66 94 95 70 
11 82 80 105 117 117 82 
12 62 60 70 75 85 72 
13 57 59 62 78 78 63 
14 124 111 120 145 145 95 
15 56 56 56 58 75 56 
16 47 45 43 51 62 52 
Mean 69 67 68 85 92 71 
SD 21 19 30 28 24 15 
Mean systemic blood pressure (mmHg) 
1 104 104 104 106 96 92 
2 82 90 90 88 88 86 
3 96 94 100 92 92 88 
4 84 100 85 80 84 84 
5 100 96 104 112 104 104 
8 114 117 96 104 104 108 
9 70 95 100 107 71 96 
10 102 87 109 101 89 104 
11 99 94 91 93 93 93 
12 81 83 88 80 83 92 
13 88 88 91 94 94 94 
14 109 107 100 90 90 103 
15 86 91 98 93 84 91 
16 100 107 108 119 118 110 
Mean 94 97 97 97 92 96 
SD 12 9 8 12 11 8 
Cardiac index (1 /min /m') 
1 3.7 3.6 3.6 4.9 6.0 5.6 
2 4.3 4.2 5.0 6.8 6.8 5.0 
3 4.0 3.9 3.8 5.7 6.0 4.6 
4 3.9 3.8 3.9 4.0 5.5 4.8 
5 4.7 4.6 4.9 6.7 10.0 6.2 
6 4.0 3.8 4.6 5.6 5.6 3.9 
7 2.7 2.7 2.8 3.8 4.1 2.8 
8 2.9 3.1 3.7 4.4 4.4 3.5 
9 2.4 2.3 2.2 3.0 3.6 2.9 
10 2.6 2.4 2.5 3.9 4.4 2.7 
11 3.8 3.4 4.9 5.2 5.2 3.6 












































Subject Baseline Control Adenosine dose (mg /min) 5 min post 
4.3 6.1 Maximum 
Mean right atrial pressure (mmHg) 
1 3 4 4 5 5 5 
2 -2 -1 -1 0 0 -1 
3 3 3 2 1 3 3 
4 1 2 1 1 4 1 
5 -2 -1 -1 -3 -2 -1 
6 2 2 2 4 4 2 
7 0 3 1 1 1 2 
8 4 2 5 3 3 3 
9 4 4 3 4 4 4 
10 3 4 4 4 4 3 
11 5 5 6 6 6 5 
12 -2 -1 -2 -2 6 1 
13 3 3 3 2 2 4 
14 -1 -2 0 -3 -3 0 
15 -4 -3 -3 -3 -3 -3 
16 0 2 1 1 0 2 
Mean 2 2 1 2 2 
SD 3 2 3 3 3 2 
Mean pulmonary artery pressure (mmHg) 
1 12 16 15 23 20 16 
2 12 11 8 18 18 10 
3 10 15 12 13 19 15 
4 10 14 8 8 8 7 
5 9 9 8 10 16 11 
6 12 11 15 23 23 11 
7 7 8 6 7 13 10 
8 7 8 10 19 19 13 
9 8 11 11 12 10 17 
10 14 13 14 12 14 14 
11 14 14 16 20 20 18 
12 12 15 10 11 27 22 
13 13 13 13 15 15 15 
14 7 7 8 9 9 12 
15 8 8 8 6 11 8 
16 10 12 13 13 19 17 
Mean 10 12 11 14 16 14 
SD 2 3 3 5 5 4 
Mean pulmonary capillary wedge pressure & (LVEDP) (mmHg) 
1 8 10 10 13 16 10 
2 2 1 0 8 8 2 
3 4 7 5 4 14 8 
4 2 3 2 3 5 2 
5 1 2 3 3 5 2 
6 6 6 13 15 15 5 
7 1 3 2 2 7 6 
8 2 1 4 13 13 5 
9 1 (0) 6 7 6 5 (11) 10 
10 7 (10) 5 6 2 7 (8) 5 
11 4 (7) 8 10 11 11 (9) 9 
12 2 (4) 4 2 4 20 (26) 8 
13 5 (10) 5 6 11 11 (27) 10 
14 4 (-6) 3 2 3 3 (-1) 5 
15 -1 (2) 0 2 0 2 (10) 0 
16 4 (12) 6 9 10 12 (19) 12 
Mean 3 (5) 4 5 7 10 (14) 6 
SD 2 (6) 3 4 5 5 (10) 4 
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Subject Baseline Control Adenosine dose (mg /min) 5 min post 
4.3 6.1 Maximum 
Systemic vascular resistance (dyne.s.cm "5) 
1 1111 1108 1134 839 608 624 
2 862 941 802 564 564 758 
3 949 949 1044 642 609 755 
4 836 1015 854 775 578 689 
5 931 903 934 739 457 734 
8 1645 1637 1052 1000 1000 1304 
9 1066 1501 1710 1294 710 1189 
10 1714 1782 1896 1101 852 1652 
11 1131 1211 806 778 778 1141 
12 1074 1002 1102 796 642 930 
13 1388 1429 1649 1341 1341 1506 
14 1186 1124 969 891 891 1151 
15 1366 1360 1597 1249 774 1279 
16 1660 1822 1894 1668 1306 1588 
Mean 1209 1270 1247 977 794 1093 
SD 299 319 408 314 267 350 
Pulmonary vascular resistance (dyne.s.cm -5) 
1 44 66 57 83 27 43 
2 103 103 70 64 64 70 
3 61 83 75 64 34 62 
4 81 114 61 49 22 42 
5 73 65 44 45 47 63 
6 72 63 21 68 68 73 
7 101 84 64 60 67 66 
8 75 100 71 59 59 99 
9 113 82 70 75 53 90 
10 121 148 144 113 70 147 
11 120 68 57 81 81 117 
12 129 131 98 68 58 143 
13 131 134 131 58 58 84 
14 32 41 58 58 58 78 
15 137 116 95 78 80 109 
16 100 104 71 42 77 74 
Mean 93 94 74 67 58 85 
SD 32 30 31 17 18 31 
PR interval (ms) 
1 162 164 166 
2 158 164 164 
3 192 190 189 
4 223 233 234 
5 203 198 193 
7 194 199 198 
8 171 176 178 
9 185 168 191 
10 154 158 174 
11 194 190 159 
12 189 182 185 
13 169 178 179 
15 175 181 187 
16 204 200 212 
Mean 184 184 186 
SD 20 20 20 
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Subject Baseline Control Adenosine dose (mg /min) 5 min post 
4.3 6.1 Maximum 
Minute ventilation (l /min) 
2 2.3 2.2 6.2 6.0 6.0 3.5 
3 3.4 3.5 4.1 5.9 7.5 1.9 
4 7.4 8.4 4.7 10.0 11.8 3.9 
5 3.0 3.0 4.0 5.9 8.2 3.2 
6 3.3 2.4 7.2 6.8 6.8 1.9 
7 4.3 4.8 9.4 9.4 9.7 3.1 
8 3.7 3.7 7.1 6.2 6.2 3.4 
9 7.2 7.3 8.3 11.4 15.3 5.0 
10 6.7 4.8 5.2 11.3 6.6 3.8 
11 4.1 4.9 11.8 10.1 10.1 3.4 
12 8.6 7.7 9.8 9.5 11.3 5.9 
Mean 4.9 4.8 7.1 8.4 9.0 3.5 
SD 2.1 2.1 2.5 2.3 2.9 1.2 
Oxygen consumption (ml /kg /m2) 
1 4.6 4.3 4.1 5.1 4.9 6.8 
2 4.2 4.3 4.5 4.9 4.9 5.7 
3 4.8 4.7 4.3 4.7 4.6 6.1 
4 5.5 5.3 5.8 5.2 5.4 5.9 
5 5.6 5.5 5.5 5.5 6.2 7.0 
6 3.2 3.4 3.1 4.0 4.0 3.7 
7 2.6 2.8 2.5 2.9 3.2 2.9 
8 2.6 2.7 2.5 2.8 2.8 3.3 
9 2.6 2.5 2.4 2.6 2.4 2.7 
10 2.8 3.0 2.8 3.3 4.2 3.6 
11 3.0 2.9 2.6 2.5 2.5 2.5 
12 3.0 3.3 3.3 2.9 3.0 3.3 
13 3.2 3.0 2.8 3.1 3.0 3.3 
14 2.8 3.0 2.9 3.0 3.0 3.5 
15 2.2 2.5 2.1 2.3 2.3 2.4 
16 2.5 2.5 2.5 2.8 2.7 2.4 
Mean 3.4 3.5 3.4 3.6 3.7 4.0 
SD 1.1 1.0 1.1 1.1 1.2 1.6 
Subject B Max 5' post B Max 5' post B Max 5' post 
PO2 (mmHg) PCO2 (mmHg) pH 
9 66 77 71 40 34 42 7.41 7.47 7.39 
10 99 67 86 35 29 31 7.44 7.49 7.47 
11 80 83 63 39 28 34 7.41 7.50 7.44 
12 72 83 73 47 34 41 7.36 7.45 7.39 
13 73 77 73 36 32 39 7.39 7.44 7.39 
14 103 102 90 31 26 30 7.42 7.46 7.42 
15 83 94 68 43 34 42 7.36 7.44 7.37 
16 86 97 66 42 28 38 7.34 7.45 7.36 
Mean 83 85 74 39 31 37 7.39 7.46 7.40 
SD 13 12 9 5 3 5 0.03 0.02 0.04 
B, baseline; Max, maximum dose of adenosine; 5' Post, 5 min following the infusion. 
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Patient details are shown in Chapter 8. 
BASELINE VALUES 
Subject Placebo Adenosine dose (mg /min) 























































































































Heart rate (beats /min) 




78 87 94 
85 79 86 
84 
6 
Systolic blood pressure (mmHg) 




108 110 107 
137 134 135 
133 
14 
Diastolic blood pressure (mmHg) 




51 51 50 
61 59 60 
65 
10 
Minute ventilation (l /min) 




6.2 6.7 6.5 
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Subject Placebo Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 11.9 16.8 Maximum 
PaCO2 
1 52 51 53 51 53 51 51 
2 45 45 44 44 
3 41 40 41 41 41 
4 49 49 
5 59 58 57 60 61 61 
6 34 36 34 34 35 34 34 
Mean 46 46 46 47 
SD 10 9 9 9 
pH 
1 7.37 7.37 7.36 7.38 7.38 7.37 7.37 
2 7.36 7.37 7.36 7.36 
3 7.38 7.39 7.38 7.39 7.39 
4 7.35 7.35 
5 7.35 7.36 7.36 7.35 7.35 7.35 
6 7.45 7.45 7.45 7.46 7.46 7.46 7.46 
Mean 7.38 7.39 7.38 7.38 
SD 0.04 0.03 0.04 0.04 
VALUES DURING ADENOSINE INFUSION 
Subject Placebo Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 11.9 16.8 Maximum 
Heart rate (l /mín) 
1 72 85 78 75 71 72 72 
2 93 93 100 100 
3 82 84 92 122 122 
4 77 80 82 81 81 
5 79 78 80 88 99 99 
6 83 83 83 81 81 69 69 
Mean 81 84 86 90 
SD 7 5 8 20 
Systolic blood pressure (mmHg) 
1 116 123 125 121 126 147 147 
2 149 158 162 162 
3 149 154 162 206 206 
4 137 141 139 150 150 
5 102 113 112 116 124 124 
6 128 140 138 135 133 149 149 
Mean 130 138 140 156 
SD 19 18 20 
27 
Diastolic blood pressure (mmHg) 
1 56 58 57 59 61 63 
63 
2 80 80 87 
87 
3 72 81 113 114 
114 
4 66 67 69 72 
72 
5 48 52 51 52 53 
53 
6 54 61 59 56 












Subject Placebo Adenosine dose (mg /min) 
2.3 4.3 6.1 8.5 11.9 16.8 Maximum 
Respiratory rate (breaths /min) 
1 32 27 30 25 27 33 33 
2 17 18 19 19 
3 23 22 25 32 32 
4 20 22 22 20 20 
5 17 20 17 19 18 18 
6 23 24 23 24 23 19 19 
Mean 22 22 23 23 
SD 6 3 5 7 
Tidal volume (L) 
1 0.26 0.35 0.27 0.45 0.38 0.38 0.38 
2 0.29 0.27 0.29 0.29 
3 0.36 0.40 0.39 0.28 0.28 
4 0.33 0.34 0.36 0.43 0.43 
5 0.40 0.40 0.45 0.44 0.52 0.52 
6 0.55 0.45 0.44 0.49 0.53 0.67 0.67 
Mean 0.36 0.37 0.37 0.43 
SD 0.10 0.06 0.07 0.15 
Minute ventilation (l /min) 
1 8.4 9.4 8.1 11.5 10.2 12.2 12.2 
2 4.9 4.7 5.5 5.5 
3 8.6 8.8 9.9 9.0 9.0 
4 6.6 7.4 8.1 8.7 8.7 
5 6.8 8.3 7.3 8.4 9.2 9.2 
6 12.5 10.8 10.0 11.7 12.2 12.6 12.6 
Mean 8.0 8.3 8.2 9.5 
SD 2.6 2.1 1.7 2.6 
P02 (mmHg) 
1 61 60 61 59 58 60 60 
2 64 60 70 70 
3 63 67 56 56 56 
4 64 64 
5 48 45 49 49 50 50 
6 60 63 62 60 54 49 49 
Mean 59 59 60 58 
SD 6 8 8 8 
PCO2 (mmHg) 
1 50 49 51 50 51 49 49 
2 44 41 42 42 
3 42 38 39 42 42 
4 43 43 
5 60 60 56 55 58 58 
6 35 34 36 36 36 37 
37 
Mean 46 44 45 
45 













































Subject Baseline Placebo Adenosine dose (mg /min) 
2.3 4.3 Maximum 
FEY,' (l) 
1 0.41 0.49 0.42 0.43 0.46 
2 0.26 0.28 0.26 0.26 
3 0.39 0.35 0.40 0.35 0.34 
4 0.51 0.38 0.43 0.43 0.39 
5 0.28 0.24 0.27 0.22 0.16 
6 0.67 0.69 0.63 0.68 0.62 
Mean 0.45 0.40 0.40 0.39 0.37 
SD 0.15 0.17 0.13 0.16 0.16 
FVC (l) 
1 1.22 1.28 1.29 1.26 1.33 
2 0.86 0.75 0.84 0.84 
3 0.97 0.92 1.03 1.01 0.83 
4 1.11 0.91 0.89 1.02 0.91 
5 0.92 0.61 0.74 0.58 0.39 
6 2.17 2.22 1.98 2.28 1.94 
Mean 1.28 1.13 1.11 1.17 1.04 
SD 0.51 0.57 0.47 0.59 0.53 
FEVI/FVC (%) 
1 34.0 39.1 32.3 34.5 34.8 
2 29.9 37.0 30.4 30.4 
3 40.5 38.5 38.9 35.3 41.6 
4 45.9 42.0 49.2 42.0 43.0 
5 30.9 39.2 36.4 37.2 41.2 
6 31.0 31.2 32.0 29.6 31.9 
Mean 36.4 36.6 37.6 34.9 37.1 
SD 6.6 4.9 6.3 4.6 5.5 
FEF25-75% (l/s) 
1 0.20 0.21 0.17 0.18 0.19 
2 0.09 0.12 0.11 0.11 
3 0.16 0.17 0.17 0.16 0.16 
4 0.32 0.17 0.21 0.19 0.18 
5 0.07 0.10 0.08 0.06 
6 0.24 0.21 0.24 0.23 0.19 
Mean 0.23 0.15 0.17 0.16 0.15 
SD 0.07 0.06 0.05 0.06 0.05 
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CHANGES IN FRC (1) 
Subject Time (min) Mean 
of 
minutes 1 to 5 1 2 3 4 5 
Placebo infusion 
1 0.00 -0.07 0.04 -0.04 0.00 -0.01 
2 -0.04 -0.04 -0.08 0.00 -0.02 -0.04 
3 -0.03 -0.08 -0.20 -0.21 -0.23 -0.15 
4 -0.10 -0.05 0.05 -0.03 0.08 -0.01 
5 0.18 0.06 0.14 0.10 0.04 0.10 
6 0.03 -0.06 -0.06 -0.03 0.03 -0.02 
Mean 0.01 -0.04 -0.02 -0.03 -0.02 -0.02 
SD 0.10 0.05 0.12 0.10 0.11 0.08 
Maximum dose of adenosine 
1 0.00 0.00 0.19 0.22 0.34 0.15 
2 0.06 0.24 0.22 0.18 
3 0.15 0.34 0.41 0.30 
4 -0.03 0.25 0.29 0.41 0.34 0.25 
5 0.24 0.28 0.28 0.24 0.22 0.25 
6 0.05 0.54 0.67 0.72 0.77 0.55 
Mean 0.08 0.27 0.34 0.28 
SD 0.10 0.17 0.18 0.14 
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APPENDIX 7 - PUBLICATIONS FROM THE THESIS 
The following publications have arisen from the work of 
this thesis: 
Reid PG, Watt AH, Routledge PA & Smith AP (1987). 
Intravenous infusion of adenosine but not inosine 
stimulates respiration in man. Br J Clin Pharmacol 
23:331 -8. 
Watt AH, Reid PG, Stephens MR & Routledge PA (1987). 
Adenosine - induced respiratory stimulation in man depends 
on site of infusion. Evidence for an action on the 
carotid body? Br J Clin Pharmacol 23:486 -90. 
Reid PG, Fraser AG, Watt AH, Henderson AH & Routledge PA 
(1990). Acute haemodynamic effects of intravenous 
infusion of adenosine in conscious man. Eur Heart J 
11:1018 -28. 
Reid PG, Watt AH, Penny WJ, Newby AC, Smith AP & 
Routledge PA (1991). Plasma adenosine concentrations 
during adenosine - induced respiratory stimulation in man. 
Eur J Clin Pharmacol 40 (in press). 
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Br. J. clin. Pharmac. (1987), 23, 331 -338 
Intravenous infusion of adenosine but not inosine stimulates 
respiration in man 
P. G. REID, A. H. WATT, P. A. ROUTLEDGE & A. PETER SMITH' 
Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff 
and 'Thoracic Unit, Llandough Hospital, Penarth, South Glamorgan 
1 The effects on respiration of intravenous infusions of the endogenous nucleoside 
adenosine and its deaminated metabolite, inosine, administered in random order, single - 
blind, were compared in six healthy volunteers. 
2 The infusion rate of each nucleoside was initially 3.1 mg min -1 and was increased 
stepwise every 2 min, as tolerated, up to a possible maximum of 23.4 mg ml -1. The 
maximum dose rates received by all subjects were 8.5 mg min -1 for adenosine and 16.8 mg 
min -1 for inosine. 
3 Adenosine infusion at rates of 6.1 mg min -1 and above caused a significant increase in 
minute ventilation, principally due to an increase in tidal volume, with an associated 
significant fall in end -tidal Pco2. Mean inspiratory flow rate increased and expiratory 
duration decreased during adenosine infusion, but there was no change in inspiratory 
duration. 
4 Adenosine infusion also caused a significant increase in heart rate and a slight, but 
significant increase in systolic blood pressure. 
5 Infusion of inosine at dose rates up to 16.8 mg min -1 produced no pharmacological 
effects. 
6 This study shows that adenosine by infusion produces sustained respiratory stimulation 
in man and demonstrates that it does not depend on prior conversion of adenosine to 
inosine or related metabolites and that it is not secondary to systemic hypotension. 
Keywords adenosine inosine respiration 
Introduction 
The endogenous nucleoside adenosine exerts a 
variety of physiological and pharmacological 
effects (Lancet, 1985). Recently, dose depen- 
dent stimulation of respiration in man in associa- 
tion with biphasic heart rate changes produced 
by intravenous boluses of adenosine has been 
described (Watt & Routledge, 1985, 1986). 
Adenosine is rapidly metabolised, either by re- 
incorporation into the nucleotide pool or by 
degradation initially to inosine (Klabunde, 1983) 
and has an in vitro half -life in human whole 
blood of less than 10 s (Klabunde, 1983). Signifi- 
cant metabolism of adenosine would therefore 
be expected during the observed 15 -20 s interval 
between injection of adenosine and the onset of 
respiratory stimulation. It is therefore unclear 
whether the effects on respiration observed were 
due to adenosine itself or a metabolite. 
Other effects of adenosine include hypotension 
when administered in large doses (Sollevi et al., 
Correspondence: Dr P. G. Reid, Department of Pharmacology and Therapeutics, University of Wales College of 
Medicine, Heath Park, Cardiff CF4 4XN 
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1984) and this itself might cause respiratory 
stimulation. 
In this study we compared the effects on res- 
piration, heart rate and blood pressure of intra- 
venous infusions of adenosine and its metabolite 
inosine in order to clarify the mechanism of the 
previously reported respiratory stimulation pro- 
duced by adenosine and to investigate whether 
the transitory effects seen after intravenous bolus 
doses of adenosine could be sustained by con- 
tinuous infusion of the drug. 
Methods 
Eight healthy volunteers (seven male) aged 23 
to 33 years gave informed, written consent to 
participate in the study which was approved by 
the Hospital Ethics Committee. All subjects 
were asked to abstain from caffeine- containing 
beverages for at least 12 h prior to the study. 
Adenosine and inosine were administered in 
random order, single -blind, by intravenous in- 
fusions separated by 30 min. This interval was 
chosen on the basis of our finding in a pilot study 
that the cardiorespiratory effects produced by 
adenosine infusion resolve within 1 to 2 min of 
stopping the infusion. The infusion rate of each 
nucleoside was initially 3.1 mg min-1 and was 
increased every 2 min up to a possible maximum 
of 23.4 mg min -1 (maximum possible number 
of stages: 7). Each infusion was discontinued 
following administration of a dose of 23.4 mg 
min-1 or earlier at the request of a subject. The 
maximum dose rates received ranged from 8.5 to 
23.4 mg min -1 for adenosine and 16.8 to 23.4 mg 
min -1 for inosine. 
The electrocardiogram (ECG) was monitored 
throughout each infusion. Recordings of the 
ECG and measurements of blood pressure (using 
an Accoson mercury sphygmomanometer, taking 
phase V as diastolic) were made at baseline and 
at 1 min intervals throughout each infusion. 
A respiratory trace was obtained from a Lectro- 
med type 4320 respiration transducer (calibrated 
by a spirometer) secured around the chest. We 
have found this to give a linear response to 
increasing tidal volume in supine subjects. Pco2 
was measured continuously in gas sampled by a 
catheter, whose tip was clipped to the upper 
front teeth, using a PK Morgan Ltd. Type 901 
MK.2 high speed response CO2 analyser. The 
respiratory and Pco2 traces were recorded on an 
Ormed MX 216 recorder. Respiratory variables 
(respiratory rate, tidal volume, minute ventila- 
tion, inspiratory duration, expiratory duration 
and total breath duration) and end -tidal Pco2 
were subsequently derived from the traces 
obtained. Subjects were asked to report any 
subjective sensations at 1 min intervals and were 
aware that an infusion would be stopped im- 
mediately at their request. In four subjects spiro- 
metry was performed prior to and immediately 
after each infusion using a Micromedical Instru- 
ments Pocket Spirometer (Chowienczyk & 
Lawson, 1982). 
The solutions used were sterile preparations 
of adenosine (Sigma) or inosine (Sigma) in 0.9% 
sodium chloride at concentrations of 5 mg m1 -1. 
Infusion rates were regulated using a Harvard 
infusion pump, model 2681. 
Comparisons of respiratory rate, tidal volume, 
minute ventilation, end -tidal Pco2, heart rate 
and blood pressure at different infusion rates, up 
to 8.5 mg min -1 for adenosine and 16.8 mg min -1 
for inosine, were made using two -way analysis of 
variance and Student Newman -Keuls test. In 
one subject the study was stopped because of 
occipital headache and in one subject an in- 
adequate respiratory trace was obtained. Data 
were therefore analysed for six subjects. Student's 
paired t -test was used to compare baseline values 
of the above variables as well as mean inspiratory 
flow, inspiratory duration, expiratory duration 
and inspiratory duration over total breath dura- 
tion (TIITot) with values at the maximum dose 
of each nucleoside tolerated, and to compare 
spirometric variables (peak expiratory flow rate 
(PFR), forced expiratory volume in 1 s (FEVI) 
and forced vital capacity (FVC)) before and 
after each infusion. 
Results 
The effects of adenosine infusion on respiratory 
rate, tidal volume, minute ventilation and end - 
tidal Pco2 and on heart rate and blood pressure 
are shown in Figures 1 and 2 respectively. All 
subjects received up to 8.5 mg min of adenosine 
but the maximum infusion rate tolerated ranged 
from 8.5 to 23.1 mg min -1 (mean ± s.d.: 13.5 ± 
5.7 mg min -1). Data are therefore presented for 
infusion rates up to 8.5 mg min -1 and for the 
maximum infusion rate received by each subject. 
Minute ventilation increased significantly 
during adenosine infusion from 6.6 ± 4.51 min -1 
at baseline to 13.0 ± 5.7 I min -1 at an infusion 
rate at 8.5 mg min-1, and 19.2 ± 11.21 min-1 at 
the maximum infusion rate (P < 0.001 and P < 
0.005 respectively). These changes were pre- 
dominantly due to an increase in tidal volume 
from 0.5 ± 0.41 at baseline to 0.9 ± 0.41 during 
adenosine infusion at 8.5 mg min -1, and 1.2 ± 
0.6 1 at the maximum infusion rate (P < 0.001 
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Figure 1 Respiratory rate, tidal volume, minute ventilation and end -tidal Pco2 during adenosine 
infusion. Data are shown as mean ± s.d.. n = 6 except for 3.1 mg min -1 where n = 5. For explanation of 
maximum dose please see text. 
*P < 0.05, * *P < 0.01, * * *P < 0.001 for comparisons with baseline. 
The changes in respiratory rate were only 
significant at the maximum infusion rate (16 ± 
4breaths min-1 vs 13 ± 3 breaths min-1 at base- 
line; P < 0.01). 
The increase in ventilation during adenosine 
infusion was accompanied by an increase in 
mean inspiratory flow (tidal volume /inspiratory 
duration) from 16.8 ± 9.61 min -1 at baseline to 
46.8 ± 21.0 1 min at the maximum infusion 
tate (P < 0.05). The expiratory duration fell 
from 3.1 ± 1.0 s at baseline to 2.4 ± 0.9 sat the 
maximum infusion rate (P < 0.01) but there was 
no change in inspiratory duration (1.7 ± 0.5 sat 
baseline vs 1.5 ± 0.5 s at the maximum infusion 
rate; 0.1 < P < 0.2) or TI/TTor (0.4 ± 0.1 at 
baseline and at the maximum infusion rate). 
End -tidal Pco, fell significantly during adeno- 
sine infusion from 38 ± 3 mm Hg at baseline to 
32 ± 4 mm Hg at an infusion rate of 8.5 mg min-1, 
and 27 ± 5 mm Hg at the maximum infusion rate 
(P < 0.001 and P < 0.01 respectively). 
Heart rate increased during adenosine infusion 
from 67 ± 7 beats min-1 at baseline to 86 ± 15 
beats min -1 at an infusion rate of 8.5 mg min -1, 
and 105 ± 9 beats min -1 at the maximum infusion 
rate (P < 0.01 and P < 0.001 respectively). One 
subject developed a transient bradycardia of 30 
min -1 with second degree heart block for a few 
beats during breath -holding immediately after 
discontinuing adenosine infusion at a rate of 16.8 
mg min -t. Rhythm in this subject quickly reverted 
to sinus tachycardia. In no other subject was a 
bradycardia seen. 
Systolic blood pressure increased significantly 
during adenosine infusion from 120 ± 10 mm Hg 
at baseline to 131 ± 11 mm Hg at an infusion rate 
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Adenosine infusion rate (mg min') 
Figure 2 Heart rate and blood pressure during adenosine infusion. Data are shown as mean ± s.d., n = 6 
except for 3.1 mg min -1 where n = 5. For explanation of maximum dose please see text. 
*P < 0.05, * *P < 0.01, * * *P < 0.001 for comparisons with baseline. 
of 8.5 mg min -1, and 134 ± ± 15 mm Hg at the 
maximum infusion rate (P < 0.01 and P < 0.05 
respectively). Diastolic blood pressure changed 
biphasically increasing from 73 ± 14 mm Hg at 
baseline to 80 ± 10 mm Hg during adenosine 
infusion at 4.3 mg min -1, with a fall at higher 
infusion rates, to 66 ± 19 mm Hg at the maxi- 
mum infusion rate. These changes were, how- 
ever, not statistically significant (P > 0.2). Signi- 
ficant hypotension did not occur during adeno- 
sine infusion at any of the doses used in this 
study. 
In contrast to the changes observed during 
adenosine infusion, no significant changes in the 
above variables were observed during inosine 
infusion, despite the higher maximum infusion 
rate (16.8 mg min -1) received by all subjects. 
Respiratory rate, tidal volume and minute venti- 
lation during inosine infusion are shown in 
Figure 3 and heart rate and blood pressure in 
Figure 4. Results for mean respiratory flow, 
inspiratory duration, expiratory duration, and 
TI/TTot (baseline vs infusion at 16.75 mg min -1 
were 21.0 ± 9.6 vs 20.4 ± 7.2 1 min-1, 1.5 ± 0.6 
vs 1.7 ± 0.6 s, 3.4 ± 0.7 vs 3.0 ± 1.3 s, and 0.3 ± 
0.1 vs 0.4 ± 0.1 respectively (P > 0.2 for all 
comparisons). 
During adenosine infusion facial flushing was 
reported by all eight subjects, dyspnoea by seven, 
throat discomfort by five, epigastric discomfort 
by four, headache by four and retrosternal dis- 
comfort by two. One subject was able to tolerate 
the maximum dose of adenosine infused (23.4 
mg min -1). In all other subjects the infusion was 
stopped at a lower dose rate because of the 
degree of dyspnoea and other sensations experi- 
enced. Three subjects experienced paraesthesiae 
in the hands at the end of the study. All sensations 
resolved within 1 to 2 min after stopping the 
infusion. 
During inosine infusion one subject reported 
lightheadedness but all other subjects were 
asymptomatic. 
No subject reported wheeziness and spiro- 
metry showed no significant changes in the four 
subjects tested. In this group FEVI, PEFR and 
FVC (best of three readings; mean ± s.d.) were 
4.25 (± 0.50) 1, 635 (± 65) 1 min -1 and 5.24 (± 
0.63)1 respectively at baseline and 4.10 (± 0.47) 
1, 594 (± 48) 1 min -1 and 5.27 (± 0.56) 1 respec- 
tively immediately following adenosine infusion. 
Values for FEVI, PFR and FVC prior to inosine 
infusion were 4.12 (± 0.45)1, 572 (± 60)1 min -1 
and 5.20 (± 0.72) 1 respectively, and immediately 
following inosine infusion were 4.19 (± 0.49) I, 
588 (± 73)1 miri 1 and 5.30 (± 0.63)1 respectively. 
Discussion 
This study confirms the respiratory stimulant 
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Figure 3 Respiratory rate, tidal volume, minute ventilation and end -tidal Pco2 during inosine infusion. 
Data are shown as mean ± s.d. 
demonstrated as a transient effect following 
intravenous boluses of adenosine (Watt & 
Routledge, 1985), and shows that respiratory 
stimulation is sustained during infusion of the 
nucleoside. Similar findings have recently been 
reported in abstract form by Biaggioni et al. 
(1986). 
Adenosine is rapidly removed from the circu- 
lation principally by cellular uptake and then 
either metabolised by deamination to inosine 
or reincorporated into the nucleotide pool 
(Klabunde, 1983). The present study has shown 
that intravenous inosine is without effect on 
respiration in the dose range studied and there- 
fore the respiratory stimulation produced by 
adenosine in this dose range does not depend on 
prior metabolism to inosine. 
Our data do not exclude the possibility that 
phosphorylation of adenosine is a prerequisite 
for its respiratory stimulant effect. However, it 
has been shown in the cat that adenosine in- 
creases neural discharges from the carotid body 
(McQueen & Ribeiro, 1981), whereas a stable 
analogue of adenosine triphosphate (ATP) was 
without effect (McQueen & Ribeiro, 1983). In 
addition studies using long acting analogues of 
adenosine suggest that it acts via cell surface 
receptors of the A2 subtype in the carotid body 
(Ribeiro & McQueen, 1986). 
Mean inspiratory flow can provide an index 
of `inspiratory drive' provided the mechanical 
properties of the respiratory system are fixed 
(Remmers, 1976). The changes observed in this 
study during adenosine infusion, namely an in- 
crease in mean inspiratory flow and a reduction 
in expiratory duration are qualitatively similar 
to those produced by a number of respiratory 
stimuli, including hypoxia and hypercapnia 
336 P. G. Reid et al. 
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Figure 4 Heart rate and blood pressure during inosine infusion. Data are shown as mean ± s.d. 
(Remmers, 1976). We found no change in in- 
spiratory duration during adenosine infusion. 
It has been suggested that whereas inspiratory 
duration may remain constant during hyper - 
capnia until tidal volume is increased to 3 -5 
times the resting value, there is a progressive 
shortening of inspiratory duration during pro- 
gressive isocapnic hypoxia (Rebuck et al., 1976). 
Others, however, have found no change in in- 
spiratory duration during ventilatory stimula- 
tion by hypoxia, hypercapnia and exercise 
(Cunningham & Gardner, 1972; Jennett et al., 
1974). In any case a reduction in inspiratory 
duration when it occurs is considerably less than 
the reduction in expiratory duration. 
The present results together with our finding 
in man that perfusion of the carotid circulation 
by adenosine -rich blood is necessary to produce 
respiratory stimulation (Watt et al., 1986) and 
the findings of Dixon et al. (1986) that adenosine 
potentiates ventilatory responses to hypoxia but 
not hypercapnia in man are consistent with the 
hypothesis that adenosine stimulates respiration 
by an action in the carotid body. This is supported 
by findings in the rabbit (Buss et al., 1986) and 
the rat (Monteiro & Ribeiro, 1986) that stimula- 
tion of respiration by adenosine is abolished by 
section of the nerve supply to the carotid body 
and the finding in a number of species that 
various adenosine analogues act centrally as 
respiratory depressants (Hedner et al., 1982; 
Eldridge et al., 1984 and Wessberg et al., 1985). 
Studies using adenosine antagonists at cell sur- 
face receptors, e.g. aminophylline, or inhibitors 
of nucleoside transport e.g. dipyridamole, would 
further characterise the mechanism(s) involved. 
Adenosine acts as a vasodilator in several 
vascular beds (Berne, 1980; Berne et al., 1974; 
Proctor, 1984) and both ATP, which is rapidly 
hydrolysed to adenosine in vivo, and adenosine 
have been used as hypotensive agents in man 
(Fukunaga et al., 1982; Sollevi et al., 1984). In 
the present study hypotension was not an effect 
of adenosine infusion, but on the contrary a 
mild, but statistically significant increase in sys- 
tolic blood pressure was observed. The observed 
respiratory stimulation is therefore not attri- 
butable to hypotension which has only been 
reported during adenosine infusion to anaes- 
thetised subjects who were pretreated with 
dipyridamole (Sollevi et al., 1984). A rise in 
systolic blood pressure in association with a 
decreased diastolic blood pressure and increased 
heart rate has been reported by others (Biaggioni 
et al., 1985) who found plasma noradrenaline 
and adrenaline levels to be elevated during 
adenosine infusion. The pressor effect of adeno- 
sine may represent a non -specific sympathetic 
response to the subjective sensations experienced 
or alternatively may be secondary to stimulation 
of the carotid body which has been described in 
animals (Daly & Scott, 1962). Further studies 
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are necessary to clarify the mechanism(s) of the 
observed blood pressure changes. 
Adenosine administered by intravenous bolus 
produces a biphasic heart rate response: an initial 
transient bradycardia followed by a more sus- 
tained tachycardia (Watt & Routledge, 1986). 
The initial bradycardia is seen in isolated hearts 
and probably represents a direct negative chron- 
otropic effect of adenosine on the sinoatrial and 
atrioventricular nodes (Szentmiklosi et al., 1980). 
In the present study only an increase in heart 
rate was seen during adenosine infusion, as has 
been reported by others (Biaggioni et al., 1985). 
The mechanism of this requires elucidation. In 
dogs a tachycardia following carotid body stimu- 
lation has been seen as a reflex secondary to 
increased ventilation (Daly & Scott, 1958). A 
similar mechanism may in part explain the heart 
rate changes seen in the present study. Negative 
chronotropic effects of intravenous adenosine 
boluses are probably exerted in the heart before 
other responses that may have a positive chrono- 
tropic effect, e.g. carotid body stimulation, can 
begin to take effect. Absence of a `bolus effect' 
may explain why only an increase in heart rate 
was seen in this study using an intravenous in- 
fusion of adenosine. 
Inhaled adenosine causes bronchonstriction 
in asthmatics, but not normal subjects (Cushley 
etal., 1983). The mechanism is unclear (Cushley 
&Holgate, 1985). In the rat intravenous adeno- 
sine has been found to cause bronchoconstric - 
tion (Pauwels & Van Der Straeten, 1983). In the 
present study no subject reported a sensation of 
wheeze and in the four subjects in whom spiro- 
metry was performed there were no significant 
changes. Biaggioni et al. (1986) observed no 
change in spirometry in 12 subjects receiving 
adenosine infusion. Unlike the bronchoconstric- 
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Adenosine -induced respiratory stimulation in man depends on 
site of infusion. Evidence for an action on the carotid body? 
A. H. WATT, P. G. REID, M. R. STEPHENS' & P. A. ROUTLEDGE 
Department of Pharmacology and Therapeutics, University of Wales College of Medicine, and 'Department of 
Cardiology, University Hospital of Wales, Heath Park, Cardiff 
Adenosine is an endogenous nucleoside which stimulates respiration in man and other 
mammals. In animals adenosine appears to initiate respiratory stimulation within the 
carotid body, but whether this is the site of action in man is not known. We administered 
adenosine by intra- aortic infusion to 12 subjects undergoing cardiac catheterisation. When 
adenosine was infused at three sites proximal to the carotid circulation, minute ventilation 
was significantly higher than baseline values or those during adenosine infusion at a more 
distal site. These results support the hypothesis that adenosine -induced respiratory 
stimulation in man is mediated in the carotid body. 
Introduction 
Adenosine is an endogenous nucleoside which 
exerts various pharmacological effects (Berne, 
1980; Lancet, 1985; Newby, 1984), many of which 
appear to be related to the balance between 
energy (or oxygen) supply and demand (Newby, 
1984). 
We recently identified a dose -related respira- 
tory stimulant effect of adenosine in man (Watt 
& Routledge, 1985), and suggested that this 
effect was likely to be carotid body mediated and 
that it might be relevant to the ventilatory stimu- 
lation produced by hypoxia which is carotid body 
dependent in man and some other mammals 
(Chalmers et al., 1967; Lugliani et al., 1971). 
Adenosine has a half -life in human blood of 
less than 10 s (Klabunde, 1983). Therefore if 
adenosine -induced respiratory stimulation in 
man is carotid body mediated then it would 
be expected that administration of adenosine 
proximal to the carotid circulation would stimu- 
late respiration whereas more distal administra- 
tion of the nucleoside would have no such effect. 
We examined this hypothesis in 12 patients 
undergoing cardiac catheterisation. 
Methods 
Informed, written consent was obtained from 12 
patients (10 male, aged 55 ± 7 years) scheduled 
to undergo cardiac catheterisation on clinical 
grounds for investigation of chest pain. Adeno- 
sine was administered according to a protocol 
approved by the hospital ethics committee. 
Careful consideration was given to the possibility 
of adverse cardiac events in such patients but it 
was considered that clinically significant adverse 
events were unlikely in view of the short half -life 
of adenosine, less than 10 s (Klabunde, 1983), 
and the ease of catheter withdrawal to a more 
distal part of the aorta. 
Adenosine was administered by continuous 
intra- aortic infusion sequentially at five sites: 
(1) immediately above the aortic valve, (2) mid - 
ascending thoracic aorta, (3) top of the aortic 
arch, (4) mid -descending thoracic aorta and (5) 
just proximal to the top of the aortic arch (see 
Figure 1). Sites 1, 2 and 5 are proximal to the 
carotid circulation, site 3 is close to the origin of 
those vessels, and site 4 is situated distal to the 
carotid vessels. The initial rate of intra- aortic 
adenosine infusion was derived from our experi- 
Correspondence: Dr A. H. Watt, Department of Pharmacology and Therapeutics, University of Wales College 






Figure 1 Schematic diagam showing infusion sites in 
the thoracic aorta in relation to the origin of the carotid 
circulation. Right common carotid artery (RCA), left 
common carotid artery (LCA), left subclavian artery 
(LSA), descending thoracic aorta (DTA) and aortic 
valve (AV). 
ence of intravenous adenosine infusion: an 
intravenous infusion rate of 6 mg min-1 pro- 
duced slight respiratory stimulation in man 
(Reid et al., 1987). We assumed a half -life of 
adenosine in blood of about 10 s (Klabunde, 
1983) and a circulation time of 20 s (from an 
antecubital vein). The infusion rate at site 1 was 
therefore initially 1.58 mg mint, and was in- 
creased as necessary to a level which produced a 
moderate increase in minute ventilation. In this 
group of patients the final dose was 2.86 ± 0.97 
mg min- (mean ± s.d.), and the infusion was 
continued at a constant rate throughout the 
remainder of the study, as the cardiac catheter 
was moved at 1 min intervals from one site to the 
next. Patients were `blind' to the timing and 
direction of catheter movements. 
An electrocardiogram was recorded through- 
out the study. A respiratory trace was recorded 
at 1 min intervals from a Lectromed type 4320 
respiration transducer (which had been calibrated 
against a spirometer) on an Ormed MX216 re- 
corder. Minute ventilation was calculated from 
the product of tidal volume and respiratory rate. 
Intra- aortic pressure was measured in eight sub- 
jects via the cardiac catheter before and im- 
mediately after the adenosine infusion. In four 
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patients right femoral artery pressure was 
measured at 1 min intervals from a side -arm of a 
sheath through which the cardiac catheter had 
been inserted. Patients were asked at 1 min 
intervals to report any subjective sensations. 
The adenosine solution used was a sterile 
preparation of adenosine (Sigma) in 0.9% 
sodium chloride at a final adenosine concentra- 
tion of 5 mg m1 -1. Infusion rates were controlled 
using a Harvard model 2681 infusion pump. 
Eight patients were taking oral 3- adreno- 
ceptor blockers, seven oral or dermal nitrate 
preparations and five oral calcium antagonists. 
One patient was receiving amiodarone, one 
bendrofivazide, and one frusemide (20 mg daily). 
All therapy, other than sublingual nitrates, was 
stopped at least 12 h prior to the study. 
Comparisons of log- transformed minute 
ventilation, heart rate and blood pressure at 
different sites were made using two -way analysis 
of variance and Student Newman -Keuls test. 
Blood pressure before and after the adenosine 
infusion was compared using Student's paired 
t -test. 
Results 
Respiratory, heart rate and blood pressure data 
are summarised in Table 1. In one patient the 
trace recorded at position 4 could not be measured 
and in one patient the study was stopped prema- 
turely because of epigastric discomfort. Data 
were therefore analysed for the remaining 10 
patients. 
There was a significant difference in minute 
ventilation at different infusion sites (F = 5.444, 
Num d.f. = 5, Den d.f. = 45, P < 0.002). Minute 
ventilation at baseline and site 4 did not differ 
from each other (Q = 0.989, P > 0.50) but were 
significantly less than minute ventilation at sites 
1, 2 or 5 (P < 0.025 for each comparison). 
Minute ventilation at site 3 was intermediate and 
did not differ significantly from that at any other 
site. There were no other significant inter -site 
differences in minute ventilation. 
The difference in minute ventilation was attri- 
butable to inter -site differences in tidal volume 
(F = 3.886, Num d.f. = 5, Den d.f. = 45, P < 
0.02). Tidal volume during adenosine infusion at 
sites 1, 2 and 5 was higher than at baseline (P < 
0.05 for each comparison). Tidal volume at site 4 
did not differ from baseline (Q = 0.711, P > 
0.50), but approached a significant difference 
from sites 1, 2 and 5 (0.05 < P < 0.10 for each 
comparison). There was no difference in respira- 
tory rate at different infusion sites (F = 1.482, 
Num d.f. = 5, Den d.f. = 45, P > 0.20). 
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Table 1 Respiration, heart rate and mean blood pressure during adenosine infusion at the sites described. Data 
are shown as mean ± s.d. 
Variable n Baseline Site 1 Site 2 Site 3 Site 4 Site 5 




10 16.1 ± 3.6 16.3 ± 3.6 16.6 ± 5.0 15.1 ± 2.4 13.8 ± 3.4 16.7 ± 3.0 




10 59 ± 10 63 ± 12 68 ± 14 70 ± 13 69 ± 14 73 ± 15 
Mean right femoral 
artery pressure 
(mm Hg) 
4 92 ± 10 94 ± 16 99 ± 12 94 ± 14 92 ± 12 102 ± 13 
There was also a significant difference in heart 
rate at different infusion sites (F = 13.974, Num 
d.f. = 5, Den d.f. = 45, P < 0.001). Heart rate at 
baseline and at site 1 was significantly less (P < 
0.01 for each comparison) than heart rate at sites 
2, 3, 4 or 5 which were not significantly different 
from one another. 
In the eight patients in whom mean intra- 
aortic pressure was measured before (89 ± 8 
mm Hg) and immediately after (84 ± 12 mm Hg) 
adenosine infusion, there was no significant 
change (t= 1.754, d.f. = 7, P> 0.10). In the four 
patients in whom right femoral artery pressure 
was measured at each infusion site no significant 
changes were demonstrable (F = 1.054, Num 
d.f. = 5, Den d.f. = 15, P > 0.50). 
Adverse effects were reported by a number of 
patients during adenosine infusion but these 
were mild with one exception. That patient, who 
had a symptomatic hiatus hernia, experienced 
epigastric pain during adenosine infusion at site 
4 and the study was promptly terminated at the 
patient's request. While no other subject re- 
quested that the study be terminated (although 
all were aware that they might do so) eight 
reported dyspnoea, eight had chest discomfort 
(six at site 4), eight experienced epigastric dis- 
comfort (one at site 1, six at site 4), two reported 
nausea, six mentioned facial flushing and four 
described discomfort in the neck or throat. All 
subjective sensations resolved within 60 s of 
stopping the adenosine infusion. 
Discussion 
The present study confirms the respiratory- 
stimulant effect of adenosine in man which we 
reported previously (Watt & Routledge, 1985; 
Reid et al., 1987). Further the results demonstrate 
that the respiratory- stimulant effect of intra- 
venous adenosine depends on the site of admin- 
istration. Adenosine infused distal to the carotid 
circulation (site 4) caused no respiratory stimu- 
lation, but infusion of adenosine proximal to the 
carotid circulation caused a respiratory stimula- 
tion both before (sites 1 and 2) and after (site 5) 
more distal adenosine infusion. 
These findings raise the question of why 
adenosine- induced respiratory stimulation should 
depend on perfusion of the carotid circulation. 
The effect could be mediated by the carotid 
bodies or brain chemoreceptors. The latter 
alternative appears unlikely because adenosine 
analogues depress respiration when applied 
locally to the brain (Eldridge et al., 1984; Mueller 
et al., 1984). We found that adenosine- induced 
respiratory stimulation in the rabbit was 
abolished by bilateral division of the afferent 
nerve supply to the carotid bodies (Buss et al., 
1986) and others have demonstrated the same 
finding in the rat (Monteiro & Ribeiro, 1986). 
This suggests that adenosine stimulates respira- 
tion by an action on the carotid body in those 
species. The data presented above support but 
do not prove the hypothesis that adenosine- 
induced respiratory stimulation in man is also 
carotid body mediated. 
The pattern of site -dependent changes in 
heart rate differed from that of minute ventila- 
tion. Heart rate increased after adenosine in- 
fusion was started; the increase over baseline 
values being apparent during infusion at sites 2, 
3, 4 and 5. We did not identify any fall in blood 
pressure to account for the changes in heart rate. 
It is not clear why heart rate did not increase at 
site 1, but it may partly be because a sufficiently 
high concentration of adenosine might be per- 
fusing the coronary circulation, to exert a negative 
chromotropic effect on the sinoatrial node 
(Szentmiklosi et al., 1980) to oppose any increase 
in heart rate produced by other mechanisms. 
The increase in heart rate seen at other sites may 
be a reflex, perhaps secondary to the increase in 
ventilation produced by carotid body stimula- 
tion, as has been observed in the dog (Daly & 
Scott, 1958). If this is the case it is unclear why 
the changes in heart rate show a pattern different 
from the respiratory changes. Heart rate does 
not return rapidly to baseline following boluses 
of adenosine (see figure in Watt & Routledge, 
1986) so it is possible that in the present study 
there was insufficient time during the period of 
infusion at site 4 for a return to baseline heart 
rate to occur. Alternatively a sympathetic reflex 
secondary to the adverse effects experienced 
may have contributed to the tachycardia and 
hence its persistence during infusion at site 4 
where some adverse effects were more common. 
Evidence of sympathetic stimulation by adeno- 
sine has been provided by Biaggioni et al. (1985) 
who reported elevated plasma adrenaline and 
noradrenaline levels in association with increased 
heart rate and systolic blood pressure during peri- 
pheral infusion of adenosine. The mechanism 
of this sympathetic activation remains to be 
elucidated. 
Eight of the 10 patients were receiving treat- 
ment with ß- adrenoceptor blockers and this is 
likely to have reduced the magnitude of the 
heart rate changes in those patients. In the two 
patients who were not receiving ß- adrenoceptor 
blockers heart rate increased by up to 34 beats 
min -1, while in the ß- adrenoceptor blocked 
patients heart rate increased by up to 19 beats 
min-1 from baseline. 
Intravenous adenosine in high doses is known 
to lower blood pressure in anaesthetised man 
(Sollevi et al., 1984) and in laboratory mammals 
(Fukunaga et al., 1982). At the doses used in the 
present study no changes in arterial blood pres- 
sure were detected. Numbers were small, there- 
fore a Type II error is a possibility but in other 
studies using intravenous adenosine infusion we 
and others observed respiratory stimulation 
without hypotension and with an increase 
in systolic blood pressure (Reid et al., 1987; 
Biaggioni et al., 1986). Therefore it is unlikely 
that hypotension is a necessary factor contri- 
buting to the observed adenosine- induced res- 
piratory stimulation. 
The occurrence of chest discomfort in some 
patients during intra- aortic infusion is of interest 
in the context of the adenosine -induced retro- 
sternal discomfort reported recently by Sylven 
et al. (1986). They proposed that exogenous 
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adenosine produced such transient chest dis- 
comfort by directly stimulating afferent cardiac 
nerves, and further proposed that adenosine 
released spontaneously during cardiac ischaemia 
contributes to the pain of angina pectoris. They 
provided no information as to changes in coronary 
flow associated with such sensations or whether 
such sensations are ever cardiac in origin. We 
have shown that adenosine increases coronary 
flow in man (Watt et al., 1986) and in 9 of those 
10 patients transient retrosternal discomfort 
occurred in association with doubled coronary 
flow. Thus retrosternal discomfort is not attri- 
butable in those patients with normal coronary 
arteries to a fall in coronary blood flow. The 
present study provides information on the site of 
origin of adenosine- induced chest discomfort. In 
seven of the eight patients reporting such dis- 
comfort, it occurred during adenosine infusion 
at sites 3 and 4. When one considers that the 
half -life of adenosine in human blood is less than 
10 s (Klabunde, 1983), it is unlikely that such 
chest sensations in those patients are cardiac in 
origin. In the single patient who reported `chest 
tightness' during adenosine infusion at site 1 but 
at no other site, the heart might appear to be the 
source of adenosine -induced discomfort. That 
patient had a 50% left anterior descending 
coronary artery stenosis. Coronary flow increases 
distal to stenoses of that degree in animal hearts 
in response to vasodilators (Knabb et al., 1985) 
so a fall in absolute coronary flow distal to the 
stenosis is unlikely in that patient. The occurrence 
of `chest tightness' in that patient would there- 
fore appear to provide support for a possible 
cardiac origin of adenosine -induced retrosternal 
discomfort in some circumstances. 
Adenosine reproduces the epigastric pain of 
duodenal ulceration (Watt et al., 1987). While 
epigastric discomfort of some degree occurred 
in 8 of 10 patients in this study, in only the 
patient with a hiatus hernia was the discomfort 
marked. It may be, therefore, that not only 
duodenal ulceration but also other inflammatory 
lesions of the upper gastrointestinal tract may 
predispose to adenosine -induced epigastric dis- 
comfort by mechanisms as yet undefined. 
We previously suggested that adenosine 
stimulates respiration in man by an action on the 
carotid body (Watt & Routledge, 1985). The 
results of the present study support this sugges- 
tion and are consonant with the data supporting 
the carotid body as being the site of adenosine- 
induced respiratory stimulation in the rabbit 
(Buss et al., 1986) and rat (Monteiro & Ribeiro, 
1986). The ventilatory response to hypoxia in 
man is also carotid body dependent (Lugliani et 
al., 1971). It remains to be established whether 
490 A. H. Watt et al. 
adenosine plays a role in the mechanisms by 
which the ventilatory response to hypoxia is 
initiated in the carotid body. 
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Acute haemodynamic effects of intravenous infusion of 
adenosine in conscious man 
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agents. 
The acute haemodynamic effects of intravenous infusion of adenosine, a dilator of most vascular beds, wer 
studied in 16 patients (seven with coronary artery disease, nine with normal coronary arteries) undergoin 
cardiac catheterization for investigation of chest pain. 
At the lowest dose used (4.3 mg min- ' ) adenosine increased minute ventilation by 44% (P < 0.01, n= 11 
and reduced pulmonary vascular resistance by 20% (P < 0.05) without causing other significant haemo 
dynamic changes. Symptoms, including chest discomfort in 14 patients and dyspnoea in 11, limited th 
maximum dose to 8.5 ± 2.3 mg min - r ( mean ± SD, 108 ± 24 pg kg- r min- ¡) . At this dose, adenosine reduce, 
pulmonary and systemic vascular resistance (by 38% and 34 %, respectively) and increased heart rate (b 
34 %) , stroke index (by 12 %) and cardiac index (by 52 %). Systemic blood pressure and right atrial pressur 
did not change. Unexpectedly, adenosine increased left ventricular end -diastolic pressure (LVEDP) (fron 
5 ± 6 to 14 ± 10 mmHg, n =8), pulmonary capillary wedge pressure (from 3 ± 2 to 10 ± 5 mmHg, n= 16 ) am 
consequently mean pulmonary artery pressure (from 10 ± 2 to 16 ± 5 mmHg) . Minute ventilation increased k 
84% (n =11). resulting in htipocapnia (Pco.: 31 ±3 mmHg, n =8) and alkalosis (pH.. 7.46 ±0.02, n =8) 
Oxygen consumption was unchanged during the infusion, but increased by 21% 5 min post infusion. All effect. 
were similar in patients with and without coronary artery disease. 
Adenosine therefore causes pulmonary and systemic vasodilation and respiratory stimulation. Symptom. 
and an increase in LVEDP of uncertain cause, which occur with high doses, may limit the use of adenosine as ( 
systemic vasodilator in conscious subjects. However at lower doses adenosine causes selective pulmonary 
vasodilation which merits further study. 
Introduction 
The nucleoside adenosine is a potent vasodilator in 
many tissuesl1-61 and has been used to induce hypo- 
tension in patients undergoing intracranial sur- 
gery17.81. It has been suggested that adenosine might 
be useful to reduce afterload in patients with heart 
failurelyl. However, infusion of adenosine into con- 
scious subjects produces effects not seen during 
anaesthesia, such as marked stimulation of respi- 
ration1101, a further action which may have 
therapeutic application. 
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nios_#,Aav ion/ i iniQ nnin 
The haemodynamic effects of adenosine infusion 
and their relationship to the respiratory changes it 
conscious subjects have not been fully defined an( 
were therefore the subject of this study. 
Methods 
We studied 16 patients (11 men), aged 37 to 6, 
years (mean ± SD: 52 ± 8) and weighing 63 to 95 kl 
(mean 78 ± 10 kg), undergoing cardiac catheter 
ization for investigation of chest pain. Patients witl 
unstable angina or heart failure were excluded. Wt 
included some patients suspected of having non 
cardiac chest pain who nevertheless require( 
coronary arteriography: nine patients had norma 
coronary arteriograms. Exercise stress tests per 
formed in eight of these patients were negative 
Although we did not specifically exclude micro 
vascular angina, all nine were ultimately considere( 
© 1990 The European Society of Cardiolog 
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o have non -cardiac pain (musculoskeletal pain: 
ive, oesophageal spasm: two, hyperventilation syn- 
Irome: two). The other seven patients had coronary 
utery disease (two with triple vessel, two with 
rouble vessel, and three with single vessel disease). 
The study was approved by the Hospital Ethics 
leview Committee (1986) and all patients gave 
roitten informed consent. 
Patients were receiving a variety of medications 
rcluding a ß- adrenoceptor antagonist (atenolol) 
Ave cases, a calcium antagonist in four, a long- 
ding nitrate in two, a diuretic in one and amio- 
arone in one. Treatment with a ß- adrenoceptor 
atagonist (atenolol) in three further patients had 
ven discontinued 30 -45 h previously. All patients 
rceived diazepam 10 mg orally 1 h before catheter - 
:ation. All had abstained from caffeine- containing 
everages for at least 6 h. 
A pigtail catheter (7F gauge) was inserted 
Trough an 8F sheath in the right femoral artery for 
:easurement of systemic and, in some patients, left 
ratricular pressures. A balloon tipped catheter 
swan -Ganz, 7F gauge) was inserted via a 9F sheath 
r the right femoral vein and positioned for 
:easurement of right atrial pressure, pulmonary 
nery pressure and pulmonary capillary wedge 
ressure (PCWP). The study was then performed 
;flowing an equilibration period of at least 10 min 
ad before any angiograms. 
FUSION PROTOCOL 
After baseline measurements solutions were 
fused single blind via the femoral venous 
.oath using a Harvard infusion pump, model 2681. 
acebo (0.9% sodium chloride) was given for 
min, followed by a sterile solution (5 mg ml -') of 
enosine (Sigma) with dosage increments every 
nin. The initial dose of adenosine, 4.3 mg min-1, 
.d previously been found to produce mild 
'ectsvot. Subsequent doses were 6.1, 8.5, 11.9 mg 
r' as determined by the infusion pump. At the 
d of each stage, patients were asked to report any 
mptoms and if they were willing to continue to the 
at dose. 
t4SUREMENTS AND SAMPLES 
Except as indicated below, measured variables 
?re recorded following the equilibration period 
tseime), during the final 3.5 min of each infusion 
!ge and 5 min following the end of the infusion. 
`erst adenosine stage was continued for 2.5 min 
'or to measurements being made to allow clearing 
lhedeadspace of the infusion sheath. We reasoned 
that steady -state concentrations of adenosine 
would be achieved quickly because of its short half - 
life ( < 10 s)1111 and because, at the doses used, recir- 
culating venous concentrations are unchanged 
(unpublished observations). 
The electrocardiogram (ECG) was recorded 
throughout from a single bipolar lead (modified 
standard lead 2) and used to determine heart rate 
(HR) and PR interval. Pressures (mean of at least 
five non -ectopic beats) were recorded via fluid -filled 
catheters connected to Bell and Howell strain gauge 
transducers, a Cambridge amplifier, and a 
Mingograph multichannel recorder (eight patients), 
or to Hewlett Packard quartz transducers and ampli- 
fier and a Gould recorder (eight patients). Patients 
were supine and the zero reference level was at the 
sternal angle. Cardiac output (mean of at least three 
estimations) was measured by the thermodilution 
technique using an Instrumentation Laboratories 
computer. Arterial BP was not measured in two 
patients (numbers 6 and 7) because of a transducer 
fault. In the last eight patients (three with coronary 
disease) left ventricular end -diastolic pressure 
(LVEDP) was also measured at baseline and during 
the final infusion stage. 
Respiration was recorded using a respiratory 
inductance plethysmograph (Respitrace Corpor- 
ation Inc.) in the first 12 patients. Isovolume 
manoeuvres performed by each patient were used to 
determine the relative contributions of the abdomi- 
nal and ribcage signals. Volume calibration was 
then performed using a spirometer (Micro Medical 
Instruments). A spirometer fault prevented this in 
the first case. Respiratory rate, tidal volume and 
minute ventilation were determined from the respir- 
atory trace, recorded using a chart recorder 
(Rikadenki). 
Blood (1 ml) was sampled from the pulmonary 
artery and aorta at each stage for determination 
of oxygen saturation (OSM2 Hemoximeter, Radi- 
ometer, Copenhagen). Samples (2 ml) were also 
obtained in the last eight patients at baseline, during 
the final infusion stage, and 5 min post- infusion, for 
determination of arterial blood gas tensions and pH 
(Ciba- Corning Model 178 Blood Gas Analyser). 
Derived haemodynamic indices were calculated 
using standard formulaet'-I. Total body oxygen 
consumption was calculated from arteriovenous 
oxygen content difference and cardiac output 
[13]. 
STATISTICS 
Repeated measures analysis of variance and the 
Student -Newman -Keuls test, or the paired t -test, 
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Figure t Changes in heart rate, systemic blood pressure, cardiac index and stroke volume index during 
adenosine infusion. Data are mean ±SD. n =16 except where shown. B= baseline; C= control infusion; I =1st 
infusion stage; II =2nd infusion stage; M = maximum infusion rate; 5' =5 min post infusion. (For explanations 
of infusion stages please see text.) *P <0.05; * *P <0.0I; ***P <0.001: (for comparisons with baseline). 
where appropriate, were used to analyse changes in 
measured variables. Differences between sub- 
groups according to diagnosis and treatment were 
compared using the unpaired t -test, the Mann - 
Whitney U -test or the Kruskal- Wallis test for non - 
parametric analysis of variance, as appropriate. 
Correlations were examined using the product - 
moment or Spearman rank correlation coefficients. 
P <0.05 was considered significant. 
Results 
The maximum dose of adenosine given ranged 
from 6.1 to 11.9 mg min -' (mean 8.5 ±2.3 mg 
min - ', equivalent to 107.9 ±24.3.ig kg -' 
and correlated with both body weight (r =0.60, 
P < 0.02) and body surface area (r = 0.74, 
P <0.001). All patients received at least two doses 
(4.3 and 6.1 mg min -1, equivalent to 56.5 ±7.8 and 
79.3± 10.9.tg kg -' min -1). 
EFFECTS OF PLACEBO 
There were no significant changes during the 
placebo saline infusion (Figs 1 -5, Table 1). 
EFFECTS OF ADENOSINE 
(a) Lowest dose 
At the lowest dose of adenosine, pulmonary vas- 
cular resistance fell by 20% (Fig. 3), but there were 
no other significant haemodynamic changes (Figs 
1 -3). Minute ventilation, however, was increased 
by 44% (Fig. 5). 
(b) Maximum dose (Table 1) 
At the maximum dose, adenosine infusion 
increased HR by 34% but did not affect systolic, 
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Figure 1 Changes in mean right atrial, pulmonary artery and pulmonary 
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Figure 3 Changes in systemic and pulmonary vascular 
resistance during adenosine infusion. Abbreviations as in 
Fig. I. 
I 
diastolic or mean systemic BP (Fig. 1). PR interval 
was unchanged. Cardiac index increased by 52% 
and stroke index by 12% (Fig. I). Mean PCWP and 
pulmonary artery pressure both increased by 
6 ±5 mmHg to 10 ±5 and 16 ±5 mmHg, respect- 
ively. Mean right atrial pressure did not change sig- 
nificantly (Fig. 2). Pulmonary and systemic vascular 
resistance fell, by 38% and 34% respectively (Fig. 3). 
Total oxygen consumption showed no significant 
change (Fig. 4). The product of systolic BP and HR, 
an approximate index of myocardial work, 
increased by 28% (Fig. 4). LVEDP, measured in 
eight patients, increased by 9 ±8 mmHg to 
14± 10 mmHg. The change in PCWP in this group 
(3 ±2 to 9 +6 mmHg, P <0.05) was similar to the 
change in the eight patients (four with coronary 
artery disease) in whom LVEDP was not measured 
directly (3 ±3 to 10 ±5 mmHg, P <0.001). 
Minute ventilation increased by 84 %, due largely 
to a 60% increase in tidal volume (Fig. 5). The 
arterial carbon dioxide tension fell by 8 mmHg to 
31 ±3 mmHg and arterial pH increased from 
7.39 +0.03 to 7.45 ±0.02. The arterial oxygen ten- 
sion increased slightly (by 2 mmHg), but this was 
not statistically significant (Fig. 5). 
There was a significant correlation between the 
percentage increases in heart rate and minute venti- 
lation (r5= 0.615, P <0.05, n =12), but neither of 
these còrrelated significantly with the percentage 



























* * * 
B C - a M 5' B M 
4 Changes in oxygen consumption and double product during adenosine infusion. 
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Figure 5 han zes in respiration, blood gas tensions and pH during adenosine infusion. P0,--arterial oxygen tension. 
P00,-=arteri2..1 carbon dioxide tension. 'Other abbreviations as in Fig. I, 
decrease in eilher pulmona_ry vascular resistance 
n= and r = -0-406, n=- 12, respect- 
) vas.:..lar resistance (r5=0-297. 
= 14 an:. 7 = -.(H091, n =10, respectively), 
(e) Highest dose without symptoms 
Ten patients received at least one dose of adeno- 
sine without experiencing symptoms. In these 
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(n =16 except where indicated) 
69 ±21 
0.18 ± 0.02 
67+ 19 
0.18 ± 0.02 
P* 
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92±24 <0.001 <0.001 
0.19±0.02 NS NS 
127+20 134+16 124+16 NS 
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mare mean ± SD. * P values refer to comparisons of values during adenosine 
infusion with values at baseline (a) and during 
abo infusion (b). NS = not significant. LV = left ventricular. PO, = oxygen 
tension. PCO, = carbon dioxide tension. 
gin: 4.7 ±0.7 mg min -', range: 4.3 -6.1 mg 
a') caused a 21% fall in pulmonary vascular 
stance but no other significant changes (Table 2). 
tPTOMS 
the dose at which symptoms were first reported 
ied (Fig. 6). Precordial discomfort was reported 
14patients: six of the seven with coronary disease 
(eight of the nine with normal angiography. Ten 
Tents compared the character of the discomfort 
with their usual chest pain: six (three with coronary 
disease, three without) thought it was the same and 
four (two with coronary disease, two without) 
thought it was different. Two patients who experi- 
enced their usual chest pain developed 1 -mm ST 
segment depression. One had normal angiography, 
the other two -vessel disease. 
Dyspnoea was reported by 11 patients and 
usually first occurred at higher doses than 
pre - 
cordial discomfort (Fig. 6). Other symptoms 
in- 
cluded flushing of the head or neck in six patients 
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Table 2 Changes during adenosine infusion at the maximum dose given without causing symptoms 
Baseline Placebo Adenosine 
(n = 10 except where indicated) a 
P* 
b 
Heart rate (beats min I) 6I±8 59±7 62±8 NS NS 
Cardiac index (1 min ' m ') 3.4±0.9 3.3±0.8 3.6±1.4 NS NS 
Mean pulmonary artery 
pressure (mmHg) 10±2 12±3 10±3 NS NS 
Mean pulmonary capillary 
wedge pressure (mmHg) 3±3 4±3 4±3 NS NS 
Pulmonary vascular resistance 
(dyne.s.cm -`) 96±30 99±28 76±28 <0.05 <0.05 
Systemic vascular resistance 
( dyne.s.cm `) (n = 9) 1104±280 1173±306 1168±400 NS NS 
Minute ventilation 
(1 min ')(n =8) 5.4+2.4 5.2+2.3 6.7+2.2 NS NS 
Data are mean +SD. *P values refer to comparisons of values during adenosine infusion with values at baseline (a) and during 
placebo infusion (b). NS = not significant. 
(with another six visibly flushed), headache in four, 
lightheadedness in three and epigastric discomfort 
in one. 
CHANGES FOLLOWING ADENOSINE INFUSION 
Most variables were returning towards baseline 
values 5 min after the infusion (Figs 1 -3). Minute 
ventilation tended to fall below the baseline value 
(by 28 %) and this was associated with a fall in 
arterial oxygen tension to 74 ±9.5 mmHg, but these 
changes were not statistically significant (Fig. 5). 
Oxygen consumption increased to 121% of the 
baseline value 5 min after the infusion (P <0.01) 
(Fig. 4). Further data in eight subjects (not shown) 
indicated continuing elevation of oxygen consump- 
tion 10 min after the infusion. All symptoms 
resolved completely within 1 -2 min of stopping the 
infusion. 
EFFECTS OF DIAGNOSIS 
There were no significant differences in baseline 
values or changes during adenosine infusion of 
any variable, between patients with and without 
coronary artery disease. 
EFFECTS OF TREATMENT WITH ß- ADRENOCEPTOR 
ANTAGONISTS 
In the three patients whose ß- adrenoceptor 
antagonist treatment, atenolol, was discontinued 
between 30 and 45 h before the study, baseline HR 
(93 ±28 beats min') was significantly higher than 
in those continuing treatment (55 ±8 beats min') 
(P <0.05), and tended to be higher than in those 
who had never received such treatment (69± 17 
beats min -'; NS). There were no other differences in 
baseline variables between these three groups. 
There was a significantly smaller rise in LVEDP, 
during adenosine infusion, in patients in whom 
atenolol was recently withdrawn (2 ± 4 mmHg, 
n = 3) than in those who had not received such a 
drug (14 ±6 mmHg, n =4, P <0.05) (Fig. 7). The 
adenosine -induced increase in PCWP in those 
patients in whom atenolol had recently been with- 
drawn (2.0 ±4.4mmHg, n =3) was likewise 
smaller, though not significantly so, than in those 
patients who had never received such a drug 
(7.9 ±4.9mmHg, n =8) or who continued treat- 
ment (6.6 ±2.6 mmHg, n = 5). There were no other 
significant differences during adenosine infusion 
between the three groups. In particular there were 
no differences in the HR increment between 
patients not receiving a ß- adrenoceptor antagonist, 
those who were ß- blocked and those in whom such 
treatment had recently been withdrawn (24 ±9, 
21 ± 7 and 26 ± 8 beats min -1, respectively). 
Discussion 
This study demonstrates that in conscious sub- 
jects intravenous infusion of adenosine causes both 
systemic and pulmonary vasodilation. At the lowest 
dose used, there was a selective effect on the pul- 
monary circulation. At higher doses, adenosine also 
increased left ventricular filling pressure, an effect 
not previously described. 
Acute effects of i.v. adenosine 1025 
0 
Onset of first symptoms 
Onset of first chest pain 
Onset of dyspnoeo 
0 t 1 
B C I II 
I I 
III Di 5' 
'Bure 6 Onset of symptoms during adenosine infusion. 
I.,3rd infusion stage; IV =4th infusion stage. Other 
>breviations as in Fig. I . 
The haemodynamic effects of adenosine infusion 
the previously been studied in detail in anaesthe- 
patientst' "4151. The main differences observed 
this study in conscious subjects were: greater 
:reases in HR and cardiac output, no change in 
stemic BP and a rise in left ventricular filling 












Figure 7 Change in left ventricular end -diastolic pres4ure 
during adenosine infusion. Symbols indicate individual sub- 
jects. N =not treated with a ß- adrenoceptor blocker; T= 
treated with a ß- adrenoceptor blocker (open symbols indicate 
subjects in whom treatment was discontinued 30-45 h 
previously). 
drugs but, apart from ß- adrenoceptor antagonists, 
these did not appear to affect the responses to 
adenosine significantly. 
EFFECTS ON SYSTEMIC AND PULMONARY VASCULAR 
RESISTANCE 
Although adenosine has been used as a systemic 
vasodilator during anaesthesia17 81, the present 
study shows that in conscious subjects infusion 
rates of adenosine sufficient to reduce peripheral 
vascular resistance usually cause symptoms. This 
may limit the clinical use of adenosine as a systemic 
vasodilator. 
The selective effect on the pulmonary circulation 
at lower doses might be due to rapid clearing of 
adenosine from plasma during transit through the 
circulation, since adenosine is avidly taken up by 
endothelial cells") and by red blood cells and has a 
half -life of < 10 sp 
Adenosine infusion in the dog caused pulmonary 
vasodilation during normoxia and prevented the 
pulmonary pressor response to hypoxia121. Recently, 
Öwall et al. reported a 32% fall in pulmonary vascu- 
lar resistance during adenosine -induced hypoten- 
sion in anaesthetized patientst141, and McCormack 
et al. reported that adenosine relaxed pre - 
constricted human pulmonary arteries in vitro". 
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Although we did not study patients with pulmonary 
hypertension, our results suggest that the effects of 
adenosine on the pulmonary circulation in such 
patients merit investigation. 
EFFECTS ON HEART RATE AND BLOOD PRESSURE 
This study confirms previous reports that adeno- 
sine infusion in conscious subjects increases HR but 
does not affect mean arterial BP, although it may 
increase pulse pressuret10191. 
Intravenous bolus injections of adenosine cause 
an initial transient fall in HR, probably due to a 
direct cardiac effect, followed by an increase. prob- 
ably reflex in origint18t. During sustained infusion, 
lower concentrations of adenosine perfusing the 
sinus node and /or simultaneous activation of 
reflexes causing an increase in HR may explain the 
apparent absence of a negative chronotropic effect. 
The mechanisms of the increase in HR are not 
clear. A response to symptoms may contribute. 
Some but not all workers have shown sympathetic 
activation during adenosine infusion in conscious 
subjectst19--''t. There is evidence, however, that the 
increase in heart rate is mediated predominantly by 
reduced cardiac vagal tone122. This is supported 
by our finding that the increase was not modulated 
by treatment with a ß- blocker. A major component 
of the increase may be secondary to the augmen- 
tation of ventilation due to carotid body stimu- 
lationt231. The significant correlation we observed 
between the increases in heart rate and minute 
ventilation is consistent with this suggestion. Fur- 
thermore, injection of adenosine in the aortic arch 
proximal to the carotid circulation causes an initial 
increase in heart rate and systolic blood pressure 
before the onset of peripheral vasodilation, whereas 
more distal injection does nott-0J. 
That a smaller increase in heart rate is observed in 
anaesthetized subjects may be partly due to phar- 
macological or mechanical attenuation of the venti- 
latory changes, although other factors such as a 
greater direct negative chronotropic action due to 
the larger doses of adenosine used or attenuation of 
baroreceptor effects cannot be excluded. The bigger 
increase in heart rate in conscious subjects contrib- 
utes substantially to the larger rise in cardiac index 
and consequently the unchanged mean blood 
pressure despite peripheral vasodilation. 
Adenosine can also depress conduction in the 
atrioventricular nodet24t. Although a slight increase 
in mean PR interval and occasional first degree heart 
block have been observed with adenosine infusion 
during anaesthesiat14t, no such changes were 
observed in the present study, where lower doses of 
adenosine were used. 
EFFECT ON LEFT VENTRICULAR FILLING PRESSURE 
An unexpected finding in this study was an acute 
increase in PCWP and LVEDP at the higher doses 
of adenosine. 
Ischaemia may have contributed to these changes 
but they occurred equally in patients with and with- 
out coronary artery disease, with and without chest 
pain (discussed below) and, except in two patients, 
without ECG changes consistent with ischaemia. 
The rise in LVEDP might represent the conse- 
quence of a negative inotropic effect, consistent 
with the known ability of adenosine to antagonize 
both the release of norepinephrine and the fl- 
receptor-mediated responses to catecholamines in 
the myocardiumt25 -271. This might also explain the 
further observation, albeit in small numbers, that 
the rise in LVEDP was smaller in patients investi- 
gated 30 -45 h after stopping atenolol, a time when 
rebound /3-receptor hypersensitivity has been 
demonstrated1281. However, it is difficult to implicate 
a negative inotropic effect when the rise in LVEDP 
was associated with an increase in stroke output. 
Alternatively, adenosine might have reduced 
ventricular compliance by increasing turgor 
through its coronary dilator actiont't, as has been 
described in experimental animals1291. Limitation of 
such an increase in turgor by hypotension and 
reduced coronary perfusion pressure could explain 
the apparent absence of an adenosine -induced in- 
crease in left ventricular filling pressure during 
anaesthesia. 
EFFECTS OF RESPIRATION 
This study has confirmed a respiratory stimulant 
property of adenosinet1030t. Several studies suggest 
that this effect is mediated at least partly by the 
peripheral chemoreceptorst3i-34t. In this study, 
ventilation was first increased at a dose of adenosine 
that caused no haemodynamic changes apart from 
a fall in pulmonary vascular resistance. Whether 
adenosine has a physiological rôle in the control of 
respiration by the carotid bodies, as has been 
suggestedt301, and whether it could be useful clini- 
cally as a respiratory stimulant, remain to be shown. 
EFFECTS ON OXYGEN CONSUMPTION 
The increase in oxygen consumption following 
adenosine infusion is surprising. During adenosine 
infusion in anaesthetized subjects, slight falls in 
whole body oxygen consumption have been 
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observed, possibly due to shunting of blood away [3] 
from metabolically active tissues or inhibition of 
metabolic demands17351. In the present study, such 
effects might have offset the increased oxygen con- 
sumption demanded by the greater cardiac and 
respiratory work during adenosine infusion. A 
rebound phenomenon after withdrawal of such 
mechanisms may have contributed to the increase in 
oxygen consumption following the infusion. 
SYMPTOMS 
Symptoms described in this study were similar to 
those previously reported by healthy volunteers and 
patients with coronary disease110331. Sylven et al. 
suggested that adenosine release during myocardial 
ischaemia might mediate the symptom of angina1361 
There is, however, evidence that adenosine may 
have a more generalized algogenic effect133.37.381 This 
is supported by the present observations that, 
although in some patients with coronary disease 
adenosine appeared to reproduce their typical pain, 
it also did so in some patients thought to have non - 
cardiac pain, while in others with coronary disease 
it produced a discomfort different from their 
angina. 
CONCLUSIONS 
This study has shown that in conscious subjects, 
adenosine is a pulmonary and systemic vasodilator 
and respiratory stimulant, but the dose of adeno- 
sine that can be given is limited by the development 
of symptoms. At high infusion rates, adenosine 
exerts an adverse effect on left ventricular filling, of 
uncertain cause. However, at lower rates (-.5 60.tg 
kg -' min') adenosine can reduce pulmonary vas- 
cular resistance, suggesting that its effects in 
patients with pulmonary hypertension merit further 
study. 
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